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IntRODuCtIOn
Hematopoiesis
the concept that immature precursor cells (hematopoietic stem cells) con-
tinuously produce mature blood cells, a process termed hematopoiesis, was 
discovered 50 years ago. Mature blood cells have a finite lifespan and must be 
continuously replaced throughout life. the turnover of cells of the hematopoietic 
system in a man weighing 70 kg is close to 1 trillion cells per day 1. this renewal 
process is supported by only a small population of hematopoietic stem cells in 
the bone marrow. hematopoietic stem cells produce progenitor cells that are 
either dedicated to the myeloid or the lymphoid lineage (figure 1). Common 
myeloid progenitors generate platelet producing megakaryocytes (thrombus 
formation), erythrocytes (oxygen transport), mast cells and myeloblasts that 
generate neutrophils, eosinophils, basophils and monocytes (primary immune 
response). the common lymphoid progenitors give rise to B-lymphocytes (hu-
moral immunity) and different subsets of t-lymphocytes including natural killer 
cells (cell-mediated immunity) (figure 1).
acute leukemia
In healthy individuals, a tight balance is maintained between proliferation, dif-
ferentiation, and release of blood cells from the bone marrow. this balance 
is disturbed in leukemia, where malignant expansion of immature white blood 
cells, called blasts, in bone marrow and peripheral blood occurs. The first de-
scription of a patient with leukemia was published in 18272 , although it took until 
1845 before doctors recognized it as a distinct disease called “white blood” 3,4. 
two years later the term leukemia was introduced by virchow5 and his cellular 
theory of the origin of leukemia is still the basic concept of the current under-
standing of the disease. not much later a distinction between myeloid leukemia 
and lymphoblastic leukemia was discovered 6,7. Currently, leukemia is classified 
as acute or chronic and lymphoid or myeloid. acute leukemia develops rapidly 
and involves immature blood cells, whereas in contrast chronic leukemia is char-
acterized by more mature blood cells taking years to progress. acute lymphoid 
leukemia (ALL) is further subclassified in precursor-B and T-ALL 8. aLL arising from 
B-cell precursor aLL (BCP-aLL) constitute 85% of all pediatric aLL cases and is the 
most common cancer in children below the age of 18 years. aLL is diagnosed 
in about 120 new cases in the netherlands every year, with a peak incidence 
between 2-5 years of age 9. Occassionaly a more mature B-aLL type of leukemia 
can be found.
10
the main focus of this thesis was on BCP-aLL and results were frequently related 
to t-aLL.
Risk factors in pediatric acute lymphoblastic leukemia
several clinical and biological parameters are associated with prognosis of 
pediatric acute leukemia and include immunophenotype (pro-B and t-aLL are 
poor prognostic), genetic abnormalities, white blood cell count at diagnosis, 
age at diagnosis and therapy resistance. these parameters are used for risk 
stratification and accordingly for risk-adapted treatment strategies, that can be 
subdivided in low, intermediate and high risk treatment.
Genetic abnormalities in acute lymphoblastic leukemia and prognosis
a genetic predisposition for leukemia, like children with Down syndrome have, 
is rare. Leukemia is currently recognized as a sporadic disease caused by many 
different molecular genetic lesions. Recent studies suggest that childhood leu-
kemia is initiated during fetal life, as rearrangements of leukemia-associated 
genes in childhood leukemia cells have been identified retrospectively in stored 
Guthrie cards made of neonatal heel blood spots 10,11. several genetic rear-
figure 1. schematic representation of the different lineages and stages during hematopoiesis.
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rangements or abnormalities have been identified in BCP-ALL cells, as visualized 
in figure 2a for Dutch children 12. hyperdiploid leukemic cells are found in 28% 
of pediatric BCP-aLL patients and are characterized by the presence of more 
than 50 chromosomes. the pathogenetic consequences of the chromosomal 
gains remain poorly understood. the gain of chromosomes X, 4, 6, 10, 14, 17, 
18 and 21 is believed to comprise the primary genetic event in hyperdiploid 
aLL. Only recently, additional heterogenic small genetic anomalies have been 
identified as well, such as microdeletions of ETV6, CDKN2A and PAX5, and point 
mutations of fLt3, nRas, KRas, and PtPn11 13. Patient leukemic cells that harbour 
a TEL-AML1 or ETV6-RUNX1 caused by a (t12;21)(p13;q22) translocation comprise 
28% of pediatric BCP-aLL patients (figure 2a). a TEL-AML1 translocation results 
in the fusion of teL, a nuclear phosphoprotein of the ets family of transcription 
factors, and the RunX1 gene, a transcription factor regulating myeloid and 
lymphoid lineage specific genes 14. although TEL-AML1 is believed to be an 
initiating event, it is not sufficient by itself to cause leukemia 15, as for instance 
the frequency of TEL-AML1 found in surveys of blood spots far exceeds the 
incidence of childhood leukemia. Only recently it was discovered that stat3 
activity is necessary for TEL-AML1 leukemia maintenance 16. Both hyperdiploid 
patients and TEL-AML1 patients have a good 5-year event-free survival of 85% 
or higher 12,17. this good prognosis may be related to the sensitivity of these 
patients to L-asparaginase in both subtypes and sensitivity to antimetabolites 
methotrexate and 6-mercaptopurine in the hyperdiploid patients 18,19. In con-
trast, BCR-ABL1-rearranged and MLL-rearranged patients, comprising each 3% 
of BCP-aLL, respectively (figure 2a), merely reach a maximal overall survival of 
only 50% on previous treatment protocols 12. BCR-ABL1 positive aLL cells harbour 
the translocation t(9;22)(q34;q11) fusing BCR and aBL1 resulting into constitu-
tively active abl protein, a tyrosine kinase that drives proliferation and survival 
of the leukemic cells 17. this fusion protein is considered the driving force in these 
leukemic cells, as treatment with BCR-aBL1 inhibitors dasatinib and imatinib in 
these patients led to impressive improvement of outcome 20,21. MLL-rearranged 
aLL patients carry a rearrangement of the mixed lineage leukemia gene on 
chromosome 11q23. MLL is a highly promiscuous gene, as more than 50 fusion 
partner genes are identified to date. MLL-AF4 t(4;11)(q21;q23), MLL-ENL t(11;19)
(q23;p13.3) and MLL-af9 t(9;11)(p22;q23) are most frequently found in child-
hood aLL22. MLL is a histone methyltransferase which regulates gene transcrip-
tion epigenetically. MLL-rearrangements produce a constitutively active MLL 
protein leading to an aggressive form of leukemia that is mainly found in infants 
23. Poor survival of these patients is linked to resistance of leukemic cells to pred-
nisolone and L-asparaginase 12. the intermediate prognostic group consists of 
12
E2A-rearranged patients and B-other patients 12. E2A-PBX1 or TCF3-PBX1 caused 
by t(1;19)(q23;p13.3) translocations are present in 8% of childhood aLL cases in 
the netherlands 12 (figure 2a). translocations fuse the transactivation domain 
of the basic helix-loop-helix transcription factor e2a to the hOX Dna binding 
domain of PBX1. whereas e2a is an important regulator in almost all stages of 
B-cell development, PBX1 is not expressed in the lymphoid compartment 24. 
there is evidence that the oncogenic potential of the t(1;19) translocation may 
be due to the reduction of the levels of wild-type e2a or is caused by increased 
hOX activation by the e2a-PBX1 fusion protein 24. B-other patients consist of 
patients that are negative for the other five genomic alterations, i.e. TEL-AML1, 
hyperdiploid, BCR-ABL1, MLL and E2A-PBX1 rearrangements (figure 2a). Of the 
abovementioned genotype, mainly BCR-ABL1, TEL-AML1 and MLL are currently 
used for risk-adapted stratification of BCP-ALL in Dutch treatment protocols.
the availability of new genome-wide screening techniques led to the discov-
ery of new genetic abnormalities in pediatric BCP-aLL. BCR-ABL1-like patients 
comprise the largest group identified among B-other cases of Dutch leukemic 
patients (figure 2A). These patients have a similar gene expression profile as BCR-
ABL1 positive patients, but lack a BCR-ABL1 translocation 25. Characterization 
of BCR-ABL1-like patients revealed that more than 70% of these patients have 
abnormalities in B-cell differentiation genes, including IKzf1, PaX5, and eBf1 25. 
BCR-ABL1-like patients have a poor prognosis and merely reach an event-free 
survival of 50% 25,27,28.
Recent investigations have also identified B-other patients with an intra-
chromosomal amplification of chromosome 21, iAMP21 patients (figure 2B) 29. 
These patients benefit from receiving more intensive therapy in the UKALL2003 
protocol (united Kingdom)30. Recent studies also showed CRLf2 overexpression 
in 7% of BCP-aLL patients, predominantly resulting from P2RY8-CRLf2 fusion or 
IGh@-CRLf2 rearrangement (figure 2B) 31–33. Increased CRLf2 expression in the 
absence of a rearrangement is also an adverse prognostic feature in some but 
not all treatment protocols (figure 2B) 28,31. t(8;14)(q23;q32.3) leading to a gene 
rearrangement of the oncogene c-Myc are also found in children with BCP-aLL 
34. a subset of B-other patients have alterations of the ets-family transcription 
factor ERG (figure 2B). the ERG deletions result in the expression of an aberrant 
C-terminal eRG fragment that functions as a competitive inhibitor of wildtype 
eRG. these patients generally have a favorable outcome 26. Poor prognostic 
hypodiploid patients with less than 44 chromosomes is another distinct subgroup 
(figure 2B) 26. few patients have a dic(9;12)(p11-13;p11-12) and represent a 
good prognostic group (figure 2B) 35.
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several genetic abnormalitaties are also known for t-aLL (figure 2B) of which 
ETP-ALL, a recently defined subset of thymocytes that retain stem-cell-like fea-
tures, have the poorest prognosis 36.
These recently identified new genetic and prognostic abnormalities may be 
implemented in the risk stratification of future protocols, leading to improved 
treatment outcome and reduced therapy-induced cytotoxicity and mortality.
White blood cell count, age and prognosis
Discriminative and clinical predictive factors of outcome in aLL are white blood 
cell count and age at initial diagnosis. Children with a white blood cell count 
below 50,000 cells/µl tend to have a more favourable prognosis 37,38. the as-
sociation of high white blood cell count and prognosis is mainly driven by the 
fact that a higher tumor load is indicative of a more aggressive type of aLL. 
furthermore, children between 1-10 years of age have better cure rates than 
children below 1 year or above 10 years of age 37,38. the prognostic value be-
tween ages is most likely linked to peak incidences of specific genetic aberra-
tions in different age categories. hyperdiploidy is mainly found between 1 to 10 
year of age, TEL-AML1 in 2 to 5 year old patients, while MLL-rearrangements are 
primarily found in infants 37,38. Moreover, age has been linked to in vitro resistance 
to chemotherapeutic drugs and in vivo response to induction treatment 39.
a b
figure 2. frequency of genomic abnormalities in children with bCP-all and T-all.
a. frequency of genomic abnormalities in Dutch pediatric BCP-aLL patients above 1 year. B. frequency 
of all genomic abnormalities in BCP-aLL and t-aLL, including recently discovered novel genomic 
abnormalities 26.
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Therapy resistance and cellular drug resistance
therapy resistance is one of the most important risk factors for relapse. around 
1980 it was discovered that the percentage of marrow blasts on day 7 of induc-
tion therapy including vincristine, predniso(lo)ne, l-asparaginase, and dauno-
rubicin had significant prognostic value 40–42. Only a few years later PCR based 
methods were developed to detect residual leukemic cells that are below the 
limits of detection using conventional morphological assessment.
Minimal residual disease proved to be one of the most powerful predictors of 
outcome and was soon used in risk-stratification of childhood ALL 43–45. In 1983, 
the Berlin-frankfurt-Münster (BfM) study group demonstrated that peripheral 
blast count after a 7-day predniso(lo)ne pretreatment window was a predictive 
factor for treatment outcome 46. since then, in vivo predniso(lo)ne response has 
consistently been found to be one of the strongest independent prognostic fac-
tors for the prediction of treatment outcome in aLL-BfM studies 47. In addition to 
the in vivo response to predniso(lo)ne also in vitro drug resistance of leukemic 
cells was predictive for an adverse clinical outcome in BCP-aLL 48. especially 
in vitro prednisolone resistance, but also to a lesser extent l-asparaginase and 
vincristine correlated significantly to disease free survival (figure 3) 49,50.
In vitro prednisolone resistance and in vivo predniso(lo)ne response are 
correlated, although in vitro prednisolone resistance has a higher predictive 
value 51. the presence of minimal residual disease after 2 to 4 weeks of therapy 
also correlates with in vitro resistance to prednisolone, whereas this was not 
observed for vincristine, L-asparaginase and doxorubicin 52. Children with t-aLL 
are more in vitro resistant to prednisolone compared to children with the more 
favorable prognostic BCP-aLL immunophenotype 39. also children with acute 
myeloid leukemia, with survival rates reaching only 60-70%, are highly resistant 
to prednisolone, but also to all other chemotherapeutic drugs used in current 
aLL therapy regimens 53. furthermore, the poor prognostic subtypes in BCP-aLL, 
BCR-ABL1 and MLL-rearranged patients (figure 2a) are all highly resistant to 
figure 3. Relation between in vitro drug resistance and probability of disease free survival 
(pDfs) in children with newly diagnosed all49.
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prednisolone 54–56. Children with aLL who are older than 10 years or younger than 
1, are more resistant to prednisolone compared to children who are between 
1-10 years of age 39,56. Resistance to drugs increases with age, as adults are more 
resistant to predniso(lo)ne than children suffering from the same leukemic type 
57. furthermore, relapsed aLL cells acquire prednisolone resistance 58. altogether 
these results signify an important role for predniso(lo)ne resistance in treatment 
failure and relapse rate.
Prednisolone, mechanisms of action
In 1949 adrenocorticotrophic hormone (aCth) was the second drug, af-
ter aminopterin, that produced prompt although brief remissions of aLL 59. 
Predniso(lo)ne had similar activity and soon replaced aCth. another corti-
costeroid, dexamethasone was additionally added to treatment protocols. 
Predniso(lo)ne and dexamethasone are synthetic analogues of cortisone, a 
glucocorticoid that is naturally produced in the adrenal cortex and regulates 
several crucial processes, such as stress response, immune response and inflam-
mation, but also carbohydrate and protein metabolism. sixty years after the 
first discovery of its anti-leukemic capabilities, predniso(lo)ne is still the primary 
drug used in the treatment of BCP-aLL and t-aLL. It is also widely used to treat 
immunologic based diseases, such as asthma, chronic obstructive pulmonary 
disease, Crohn’s disease, pericarditis, myasthenia gravis and others. to date, 
the exact mechanism how predniso(lo)ne targets immune cells or leukemic 
cells is not completely understood. It is known that prednisolone can passively 
diffuse pass the cell membrane due to its lipophilic structure, where it binds 
PREDNISOLONE
1 2 3
INACTIVE
GR
ACTIVE
AP-1 / NF-KB
AP-1 / NF-KB
CYTOSOL
NUCLEUS
COCHA-
PERONES
ACTIVE 
GR
AP-1
NF-KB
TRANSACTIVATION/
TRANSREPRESSIONTRANSREPRESSION
GRE
RNA
DNA
ACTIVE 
GR
figure 4. Prednisolone: mechanisms of action.
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the cytosolic glucocorticoid receptor (GR/nR3C1). Binding of prednisolone 
conformationally changes the GR dispersing inactivating cochaperones such 
as hsp90, hsp70, hsp56 and hsp40, leading to homodimerization (figure 4). this 
receptor complex is then translocated into the nucleus within 20 min, where 
it binds to specific palindromic negative or positive glucocorticoid responsive 
elements leading to gene repression or activation, respectively 60,61. active GR 
can also sequester other transcription factors, such as aP-1 and nf-kB, thereby 
diminishing the transcriptional activation of aP-1 and nf-kB responsive genes 62. 
eight hours of prednisolone exposure of sensitive BCP-aLL cells already results 
in differential expression of 51 genes 63. eventually down- or upregulation of 
these numerous genes by prednisolone leads to the induction of apoptosis in 
particularly lymphoid cells.
several prednisolone responsive genes are described that might be respon-
sible for the observed induction in apoptosis, such as pro-apoptotic Bcl-2 family 
protein Bim 64, the redox-regulating thioredoxininteracting protein (txnip) 63, the 
cell cycle inhibitors p19InK4d 65 and p57(Kip2) 66, several cMYC inhibitors 65, the 
anti-proliferative genes BtG1 and BtG2 65 and many others. support for the 
presence of a transcription independent mechanism originates from the discov-
ery that a cytosolic Dna‐binding defective variant of GR still induces apoptosis 
67. It has been shown that prednisolone rapidly increases cytosolic calcium levels 
in thymocytes and inhibition of this prevents prednisolone induced apoptosis 68. 
In addition, steroids may diminish cellular antioxidant defenses, unabling cells to 
eradicate reactive oxygen species that are produced during normal metabo-
lism, eventually inducing apoptosis 69. t lymphoma cells overexpressing thiore-
doxin, an important redox protein, become resistant to glucocorticoid induced 
apoptosis 69, 70. In addition, hypoxic culture conditions prevented glucocorticoid 
induced apoptosis of thymocytes. a mitochondrial localization signal has been 
identified within the ligand binding domain of the glucocorticoid receptor 71. 
Glucocorticoids can induce translocation of the GR to the mitochondria, where 
it actively induces apoptosis. the exact mechanisms behind mitochondrial GR 
provoked apoptosis remains poorly understood. It is thought to be triggered by 
either production of reactive oxygen species, rapid calcium mobilization, or by 
direct activation of mitochondrial gene transcription (reviewed in 72). another 
non-genomic mechanism is the release of not only the GR, but also src kinase 
from cochaperones after prednisolone binding 73. src inhibition prevents glu-
cocorticoid induced apoptosis. however, the exact contribution of src kinases 
to glucocorticoid induced apoptosis is unclear, as others have also found that 
inhibition of src kinases overcomes glucocorticoid resistance 74.
17
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Modulating prednisolone resistance
Over the years, many investigations tried to elucidate and modulate predniso(lo)
ne resistance. Evidently, first studies looked at clearance of predniso(lo)ne or de-
fective expression of the glucocorticoid receptor itself. Up to five different splice 
variants of the GR have been described, the α, β, γ, GR-P and GR-a isoform. 
the expression level of the 5 splice variants both at base-line and after eight 
hours of prednisolone exposure was not associated with in vitro prednisolone 
resistance in leukemic samples of children with aLL 75. In addition, polymorphisms 
or mutations in the GR gene are no major contributors to glucocorticoid resis-
tance in childhood aLL 76. also the mRna expression levels of chochaperone 
molecules are not related to in vitro prednisolone resistance 77. Inhibition of the 
prednisolone interconverter 11β-hsD did sensitize t-aLL cell lines to prednisolone 
78. Overall these data suggest that resistance to prednisolone more likely is 
caused by mechanisms affecting the downstream intracellular signaling than 
by mechanisms affecting the effective prednisolone or GR receptor levels. for 
instance, core subunits of the swI/snf complex glucocorticoid-dependent tran-
scription regulators, sMaRCa4, aRID1a, and sMaRCB1 associate with resistance 
to predniso(lo)ne and dexamethasone. Knockdown of sMaRCa4 made a t-aLL 
cell line more resistant to prednisolone 79. Prednisolone resistant cells also have 
defects in drug-induced apoptosis mechanisms, such as caspase-3 activation 
and PaRP 80. Overexpression of anti-apoptotic MCL1 and DAPK1 significantly 
associated with predniso(lo)ne resistance 81. Indeed, down-regulation of MCL1 
in prednisolone resistant leukemic cells sensitized to prednisolone 82. In addition, 
rapamycin, a mtOR inhibitor, overcomes prednisolone resistance in leukemic 
cell lines by downregulating MCL1 83.
another apoptotic molecule involved in prednisolone sensitivity is the pro-
apoptotic BCL-2-interacting mediator of cell death (BIM). BIM expression 
increases upon prednisolone treatment in sensitive, but not in resistant cells 84,85. 
Overexpression of BIM converted a prednisolone resistant cell line into a sensi-
tive cell line 86. Calcium fluxes incited by prednisolone are necessary to induce 
apoptosis 68. Inhibiting s100a8/s100a9, both calcium scavengers, sensitized MLL- 
rearranged aLL cells to prednisolone 87. also several pro-survival mechanisms 
are associated with the failure of prednisolone to induce apoptosis. Inhibition 
of important survival proteins JnK and eRK sensitizes aLL cell lines to predniso-
lone 88, as well as inhibition of PI3 kinase, aKt 89,90 and src kinase 74. Prednisolone 
resistance is also associated with increased glucose consumption, as inhibition 
of glycolysis with 2-deoxyglucose sensitized primary patients´ BCP-aLL cells to 
prednisolone 51.
18
outline of this thesis
Predniso(lo)ne is one of the principal chemotherapeutic drugs used to treat 
children with aLL. Resistance to predniso(lo)ne, both in vitro and in vivo, is an un-
favorable prognostic factor and has been used as a risk parameter in a.o. Ger-
man COaLL and BfM protocols as well as Dutch DCOG treatment protocols 50,92. 
to date our knowledge about clinically relevant mechanisms of predniso(lo)ne 
resistance is limited. In this thesis we aimed to unravel predniso(lo)ne resistance 
and find new druggable targets that may point to new therapeutic interven-
tions overcoming predniso(lo)ne resistance in children with aLL.
In Chapter 2 we examined the role of apoptotic proteins in prednisolone resis-
tance. we hypothesized that prednisolone-mediated effects on key apoptotic 
proteins differ between in vitro prednisolone sensitive and resistant aLL patients’ 
samples. we discovered that MCL1 plays an important role in resistance and is 
associated with altered glucose consumption of leukemic cells. Our research 
showed that inhibition of glycolysis and MCL1 synergistically reduced survival 
and concomitantly reversed prednisolone resistance in leukemic cells.
In Chapter 3 we investigated which other (non-apoptotic) genes may con-
tribute to prednisolone resistance. We identified a significant increase in EMP1 
expression in in vitro prednisolone-resistant compared to -sensitive patients. 
silencing of eMP1 inhibited leukemic survival, sensitized leukemic cells to pred-
nisolone and abrogated migration and adhesion to mesenchymal stromal cells. 
eMP1 also contributed to microenvironment induced prednisolone resistance 
and was identified as an independent predictor for poor outcome in BCP-ALL.
In Chapter 4 we investigated the role of nR4a-family receptors in predniso-
lone resistance. nR4a-family gene and protein levels were increased in in vitro 
prednisolone-resistant compared to sensitive cases. Knockdown of the nR4a-
family in primary patient samples did not sensitize to prednisolone, suggesting 
that resistance to prednisolone is not caused by altered regulation of the gluco-
corticoid receptor.
In Chapter 5 we addressed the role of survival proteins associated with pred-
nisolone resistance. We identified an impaired regulation of RAS-RAF-MEK, STAT6 
and c-Met protein phosphorylation levels in prednisolone resistant leukemic cells. 
In addition, a high frequency of Ras-pathway activating mutations was found. 
Prednisolone combined with a MeK inhibitor (trametinib) eradicated almost all 
prednisolone resistant Ras-mutated primary patients’ leukemic cells.
the work presented in this thesis is discussed supplemented with perspectives 
for future studies in Chapter 6 and summarized in Chapter 7 (in english and in 
Dutch).
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aBstRaCt
In vitro and in vivo resistance to prednisolone are predictive for an adverse 
prognosis in pediatric precursor-B acute lymphoblastic leukemia. Causes of 
resistance are still poorly understood. In this study, we observed that pred-
nisolone exposure of prednisolone-sensitive patients’ leukemic cells decreased 
anti-apoptotic MCL1 protein levels by 2.9-fold, while MCL1 protein expression in 
prednisolone-resistant leukemic patients’ cells was unaffected (p<0.01). Locked 
nucleic acid oligonucleotides directed against MCL1 reduced MCL1 protein 
levels by 82±16% (p<0.05) in leukemic cells, decreased proliferation by 9-fold and 
sensitized to prednisolone up to 80.8-fold, compared to a non-silencing-control 
locked nucleic acid (p<0.05). Remarkably, we discovered that MCL1-silencing 
upregulated the glucose consumption of leukemic cells by 2.5-fold (p<0.05), 
suggesting a potential rescue mechanism mediated by glycolysis. targeting gly-
colysis by 2-deoxyglucose synergistically inhibited leukemic survival by 23.2-fold 
in MCL1-silenced cells (p<0.05). Moreover, 2-deoxyglucose and MCL1 locked 
nucleic acid concomitantly sensitized leukemic cells to prednisolone compared 
to MCL1 locked nucleic acid or 2-deoxyglucose alone (p<0.05). In conclusion, 
these results indicate the need to target both MCL1 and glycolysis simultane-
ously to inhibit leukemic survival and sensitize acute leukemia patients towards 
prednisolone.
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IntRODuCtIOn
acute lymphoblastic leukemia (aLL) is the most common cancer in children. 
although cure rates have greatly improved over recent years, treatment is 
still ineffective in 20% of patients. unsuccessful treatment can be ascribed to 
resistance of primary leukemic cells to antileukemic drugs 1. Poor prognosis is 
particularly associated with resistance to prednisolone in childhood aLL, both 
in vivo and in vitro 2. to increase current survival rates it is therefore necessary to 
overcome prednisolone resistance.
to identify therapeutic targets to overcome prednisolone resistance, we 
previously performed microarray analysis on primary precursor-B acute lympho-
blastic leukemia (BCP-aLL) cells of pediatric patients 3. this indicated a role in 
prednisolone resistance for MCL1, an anti-apoptotic member of the BCL2 family 
that is frequently overexpressed in a variety of cancers and that contributes to 
cancer cell survival and apoptosis resistance 4,5. functional studies revealed that 
silencing of MCL1 sensitized leukemic cells to prednisolone 6,7.
In addition, we and others discovered that glycolysis is increased in predniso-
lone-resistant leukemic cells 8,9. Microarray analysis on primary BCP-aLL cells of 
pediatric patients indicated an increased expression of several glycolytic en-
zymes and glucose transporters in prednisolone resistant patients 3. furthermore, 
2-deoxyglucose (2-DG), an inhibitor of glycolysis, sensitized both leukemic cell 
lines and patients’ aLL cells to prednisolone 8,9.
for three reasons, we now hypothesize that anti-apoptosis sustained by MCL1, 
and glycolysis are linked processes and concomitantly induce drug resistance 
in leukemia.1) Cellular respiration and apoptosis are closely related survival 
pathways both associated with prednisolone resistance 6–9, and other targeted 
molecular leukemia therapies, such as imatinib 10. 2) Increased glucose metabo-
lism has been directly linked to MCL1 stabilization and attenuation of apoptosis 
11,12, and 3) BCL2 family members can, besides their apoptotic function, adjust 
oxidative phosphorylation 13,14.
In the present study, we show that silencing of MCL1 by specifically designed 
locked nucleid acid antisense oligonucleotides against MCL1 mRna (MCL1 
Lna) inhibited cell survival and sensitized to prednisolone in both BCP-aLL and t-
aLL leukemic cells. Moreover, we discovered higher glucose consumption in aLL 
cells after MCL1 silencing by both shMCL1 and MCL1 Lnas. Most importantly, we 
demonstrate that 2-DG treatment of MCL1-silenced cells decreased glucose 
consumption and synergistically reduced leukemic survival. Moreover, MCL1 
Lna and 2-DG concomitantly reversed prednisolone resistance in leukemic 
cells. these data provide evidence that MCL1 and glycolysis should be targeted 
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simultaneously to effectively inhibit leukemic survival and to reverse predniso-
lone resistance in aLL.
MethODs
Cell culture and primary cells
Leukemic cells from children with newly diagnosed aLL were isolated from 
bone marrow aspirates and prednisolone resistance was assessed, as previ-
ously described 1,3. Informed consent was given by patients as approved by the 
local institutional review board. Only samples with ≥ 90% leukemic cells upon 
processing were used in the present study. Reh, 697, sem, Jurkat, Loucy and 
heK293t cells were obtained from DMsz. the leukemic cell lines were cultured in 
RPMI+Glutamax (Gibco) and heK293t cells in DMeM+Glutamax (Gibco) at 37°C 
in humidified air containing 5% CO2. Medium was supplemented with 100 Iu/ml 
penicillin, 100 µg/ml streptomycin (Gibco), 0.125 µg/ml fungizone (Gibco), and 
10% fetal Calf serum (Integro). Reh, 697 and sem are BCP-aLL cell lines with an 
ETV6-RUNX1+, E2A-PBX1+, MLL-AF4+ translocation respectively. Jurkat is a mature 
tetraploid t-aLL cell line and Loucy is an immature early t-cell precursor (etP-aLL) 
cell line. all cell lines were tested for their resistance to prednisolone. heK293t, a 
human embryonal kidney cell line, was used for the production of viral particles. 
Cell viability and cell count were determined by a trypan blue exclusion staining 
assay and analyzed by MaCsQuant.
lna transfection and 2-deoxyglucose treatment
Cell lines were cultured in the presence of either 10 µM locked nucleotide acid 
oligonucleotides directed against MCL1 (MCL1 Lna), i.e. sPC4120 (MCL1 Lna-
a), sPC4342 (MCL1 Lna-b), sPC4343 (MCL1 Lna-c), or a non-silencing control 
oligonucleotide Lna, i.e. sPC3088. twenty-four hours after Lna transfection, cells 
were cultured with and without 0.5 mM 2-deoxyglucose (sigma). supplemental 
figure 1a-B illustrates that 0.5 mM 2-deoxyglucose hampers cell count only 
modestly, while it has a quantifiable effect on glucose consumption. After 96 
hours, culture medium was replaced by fresh medium containing fresh Lna +/- 
2-DG.
apoptosis measurement
annexinv/PI double positive and annexinv single positive cells were measured 
on the BD FACS Calibur flow cytometer. 0.2*106 cells were incubated for 15 
minutes in 200µl annexinv binding buffer (Molecular probes) containing 2 µg/
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ml propidium iodide (Molecular probes) and 1:1000 annexinv alexa fluor® 633 
(Molecular probes).
Quantitative RT-PCR
MCL1 mRNA levels were quantified by incorporation of SYBR Green (Thermo 
Scientific) by quantitative real-time PCR (Applied Biosystems 7900HT). Primers 
for MCL1 were; 5’-GGaGGaGGaCGaGttGtaC-3’ (forward) and 5’-aaG GCa 
CCa aaa Gaa atG-3’ (reverse). Rna was extracted using a Rneasy minikit (Qia-
gen) according to the manufacturer’s protocol. cDna was synthesized from 1 
µg Rna by 8 Iu/µl MMLv (Promega), 20nM oligodt primers, 1µM random hexamer 
primers (Invitrogen), 200 µM dntPs and 1 Iu/µl Rnasin in MMLv-buffer (Promega). 
Primers used for the reference gene RPs20, were 5’-aaGGGCtGaGGatttttG-3’ 
(forward) and 5’-CGttGCGGCttGttaG-3’ (reverse).
Reverse Phase Protein array
Primary leukemic cells were cultured for 48h with 0 µg/ml, 1 µg/ml or 250 µg/ml 
prednisolone. Protein was isolated and lysates were spotted twice in triplicate 
on glass-backed nitrocellulose-coated array slides by the facility of Dr. e. f. 
Petricoin, George Mason university-Manassas usa. slides were stained with spe-
cific antibodies and incubated with a biotinylated secondary antibody. Slides 
were scanned using the novaRay scanner and protein levels were calculated 
relative to the total amount of protein per sample using Microvigene software. 
antibodies used were: MCL1 antibody (sigma hPa008455), Bcl-XL (Cell signaling 
2762), BCL-2 (Cell signaling 2872) and p53 (Cell signaling 9282).
Western blot and Immunoblotting
Cell pellets were lysed in lysis buffer supplemented with protease inhibitors, and 
protein concentration was quantified according to the BCA assay (Pierce). 
twenty micrograms of protein were used as input for western blot analysis us-
ing anti-MCL1 (sigma hPa008455), anti-BCL-2 (Cell signaling 2872), anti-β-actin 
(abcam ab6276), anti-Clathrin (santa Cruz sc12734), IRDye 800Cw-labeled 
anti-rabbit and IRDye 680Cw-labeled anti-mouse (Li-Cor IRDye). Protein levels 
were quantified using the Oddysey system.
In vitro MTT drug-resistance assay
Cytotoxicity of cells towards prednisolone (Bufa Pharmaceutical Products) were 
determined by the in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (Mtt) drug-resistance assay, as described previously 1.
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Glucose-consumption assay
Glucose levels were measured with the glucose assay kit (sigma, GaGO-20). 
Briefly, the supernatant of cultured cells was diluted 25 times in milliQ, supple-
mented with assay solvent containing Glucose Oxidase, Peroxidase and o-Dia-
nisidine and incubated for 30 minutes at 37°C. hereafter, 12n sulfuric acid was 
added and levels of the spectrophotometric end-product oxidized o-Dianisidine 
were measured at 540nm using the versamax (Molecular Devices). to calculate 
glucose consumption, values were compared with plain RPMI glucose levels 
and corrected for cell growth.
synergistic effect
synergistic effects were calculated from equi-effective drug concentrations 
by the equitation postulated by Berenbaum15 [Drug a in combination with B] / 
[Drug a alone] + [Drug B in combination with a]/[Drug B alone]. a synergy factor 
(fsyn) <1 indicates synergy, whereas a fsyn of 1 indicates additivity and a fsyn 
>1 points to antagonism between two drugs.
statistical analyses
Prednisolone exposure effects within either prednisolone resistant or sensitive 
patients was analyzed with a Kruskall-wallis test. a Mann-whitney u test was 
used to compare resistant to sensitive patients. the Mann-whitney u test was 
also applied to analyze the effects of shMCL1. MCL1 Lna experiments were 
compared with a T test. p<0.05 was considered statistically significant.
lentiviral production and infection
Lentiviral helper vectors pRsv-Rev (addgene plasmid 12253), pMDLg/pRRe 
(addgene plasmid 12251), pMD2.G (addgene plasmid 12259) and psPaX2 
(addgene plasmid 12260) were provided by Prof. D. trono (Geneva, switzerland). 
pLKO.1 Mission short hairpin Rna (shRna) vectors were purchased from sigma-
aldrich, i.e. shC005 against eGfP, and tRCn0000005518 and tRCn0000197024 
against MCL1. Infections were performed as follow; 70-80% confluent HEK293T 
cells were transfected with shMCL1, pMD2.G and psPaX2 complemented with 
CaCl2 and hePes-buffered saline in the presence of 25 µM chloroquine (sigma). 
Virus-containing supernatant was collected, filtered 0.45μm, and concentrated 
by ultracentrifugation at 32,000rpm, 1hr, 4°C. viral titers were determined 
with a hIv-1 p24 antigen eLIsa kit according to the manufacturer’s protocol 
(zeptoMetrix). Infection occurred during 45’ 1800 rpm spin-oculation of 0.5*106 
cells/ml with 2.5 tu/cell viral particles and 5 µg/ml polybrene (sigma-aldrich). 
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after 24h, infected cells were selected in 0.5 µg/ml in the case of 697 and Loucy, 
1 µg/ml for Reh and sem, and 2 µg/ml puromycin for Jurkat.
ResuLts
Downregulation of MCl1 by prednisolone is impaired in prednisolone 
resistant leukemic cells of patients.
Glucocorticoids are known to induce apoptosis by downregulation of anti-
apoptotic BCL-2 family members independent of p53 16,17. we analyzed protein 
expression of BCL-2 family members and p53 in three prednisolone sensitive 
and three resistant primary patient samples after exposure to prednisolone for 
48h (figure 1 and supplemental figure 2a-D). after in vitro prednisolone expo-
sure, the expression of MCL1 in leukemic cells of in vitro prednisolone sensitive 
pediatric ALL patients significantly decreased by 2.9-fold (p<0.01). Whereas, in 
prednisolone resistant aLL patient cells, these levels did not change upon pred-
nisolone exposure. Prednisolone did not affect the expression levels of BCL-XL 
, BCL2 nor p53 (figure 1 and supplemental figure 2a-D). a similar decrease in 
MCL1 but not in BCL2 was seen using an extended dilution series of prednisolone 
(supplemental figure 2e).
MCl1 is a potent target to inhibit leukemic survival and to sensitize to 
prednisolone in pediatric all.
three different newly-developed Lna oligonucleotides directed against MCL1 
were up to 90% effective in silencing MCL1 in five distinct leukemic BCP-ALL 
and t-aLL cell lines, i.e. MLL-AF4+ BCP-aLL (seM), ETV6-RUNX1+ BCP-aLL (Reh), 
E2A-PBX1+ BCP-aLL (697), etP-aLL (Loucy) and tetraploid t-aLL (Jurkat) cells 
(p<0.01 supplemental figure 3 and 4). MCL1 Lna-b provided the most potent 
and reproducible knockdown of these three MCL1 Lnas. Knockdown achieved 
by the three MCL1 Lnas was comparable to the knockdown obtained after 
stable lentiviral transduction of two short hairpin Rna directed against MCL1, 
i.e. shMCL1a and -b (p<0.05; supplemental figure 5). the MCL1 Lnas inhibited 
leukemic survival up to 90%, increased apoptosis up to 60% and sensitized to 
prednisolone up to 80.8-fold in five distinct leukemic cell lines, all compared to a 
non-silencing Lna control (p<0.05; supplemental figure 6, 7 and 8). these MCL1 
Lna results were comparable to shMCL1 results (supplemental figure 9) and 
indicates that targeting MCL1 may be clinically important.
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figure 1. Downregulation of MCl1 by prednisolone is impaired in prednisolone resistant 
leukemic cells of patients.
Leukemic cells of three in vitro prednisolone sensitive and three in vitro prednisolone resistant patients, 
were exposed in vitro for 48 hours with 0 µg/ml, 1 µg/ml or 250 µg/ml prednisolone. Protein expression 
levels of MCL1, BCL-XL, BCL-2 and p53 were analyzed by reverse phase protein array. Bar indicates the 
mean plus seM of three independent patient samples. (a Kruskal-wallis test was used to compare 0, 1, 
250 µg/ml data points indicated by 0--0 and a Mann-whitney u test was used to compare data between 
sensitive and resistant patients indicated by |--| *p<0.05, **p<0.01). a.u. arbitrary units.
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figure 2. MCl1-silenced cells upregulate glycolysis, which can be reduced by 2-DG.
Glucose consumption of MLL-AF4+ BCP-aLL, ETV6-RUNX1+ BCP-aLL, E2A-PBX1+ BCP-aLL, etP-aLL and 
tetraploid t-aLL cell line after treatment with MCL1 Lna-b and/or a non-silencing control Lna (nsC) 
with or without 0.5mM 2-DG was examined with a glucose consumption assay. to calculate glucose 
consumption, values were compared with glucose levels in plain RPMI medium and corrected for cell 
growth. Data are presented as means plus seM of three (ETV6-RUNX1+ BCP-aLL and tetraploid t-aLL) or 
two independent experiments ( *p<0.05, **p<0.01, ***p<0.001).
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MCl1-silenced cells upregulate glycolysis. Targeting glycolysis in MCl1 
silenced cells synergistically inhibits leukemic survival and concomi-
tantly reverses prednisolone resistance.
to test our hypothesis that MCL1 and glycolysis cooperate in prednisolone resis-
tance, we examined the consumption of glucose in five distinct MCL1 silenced 
cell lines. A significant increase in glucose consumption, on average 149%, 
was observed upon MCL1 silencing by MCL1 Lna (p<0.01 MCL1 Lna-b figure 
2 and MCL1 Lna-a and Lna-c supplemental figure 10) and by shMCL1 (p<0.01 
supplemental figure 11), compared to non-silencing Lna controls.
This finding suggested that MCL1 silenced cells might increase their glycolysis 
to rescue from apoptosis. this prompted us to investigate the effect of targeting 
both MCL1 and glycolysis on leukemic cell survival and prednisolone cytotoxicity. 
Co-exposure of MCL1 LNA and 2-DG significantly reduced glucose consump-
tion (p<0.05 MCL1 Lna-b figure 2 , MCL1 Lna-a and MCL1 Lna-c supplemental 
figure 10). In all cell lines, cotreatment of cells with MCL1 Lna and 2-DG syner-
gistically inhibited leukemic cell survival by 30%-75%, compared to MCL1 Lna or 
2-DG alone, except in the tetraploid t-aLL (p<0.05, fsyn <1, figure 3 Panel a and 
supplemental figure 12). furthermore, the addition of prednisolone decreased 
leukemic survival even more (p<0.05 figure 3 Panel B and supplemental figure 
13). Incubation of leukemic cells with both MCL1 Lna and 2-DG concomitantly, 
albeit moderately, sensitized to prednisolone up to 1.48-fold compared to MCL1 
Lna or 2-DG alone (p<0.05; figure 3 Panel C and supplemental figure 14).
the synergism of MCL1 Lnab, 2-DG and prednisolone was best visible in the 
intermediate responsive cells, i.e. MLL-AF4+, ETV6-RUNX1+ and etP-aLL cell line, 
since the sensitive E2A-PBX1+ cell line was already prone to die by monotherapy 
alone and the highly resistant tetraploid cell line will most likely need higher 
figure 3. MCl1 silencing together with glycolysis inhibition synergistically inhibits leukemic cell survival 
and concomitantly sensitizes to prednisolone.
Panel a: Leukemic cell survival of a MLL-AF4+ BCP-aLL, ETV6-RUNX1+ BCP-aLL, E2A-PBX1+ BCP-aLL, etP-
aLL and tetraploid t-aLL cell line after treatment with MCL1 Lna-b and/or 0.5mM 2-DG for 168 hours, 
compared to non-silencing control Lna (nsC, set at 100%). Data are presented as means plus seM of 
three (ETV6-RUNX1+ BCP-aLL and tetraploid t-aLL) or two independent experiments (*p<0.05, **p<0.01, 
***p<0.001). fsyn represents the synergy factor, where <1 indicates synergy.
Panel B: Leukemic cell survival after prednisolone exposure for three days, i.e. 96 till 168 hours after start 
of MCL1 Lna-b and/or 0.5mM 2-DG in equivalent cell lines as in panel a. Data were compared to a non-
silencing control Lna (nsC) without prednisolone (see also panel a, set to 100%), to visualize the total 
effect on cell survival after prednisolone. Data are presented as means plus seM of three (ETV6-RUNX1+ 
BCP-aLL and tetraploid t-aLL) or two independent experiments (*p<0.05, **p<0.01, ***p<0.001).
Panel C: sensitivity of leukemic cells to prednisolone was measured in a 3-day Mtt assay from t96 to 
t168 after treatment with MCL1 Lna-b and/or a non-silencing control Lna (nsC) with or without 0.5mM 
2-DG. Cell survival depicted on the Y-axis was corrected for cell death induced by MCL1 knockdown and 
0.5mM 2-DG itself in the absence of prednisolone, to visualize the absolute prednisolone effects. Data are 
presented as means plus seM of three (ETV6-RUNX1+ BCP-aLL and tetraploid t-aLL) or two independent 
experiments (*p<0.05, **p<0.01, ***p<0.001).
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figure 3
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amounts of the drugs to demonstrate an effect. Overall, these data indicate 
that MCL1-silenced cells upregulate glycolysis and that targeting glycolysis in 
MCL1 silenced cells synergistically inhibits leukemic survival and concomitantly 
reverses prednisolone resistance.
DIsCussIOn
Prednisolone is the spearhead drug used in multi-drug treatment of aLL. not only 
is the in vivo and in vitro response to prednisolone a strong prognostic factor for 
long-term clinical outcome 2, relapsed aLL patients also acquire prednisolone 
resistance disproportionately to other anti-leukemic agents 18. to date, various 
mechanisms that sensitize leukemic cells in vitro to prednisolone have been 
described, including inhibition of the prednisolone interconverter 11β-hsD, 
knockdown of the glucocorticoid-dependent transcription regulator sMaRCa4, 
inhibition of the voltage-dependent channel heRG1, which signals to eRK/PI3K/
akt survival pathways, knockdown of the calcium scavengers s100a8/s100a9, 
downregulation of anti-apoptotic MCL1, upregulation of pro-apoptotic BIM, 
and inhibition of glycolysis 6,8,9,19–22. sensitizing cells to prednisolone may therefore 
require a multifactorial approach. In this study, we provide evidence that reduc-
tion of MCL1 levels and inhibition of glycolysis synergistically inhibits leukemic 
survival and concomitantly sensitizes to prednisolone in aLL cells.
Downregulation of anti-apoptotic BCL-2 family members is hampered in pred-
nisolone resistant cells 16. In the present study, we observed that prednisolone 
exposure decreased the expression of the anti-apoptotic MCL1 in leukemic 
cells of sensitive patients, whereas that of resistant cells remained unchanged. 
Prednisolone did not affect the expression of other BCL-2 family members (BCL-
XL and BCL-2) nor p53. In line with this are microarray data on primary BCP-aLL, 
which identified higher anti-apoptotic MCL1 expression in prednisolone-resistant 
cells, but not higher Bcl-XL, BCL-2 or p53 expression 3. we observed that silencing 
of MCL1 expression by two means, shMCL1 and MCL1 Lna, induced apoptosis 
and sensitized to prednisolone in BCP-aLL and t-aLL cell lines. this is consistent 
with previous findings in other leukemic cell lines that demonstrated prednisolone 
sensitization after direct knockdown of MCL1 by shMCL1 or indirect downregula-
tion of MCL1 via inhibition of mtOR 6,7. another study reported that disruption 
of the complex between beclin-1 and MCL1 by obatoclax and exposure to 
dexamethasone activated autophagy-dependent cell-death in otherwise 
dexamethasone-resistant cells 23. however, inhibition of autophagy only slightly 
induced resistance to dexamethasone, implying direct anti-apoptotic effects 
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as well 23. Overall, these data indicate MCL1 as a potent therapeutic target 
to convert glucocorticoid resistance. however, high expression of MCL1 is not 
predictive for an adverse clinical outcome, suggesting that additional mecha-
nisms co-occur that induce prednisolone resistance in pediatric aLL 6. here, 
we observed that targeting MCL1 forces the glycolysis route thereby rescuing 
cells from prednisolone-induced apoptosis. It has been shown that BCL2 family 
members maintain the mitochondrial membrane potential by regulating the 
permeability transition pore and the atP/aDP pump, both involved in oxida-
tive phosphorylation 13,14. Knockdown of MCL1 may therefore impair oxidative 
phosphorylation, forcing cells to produce atP by glycolysis to ensure survival. this 
hypothesis is supported by our observation that treatment of leukemic cells with 
azide, a known inhibitor of oxidative phosphorylation, also increases glucose 
consumption (supplemental figure 15). furthermore, an MCL1 amino-terminally 
truncated isoform was recently discovered that facilitates atP production, respi-
ration and maintenance of oligomeric atP synthase in the mitochondria 24. Our 
three MCL1 Lnas all target the 3’ utR of MCL1 and therefore also diminish this 
truncated MCL1 isoform. furthermore, the glycolysis and apoptotic pathways 
may be connected via activity of the BCL2 family member BaD. the phosphory-
lation of aminoacid s112 in the Bh3 domain of BaD acts like a switch between 
the metabolic and pro-apoptotic functions ascribed to BaD. BaD resides in a 
mitochondrial complex together with glucokinase and contributes to the activ-
ity of this glucose-metabolizing enzyme 25. Glucokinase mediates the first step in 
glycolysis by converting glucose into glucose-6-phosphate. although it has been 
shown that MCL1 does not bind BaD directly 26, silencing of MCL1 may indirectly 
induce BaD activity and/or may trigger glycolysis in a similar way as the BaD/
glucokinase complex. as a net result the glycolytic rate (and hence glucose 
consumption) will increase and this may provide a rescue mechanism against 
prednisolone-induced cell death. this speculative functional explanation yet 
awaits further studies. Our study showed that inhibition of both glycolysis and 
MCL1 synergistically inhibit leukemic cell survival and concomitantly sensitizes 
leukemic cells to prednisolone. these results indicate the need to target both 
pathways and suggest that targeting MCL1 as a single target may not yield 
the desired clinical effect. we previously demonstrated that aLL cells increase 
glucose consumption to prevent prednisolone-induced apoptosis 8. Glucocorti-
coids inhibit intracellular glucose uptake by regulating the expression of glucose 
transmembrane transporter (GLut) 27–29. Dexamethasone decreases GLut-1 
expression in aLL cells thereby decreasing glycolysis and inducing apoptosis 30. 
we observed higher expression of GLut-1 in prednisolone resistant aLL patients 3. 
tXnIP, a negative regulator of glucose uptake 30 is correlated to GLut-1 expres-
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sion 31 and was also found upregulated after prednisolone treatment in sensitive 
patients.32 further studies are needed to demonstrate whether tXnIP and GLut-1 
facilitate the higher glucose metabolism observed after MCL1 knockdown.
Our results suggest that treatment with MCL1 Lna antisense and 2-DG repre-
sent a promising approach to decrease leukemic cell survival and to sensitize 
aLL patients to prednisolone. Lna antisense may offer a more direct and spe-
cific way of silencing MCL1 than the current BCL-2 family inhibitors R-(-)-gossypol 
(at101) and obatoclax (GX‐15‐070), 33,34 which recently entered clinical phase I/
II trials. Both inhibitors can block several members of the BCL-2 family, increasing 
the chance of side-effects in clinical practice. In contrast, LNA antisense specifi-
cally target the mRna expression of one gene. we have shown in this study that 
MCL1 Lna effectively silences MCL1 mRna and protein expression in aLL cells, 
comparable to knockdown with the more stable shMCL1. notably, no delivery 
vehicles were necessary to ensure uptake of MCL1 Lna antisense molecules 
by the aLL cells. Moreover, Lna’s are conformationally structured to prevent 
most of the current hurdles in siRna treatment, such as delivery, stability of the 
Rna molecules in circulation, strand bias and off-target effects 35. Lna antisense 
molecules are currently investigated in phase I early clinical trials for three different 
target genes: ezn-3042, an inhibitor of survivin is being investigated in children 
with relapsed aLL (www. Clinicaltrials.gov, nCt01186328); ezn-4176, which tar-
gets the androgen receptor, is being studied in adults with castration-resistant 
prostate cancer (nCt01337518); and ezn-2968, an hIf-1a-inhibitor, is being ex-
amined in advanced solid tumours and lymphoma (nCt00466583). we here pro-
vide functional in vitro proof that MCL1 Lna antisense molecules are effective in 
inhibiting leukemic cell survival and reversing prednisolone resistance and may 
offer merits to further investigate these MCL1-Lnas in clinical trials. however, as 
our data show that silencing of MCL1 increases glycolysis of cells, neither MCL1 
Lna nor Bh3 mimetics should be used as single agents. we have shown that this 
shift in energy metabolism can be exploited to concomitantly sensitize leukemic 
cells to prednisolone. 2DG may be a candidate agent since it has therapeutic 
potential and is proven to cause chemosensitisation in acute leukemia 8, breast 
cancer 36, and prostate cancer cells 37, and is now used in phase I clinical trials 
(www.Clinicaltrials.gov, nCt00096707).
In conclusion, MCL1 is a potent target to therapeutically inhibit leukemic 
survival and to reverse drug resistance in pediatric aLL. however, MCL1-silenced 
cells upregulate glycolysis, which may rescue cells from prednisolone-induced 
apoptosis. these data therefore provide evidence for concomitant causes 
of survival and resistance, and indicate that MCL1 and glycolysis should be 
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targeted simultaneously to reduce leukemic cell survival and prednisolone 
resistance in aLL.
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Supplemental Figure 1.  
The effect of 2DG on glucose consumption and proliferation.  
(A) Absolute glucose levels in the supernatant of ETV6-RUNX1+ BCP-ALL (REH) cells were measured with a 
glucose assay. RPMI control represents the amount of glucose present in culture medium incubated for 96 
hours in the absence of 2DG. Cells cultured without 2DG have consumed >90% of the glucose present in RPMI 
culture medium after 96 hrs. Exposure to increasing concentrations of 2DG reduces the amount of glucose 
that is being consumed. In cells treated with 2mM 2DG the glucose levels are virtually unaffected compared 
to RPMI control medium, indicating that no glucose has been consumed. (B) ETV6-RUNX1+ BCP-ALL (REH) cells 
were counted by a trypan blue exclusion assay after exposure to 2DG for 96 hours. Glucose consumption (A) 
and cell viability (B) are correlated. 
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Supplemental Figure 2.  
Downregulation of MCL1 by prednisolone is impaired in 
prednisolone resistant leukemic cells of patients. 
(A-D) Individual MCL1 and BCL-2 expression levels after 
prednisolone exposure of prednisolone sensitive and 
resistant patients cells indicated in Figure 1. (E) MCL1 
and BCL-2 western blot analysis of one sensitive patient 
and one resistant pediatric BCP-ALL patient´s cells after 
in vitro exposure for 48 hours with 0, 10, 100 or 250 
µg/ml prednisolone. Clathrin was used as loading 
control. 
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Supplemental Figure 3.  
LNA antisense directed against MCL1 efficiently 
silence the expression of MCL1 mRNA. MCL1 
mRNA expression was measured after treatment 
with three different LNA antisense molecules 
against MCL1, i.e. MCL1 LNA-a , MCL1 LNA-b and 
MCL1 LNA-c in five distinct leukemic cell lines . 
Values were adjusted for expression of the 
housekeeping gene RPS20 and are relative to the 
non-silencing control (NSC). Data are presented 
as means plus SEM of three (ETV6-RUNX1+ BCP-
ALL and tetraploid T-ALL) or two independent 
experiments  ( *p<0.05, **p<0.01, ***p<0.001). 
Loucy: ETP-ALL 
697: E2A-PBX1+  BCP-ALL  
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LNA antisense directed against MCL1 efficiently 
silence the expression of MCL1 mRNA. MCL1 
mRNA expression was measured after treatment 
with three different LNA antisense molecules 
against MCL1, i.e. MCL1 LNA-a , MCL1 LNA-b and 
MCL1 LNA-c in five distinct leukemic cell lines . 
Values were adjusted for expression of the 
housekeeping gene RPS20 and are relative to the 
non-silencing control (NSC). Data are presented 
as means plus SEM of three (ETV6-RUNX1+ BCP-
ALL and tetraploid T-ALL) or two independent 
experiments  ( *p<0.05, **p<0.01, ***p<0.001). 
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LNA antisense directed against MCL1 efficiently 
silence the expression of MCL1 mRNA. MCL1 
mRNA expression was measured after treatment 
with three different LNA antisense molecules 
against MCL1, i.e. MCL1 LNA-a , MCL1 LNA-b and 
MCL1 LNA-c in five distinct leukemic cell lines . 
Values were adjusted for expression of the 
housekeeping gene RPS20 and are relative to the 
non-silencing control (NSC). Data are presented 
as means plus SEM of three (ETV6-RUNX1+ BCP-
ALL and tetraploid T-ALL) or two independent 
experiments  ( *p<0.05, **p<0.01, ***p<0.001). 
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Supplemental Figure 4. 
Supplemental Figure 4.  
LNA antisense directed against MCL1 efficiently silence the expression of MCL1 protein. Protein 
expression of MCL1 was assessed at t168 with Western blot after LNA treatment. MCL1 protein 
expression was calculated with the Odyssey software, corrected for β-actin and is relative to the NSC. A 
representative Western blot for a BCP-ALL cell line, i.e. REH a ETV6-RUNX1+ BCP-ALL cell line and a T-ALL, 
i.e. Jurkat a Tetraploid T-ALL cell line is illustrated. Data are presented as mean plus SEM of three 
independent experiments (*p<0.05, **p<0.01). 
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Supplemental Figure 5. 
Supplemental Figure 5.  
Short hairpins directed against MCL1 efficiently silence the expression of MCL1.  
MCL1 mRNA expression in ETV6-RUNX1+ BCP-ALL cell line and Tetraploid T-ALL cell line was measured after 
lentiviral knockdown of MCL1 with two different constructs, i.e. shMCL1-a and shMCL1-b. Values were 
adjusted for expression of the housekeeping gene RPS20 and are relative to the non-silencing control (NSC). 
Protein expression of MCL1 was assessed with Western blot after lentiviral knockdown. MCL1 protein 
expression was calculated with the Odyssey software, corrected for β-actin and is relative to the NSC. A 
representative Western blot is illustrated.  Data are presented as mean plus SEM of three independent 
experiments (*p<0.05, **p<0.01). 
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Supplemental Figure 6. 
Supplemental Figure 6.  
Knockdown of MCL1 by MCL1 LNA inhibits 
leukemic survival.  
The effect of MCL1 knockdown by MCL1 LNA 
on cell viability and cell count of five distinct 
leukemic cell lines was determined with a 
trypan blue exclusion assay and analyzed 
with the MACSQuant. Data are presented as 
mean plus SEM of  three (ETV6-RUNX1+ BCP-
ALL and Tetraploid T-ALL) or two 
independent experiments (*p<0.05, 
**p<0.01). 
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Supplemental Figure 7. 
BCP-ALL cell line T-ALL cell line 
Supplemental Figure 7.  
Knockdown of MCL1 by MCL1 LNA increases apoptosis. MCL1 knockdown-induced apoptosis in a 
representative BCP-ALL cell line, i.e. Reh an ETV6-RUNX1+ BCP-ALL cell line and a T-ALL cell line, i.e. Jurkat a 
Tetraploid T-ALL, was assessed on a flowcytometer using an AnnexinV/PI staining. The percentage of 
apoptotic cells was calculated using the quadrant method. Data are presented as means plus SEM of three 
independent experiments (*p<0.05). 
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Supplemental Figure 8.  
Knockdown of MCL1 by MCL1 LNA sensitizes 
towards prednisolone. Sensitivity to prednisolone 
after MCL1 knockdown by MCL1 LNA was measured 
in a 3-day MTT assay. Sensitivity was corrected for 
cell death induced by MCL1 knockdown itself in the 
absence of prednisolone. Data are presented as 
mean plus SEM of three (ETV6-RUNX1+ and 
Tetraploid) or two independent experiments 
(*p<0.05, **p<0.01). 
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Supplemental Figure 9. 
Supplemental Figure 9.  
Knockdown of MCL1 by shMCL1 inhibits leukemic survival, increases apoptosis and sensitizes towards 
prednisolone. The effect of MCL1 knockdown by shMCL1 on cell viability and cell count of ETV6-RUNX1+ BCP-ALL 
cells and T-ALL cells was determined with a trypan blue exclusion assay and analyzed with the MACSQuant. MCL1 
knockdown-induced apoptosis in a BCP-ALL and T-ALL cell line was assessed on a flowcytometer using an 
AnnexinV/PI staining. The percentage of apoptotic cells was calculated using the quadrant method. Sensitivity to 
prednisolone after MCL1 knockdown was measured in a 3-day MTT assay. Sensitivity was corrected for cell death 
induced by MCL1 knockdown itself in the absence of prednisolone. Data are presented as mean plus  SEM of three 
independent experiments (*p<0.05, **p<0.01). 
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Supplemental Figure 10. 
Supplemental Figure 10.  
MCL1-silenced cells by MCL1 LNA upregulate 
glycolysis. Glucose consumption of five 
distinct leukemic cell lines after MCL1 
knockdown by MCL1-LNAs was examined with 
a glucose assay. To calculate glucose 
consumption, values were compared with 
glucose levels in plain RPMI medium and 
corrected for cell growth. Data are presented 
as means plus SEM of three (ETV6-RUNX1+ and 
Tetraploid) or two independent experiments  
 ( *p<0.05, **p<0.01, ***<0,001).        
                                              
     MCL1 LNA compared to NSC.  
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Supplemental Figure 11. 
Supplemental Figure 11.  
MCL1-silenced cells by shMCL1 upregulate glycolysis. Glucose consumption of a MCL1-silenced ETV6-
RUNX1+ BCP-ALL cell line and a tetraploid T-ALL cell line by shMCL1 was examined with a glucose assay. To 
calculate glucose consumption, values were compared with glucose levels in plain RPMI medium and 
corrected for cell growth. Data are presented as means plus SEM of three independent experiments  ( 
*p<0.05, **p<0.01). Off note, shMCL1-a is the only construct that targets exon 2 of MCL1, in contrast to 
shMCL1-b, LNA-a, LNA-b and LNA-c which are directed against exon 3. It may be that targeting exon 2 
containing MCL1 transcripts does not affect glycolysis and/or that interference with exon 3 is more 
important for a functional effect on glycolysis.  
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Supplemental Figure 12. 
Supplemental Figure 12. 
MCL1 silencing and glycolysis inhibition 
synergistically inhibits leukemic cell survival. 
Leukemic cell survival of  five distinct leukemic cell 
lines after treatment with either MCL1 LNA alone or 
in combination with 0.5mM 2-DG  was determined 
with a trypan blue exclusion assay and analyzed with 
the MACSQuant. Data are presented as means plus 
SEM of three (ETV6-RUNX1+ and Tetraploid) or two 
independent experiments (*p<0.05, ** p<0.01,). 
Fsyn represents  the synergy factor, where Fsyn<1 is 
synergistic. 
Le
uk
em
ic
 c
el
l s
ur
vi
va
l t
16
8 
(%
) 
14
57
th
e sYn
eR
G
Y O
f M
C
L1 a
n
D
 G
LYC
O
LYsIs In
 a
LL
2
0
25
50
75
100
125
150
** * *
ns
 ns
MCL1
LNA-a
MCL1
LNA-c
NSC NSC+0.5 mM 2DG
MCL1 LNA MCL1 LNA+0.5 mM 2DG
0.061 µg/ml  Prednisolone
0
25
50
75
100
125
150 **
MCL1
LNA-a
MCL1
LNA-c
NSC NSC+0.5 mM 2DG
MCL1 LNA-a MCL1 LNA+0.5 mM 2DG
*
*
*
*
0.061 µg/ml  Prednisolone
0
25
50
75
100
125
150 ** *
*
*
MCL1
LNA-a
MCL1
LNA-c
1677 µg/ml  Prednisolone
0
25
50
75
100
125
150
MCL1
LNA-a
MCL1
LNA-c
*
** * *
*
0.061 µg/ml  Prednisolone
Jurkat: Tetraploid T-ALL  
Loucy: ETP-ALL 
697: E2A-PBX1+  BCP-ALL  
SEM: MLL-AF4+  BCP-ALL  
Supplemental Figure 13. 
Supplemental Figure 13. 
MCL1 knockdown, glycolysis inhibition and prednisolone treatment concomitantly inhibit leukemic cell 
survival. Leukemic cell survival after 3-day, i.e. from t96 untill t168, prednisolone exposure of MLL-AF4+ BCP-
ALL, E2A-PBX1+ BCP-ALL, ETP-ALL and tetraploid T-ALL cells with either MCL1 LNA-b or 0.5mM 2-DG alone or in 
combination. Data were compared to NSC control without prednisolone, to visualize the total effect on cell 
survival of prednisolone, MCL LNA and 2-DG together. Data are presented as means plus SEM of three (ETV6-
RUNX1+ and Tetraploid) or two independent experiments (*p<0.05, **p<0.01).  
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Supplemental Figure 14. 
Supplemental Figure 14.  
MCL1 silencing together with glycolysis inhibition concomitantly reverses drug resistance. Sensitivity of distinct 
leukemic cell lines to prednisolone after treatment with mock LNA control, MCL1 LNA –a and LNA-b and 0.5mM 2-
DG alone or in combination was measured in a 3-day MTT assay. Sensitivity was corrected for cell death induced 
by MCL1 knockdown and 0.5mM 2-DG itself in the absence of prednisolone. Data are presented as means plus 
SEM of three or two independent experiments (*p<0.05, **p<0.01, ***p<0.001) 
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Supplemental Figure 15.  
Inhibition of oxidative phosphorylation by Azide augments glycolysis. 
Glucose consumption was calculated after treatment with a concentration range of Azide, an inhibitor of 
oxidative phosphorylation, relative to untreated ETV6-RUNX1+ BCP-ALL cells (REH), and corrected for cell 
growth. Data are presented as means plus SEM of two independent experiments  (*p<0.05). 
Supplemental Figure 15. 
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aBstRaCt
still 20% of pediatric precursor-B acute lymphoblastic leukemia (BCP-aLL) re-
lapse on or after current treatment strategies. treatment failure is associated 
with resistance to prednisolone. We aim to find new druggable targets that 
modulate prednisolone resistance. we generated microarray gene expression 
profiles of 256 pediatric ALL patient samples and identified a 3.4-fold increase in 
epithelial membrane protein 1 (EMP1) expression in in vitro prednisolone-resistant 
compared to -sensitive patients (p=0.003). eMP1-silencing in six BCP-aLL and 
t-aLL cell lines induced apoptosis and cell cycle arrest leading to 84.1±4.5% re-
duction in survival compared to non-silencing control transduced cells (shnsC) 
(p=0.014). Moreover, eMP1-silencing sensitized to prednisolone up to 8.8-fold 
(p<0.001). eMP1-silencing also abrogated migration and adhesion to mesen-
chymal stromal cells (MsCs) by 78.3±9.0% and 29.3±4.1% compared to shnsC 
(p<0.05). we discovered that eMP1 contributes to MsC-mediated prednisolone 
resistance. Pathway analysis indicated that eMP1 signals through the src kinase 
family. EMP1-high BCP-aLL patients showed a poorer 5-year event-free survival 
compared to EMP1-low patients (77±2% vs. 89±2%, p=0.003). Multivariate analy-
sis identified EMP1 as an independent predictor for poor outcome in BCP-aLL 
(p=0.004, hazard ratio:2.36(1.31-4.25). this study provides preclinical evidence 
that EMP1 is an interesting target to develop drugs for to optimize treatment of 
BCP-aLL.
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IntRODuCtIOn
survival rates of pediatric acute lymphoblastic leukemia (aLL), the most com-
mon pediatric cancer, have improved enormously over the past decades. 
however, still 20% of B-cell precursor aLL (BCP-aLL) and 25% of t-aLL patients 
relapse during or shortly after completion of contemporary treatment protocols 
for newly diagnosed pediatric aLL 1. Prednisolone is the spearhead drug used in 
multi-drug treatment of pediatric aLL and in vivo and in vitro response to pred-
nisolone predicts long-term clinical outcome 2. Moreover, relapsed aLL patients 
acquire prednisolone resistance disproportional to other anti-leukemic agents 3. 
It is therefore necessary to find new druggable targets to reverse prednisolone 
resistance.
Prednisolone, a glucocorticoid, diffuses passively into the cell, where it binds 
the glucocorticoid receptor (GR). Consequently, GR chaperone proteins are 
released whereafter GR dimers can be formed. Dimerized GR acts as a tran-
scription factor by either binding to positive or negative glucocorticoid response 
elements (GRe) in the Dna, or by binding to other transcription factors, such as 
nf-κB or aP-1 4. as a result a large number of genes are either turned on or off. 
Due to this complexity still little is known about the exact cause of resistance to 
glucocorticoids.
to examine the gene expression pattern that might cause prednisolone 
resistance in more detail, we performed microarray analysis of 256 children 
with newly diagnosed aLL that were tested in vitro to be either prednisolone 
sensitive, intermediate resistant or resistant. We identified epithelial membrane 
protein 1 (eMP1) as one of the most discriminative genes. eMP1 is a small hy-
drophobic four-transmembrane glycoprotein of 160 amino acids 5. eMP1 has 
been implicated as a cell junction protein at the plasma membrane 6,7, however 
little is known about the exact function. It has been shown to be involved in 
cell proliferation, is identified as a c-Myc target 8, is correlated to brain 9 and 
breast carcinogenesis 10, and was demonstrated to be a biomarker of gefitinib 
resistance in non-small lung carcinoma 11.
We are the first to identify a significant role for EMP1 in pediatric ALL. We have 
discovered that silencing of eMP1 inhibited leukemic survival, sensitized leukemic 
cells to prednisolone and abrogated migration and adhesion to mesenchymal 
stromal cells (MSCs). Moreover, we identified EMP1 as an independent predictor 
for poor outcome in BCP-aLL. taken together, these results point to eMP1 as 
a potential new druggable target to tackle leukemia and potentially increase 
current survival rates.
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MateRIaLs anD MethODs
Cell culture and Primary cells
Bone marrow and peripheral blood samples were collected from children al-
leged to suffer from newly diagnosed aLL and before start of initial therapy. nor-
mal bone marrow samples were obtained from children who were suspected 
for a malignancy but turned out to be negative for a hematological disorder. 
Informed consent was given by patients or parents/guidance to use excess of 
diagnostic material for research purposes as approved by the local institutional 
review board. Mononuclear cells were isolated by lymphoprep density gradient 
centrifugation, as previously described 12,13. Only samples with ≥90% leukemic 
blasts upon processing were used in the present study. the genetic subtype of 
each patient, i.e. hyperdiploid (>50 chromosomes), ETV6-RUNX1+, TCF3-PBX1+, 
MLL-rearrangement, BCR-ABL1+, BCR-ABL1-like, or B-other (negative for afore-
mentioned genomic lesions) was determined by means of fIsh, PCR and by 
utilizing the 110-probeset classifier 14. an Mtt-assay (see below for details) was 
used to select cases being either in vitro highly sensitive, intermediate resistant 
or highly resistant to prednisolone; 74, 60 and 42 of BCP-aLL cases and 27, 34 
and 19 t-aLL respectively, overall 256 samples. In total, data obtained from 373 
BCP-aLL and 116 t-aLL cases were included to study the prognostic value of 
eMP1 expression levels.
all leukemic cell lines and heK293t cells were obtained from DsMz. Reh, 697, 
naLM6 and seM are BCP-aLL cell lines with an ETV6-RUNX1, TCF3-PBX1, t(5;12) 
and an MLL-AF4 rearrangement, respectively. Jurkat is a tetraploid t-aLL and 
supt1 a t-lymphoblast cell line. all cell lines were resistant to prednisolone as 
determined by an Mts-assay. heK293t, a human embryonal kidney cell line, was 
used for the production of viral particles. hMsC-teRt cells are human mesenchy-
mal stromal cells modified with an increased telomerase activity and were a gift 
of Dr. D. Campana, st. Jude Childrens’ Research hospital, Memphis, usa 15. Cell 
viability and cell count were determined by a trypan blue exclusion staining 
assay and analyzed by MACSQuant flow cytometer (Miltenyi Biotec).
Microarrays
Rna was extracted by means of trizol isolation (Invitrogen) according to the 
manufacturer’s protocol and Rna quality and integrity determined with the 
2100 bioanalyzer (agilent). the affymetrix One-Cycle cDna synthesis kit and the 
GeneChip Ivt Labeling kit were used to synthesize cRna. Rna processing and 
hybridization to the affymetrix u133 Plus 2.0 GeneChip oligonucleotide microar-
ray were performed according to the manufacturer’s protocol. Gene-expression 
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values were calculated with affymetrix Microarray suite version 5.0. expression 
signals were scaled to the target intensity of 500 and log-transformed. Only ar-
rays with scaling factor <10 and GaPDh cRna integrity (3’/5’) <3 were used 
for subsequent analysis. all arrays were Robust Multichip average (RMa) and 
variance stabilization and normalization 2 (vsn2) normalized16 and differentially 
expressed genes between in vitro prednisolone resistant and prednisolone sensi-
tive patients were identified with Limma R Package taking along prednisolone 
intermediate patients and using subtype as a confounder in the statistical envi-
ronment R, version 2.15.0. Correction for multiple tests was performed according 
to the false discovery rate (fDR) method 17. all eMP1 probe sets were statistically 
differentially expressed between in vitro prednisolone sensitive and resistant pa-
tients. Probeset 201324_at was used for further analysis, as this probeset showed 
the most reliable differential expression between in vitro prednisolone sensitive 
and resistant BCP-aLL patients.
lentiviral production and Infection
pLKO.1 Mission short hairpin Rna (shRna) vectors were purchased from 
sigma-aldrich, i.e. a non-silencing control shC002 (shnsC) and tRCn0000117944 
against EMP1 (shEMP1). Lentiviral helper pMD2.G (addgene plasmid 12259) and 
psPaX2 (addgene plasmid 12260) were provided by Prof. D. trono (Geneva, 
switzerland). Infection occurred during 45’ 1800 rpm spin-oculation of 0.5x106 
cells/ml with 2.5 transducing units/cell (sigma). after 24h, infected cells were 
positively selected for puromycin resistance.
Quantitative RT-PCR
Rna was extracted using a Rneasy minikit (Qiagen) according to the manu-
facturer’s protocol, whereafter cDna was synthesized. EMP1 mRna levels were 
quantified by incorporation of SYBR Green (Thermo Scientific) by quantitative 
real-time PCR (applied Biosystems 7900ht). Primers for EMP1 were; 5’-ttGCtG-
GCtGGtatCttt-3’ (forward) and 5’-ttGaGGGCatCttCaCtG-3’ (reverse). 
Primers used for the reference gene RPS20, were 5’-aaGGGCtGaGGatttttG-3’ 
(forward) and 5’-CGttGCGGCttGttaG-3’ (reverse).
Protein isolation and Western blot analysis
Proteins were isolated with protein lysis buffer. subsequently the supernatant was 
used for the luminex (see below) and the remaining pellet harboring membrane 
proteins was sonicated on ice (Branson Sonifier 250) in Laemmli Sample Buffer. 
Protein concentrations were quantified with the 2-D Quant Assay (Amersham 
Biosciences). Protein (25 µg) was loaded on Bio-Rad Mini-Protean gels (tGX 
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pre-cast anyKD) and transferred to nitrocellulose membranes (Bio-Rad). Mem-
branes were blocked with 5% Bsa and probed with 1:200 anti-eMP1 (santa Cruz, 
sc-50467) and anti-β-actin 1:20,000 (abcam, ab6276) in 5% Bsa, followed by 
IRDye 800Cw- and IRDye 680Cw-labeled secondary antibody (Li-COR) respec-
tively. Protein levels were quantified using the Odyssey 3.0 application software 
(Li-COR).
luminex
Protein phosphorylation was determined with the 9-plex Multi-Pathway Mag-
netic Bead Panel (Millipore #46-680MaG) and Milliplex 8-plex human src family 
kinase kit (Millipore #48-650MaG) following the manufacturer’s protocol. to both 
kits β-tubulin beads (Millipore #64-713MaG) and GaPDh beads (Millipore #46-
667MaG) were added to correct for protein load.
apoptosis measurement
Cell viability was assessed with an annexin v/Propidium iodide (PI) staining. frac-
tions of annexin v/PI double-positive and annexinv single-positive cells were 
quantified on a MACSQuant flow cytometer (Miltenyi Biotec).
Cell cycle distribution assay
Cell cycle distribution was analyzed using the fItC Brdu flow Kit (B&D Pharmin-
gen) following manufacturer’s instructions.
In vitro drug-resistance assay
Cellular cytotoxicity of prednisolone (Bufa Pharmaceutical Products) was 
determined by the in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (Mtt) assay for patients´ samples and the (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium (Mts) assay for 
cell lines 2,13.
Cell adhesion assay
Subconfluent (80%) hMSC-TERT were irradiated with 30 Gy and either co-cultured 
in a 6-well plate with 2x106 Maroon labeled (Cellvue, eBiosciences) Reh cells in 
plain AIMV (Gibco) for 24h in the case of flowsort experiments, or overnight in 
a 24-wells plate with 0.4x106 leukemic cells in plain aIMv (Gibco) in the case of 
adhesion experiments of eMP1-silenced cells. hereafter, non-adherent leukemic 
cells were harvested from the supernatant (suspension cells), and adherent 
leukemic cells were harvested by trypsinizing the supernatant-depleted hMsC-
teRt layer with trypsin-eDta (Gibco) for 5 min at 37°C, 5% CO2. suspension and 
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adherent cells were quantified both by trypan blue exclusion assays and by the 
MACSQuant flow cytometer. In the case of the flowsort experiment, the adher-
ent Maroon-labeled leukemic cells were separated from unlabeled hMsC-teRt 
cells by fluorescence activated cell sorting (BD Biosciences FACSAria cell sorter) 
and total Rna of the suspension and adherent cells was isolated.
Transwell migration assay
Subconfluent hMSC-TERT layers were cultured in a 24-wells plate at 37°C, 5% CO2., 
whereafter they were irradiated with 30 Gy and placed on plain aIMv (Gibco) 
48h prior to migration assay. In indicated experiments, medium was collected 
from hMsC-teRt layers after 48h of culture and was subsequently used as condi-
tioned medium. Maroon-labeled leukemic cells (4x105) were transferred on top 
of a 3 µm pore polycarbonate membrane insert. In this transwell assay, leukemic 
cells were allowed to migrate overnight at 37°C in 5% CO2 to the bottom com-
partment which contained either a hMsC-teRt layer, or conditioned medium 
collected from hMsC-teRt after 48h or plain aIMv medium. subsequently, the 
amount of leukemic cells in the bottom compartment was quantified by both 
trypan blue exclusion assays and by the MACSQuant flow cytometer (Miltenyi 
Biotec).
MsCs and leukemic cells co-culture experiments
Leukemic cells (4x105) alone (condition 1) or co-cultured on top of a 80% 
subconfluent 30 Gy irradiated hMSC-TERT layer (condition 2) were cultured in 
24-wells plates in RPMI 10% fCs with or without 0.488 ug/ml prednisolone for 
3 days. hereafter, leukemic cells in condition 1 were directly harvested from 
the culture medium. In condition 2, the non-adherent leukemic cells were 
collected from the supernatant, whereafter the adherent leukemic cells were 
harvested by trypsinizing the supernatant-depleted hMsC-teRt layer. suspen-
sion and adherent cells were counted by trypan blue exclusion assays and the 
MACSQuant flow cytometer. To determine whether hMSC-TERT cells consume 
prednisolone, and thereby lower the available prednisolone-concentration in 
leukemia co-culture experiments, the hMsC-teRt layer was cultured with 0.488 
µg/ml prednisolone at 37°C, 5% CO2. after 3 days this MsC-derived prednisolone 
medium was collected and transferred to leukemic cells. In parallel, leukemic 
cells were exposed to prednisolone exposed to 37°C, 5% CO2 for 3 days (similar 
to the MsC-medium), and to a freshly made dilution of prednisolone. after 3 
days, the cytotoxic effect of prednisolone in these three media-conditions was 
compared by an Mts assay.
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statistical analysis
Spearman’s rank correlation coefficient was calculated to compare microarray 
gene expression results to qRt-PCR results. Data from other experiments were 
compared in unpaired T tests and Mann-whitney U tests, p<0.05 was considered 
statistically significant. The dose-response curves of prednisolone in combination 
with shnsC compared to sheMP1 was analyzed by repeated measurement one-
way anOva, testing the interaction between shRna*prednisolone. Cumulative 
incidence of relapse (CIR) was calculated as time to relapse and non-response 
with death as a competing event in the statistical environment R version 2.15.0 
using the method of fine and Gray 18 with the software packages mstate 0.2.6 19 
and cmprsk 2.2-2 20. event-free survival (efs) was calculated as time to relapse, 
non-response, secondary malignancy and death in IBM sPPs statistics 20 using 
Kaplan-Meier analysis and Cox proportional hazard analyses. univariate and 
multivariate analysis on event-free survival were performed in IBM sPPs statistics 
20 using Cox proportional hazard analyses which were stratified for treatment 
protocol.
ResuLts
eMP1 expression is increased in prednisolone resistant leukemic cells
Gene expression profiling revealed that the mRNA levels of EMP1 was median 
3.4-fold higher in leukemic cells of 74 prednisolone resistant compared to 42 
sensitive BCP-aLL patients calculated with limma taking along 60 prednisolone 
intermediate resistant patients and subtype as confounder (p=0.003, supple-
mental Table S1). We verified this with qRT-PCR in 23 BCP-ALL patients (figure 
1A). qRT-PCR and microarray mRNA expression levels correlated significantly 
(spearman R=0.88 p<0.0001 figure 1A) and qRT-PCR confirmed that EMP1 was 
higher expressed in prednisolone resistant patients compared to sensitive pa-
tients (figure 1B p<0.0001). Moreover, EMP1 expression was higher in BCP-aLL 
compared to normal bone marrow-derived mononuclear cells (p<0.03, figure 
1B). furthermore, EMP1 was most differentially expressed in prednisolone-resis-
tant B-other cases (23.5-fold p=0.003), followed by BCRABL1-like cases (2.2-fold 
p=0.04), ETV6-RUNX1+-rearranged cases (2.1-fold, p=0.05), and hyperdiploid 
cases (1.9-fold, p=0.1, supplementary figure s1). In t-aLL patients EMP1 expres-
sion levels differed median 2.0-fold between 27 prednisolone-resistant and 19 
sensitive cases (p=0.04 supplementary figure s1).
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figure 1. eMP1 expression is increased in prednisolone resistant leukemic cells. sheMP1 
efficiently silences the expression of EMP1 and reduces cell proliferation.
(A) Microarray expression (x-axis) was confirmed with qRT-PCR (y-axis). qRT-PCR and microarray RNA 
expression correlated significantly (Spearman R=0.88 p<0.01). (B) EMP1 mRNA levels in 12 prednisolone 
sensitive and 11 prednisolone resistant BCP-aLL patients and 3 normal bone marrow samples were 
analyzed by means of qRt-PCR. (C) eMP1 mRna levels were measured 168 hours after infection with 
sheMP1 or a non-silencing control short hairpin (shnsC) in six leukemic cell lines. values were adjusted 
for expression of the housekeeping gene RPs20 and are relative to the levels seen in shnsC-transduced 
cells of each cell line (set to 100%). (D) Protein levels of eMP1 were assessed by western blot at 168 hours 
after sheMP1 and shnsC transduction. eMP1 protein levels were corrected for β-actin and are relative to 
shnsC-transduced cells of each cell line (set to 100%). a representative western blot for a BCP-aLL cell 
line, i.e. etv6-RunX1+ and a t-aLL cell line, i.e. tetraploid t-aLL, are shown. (e) Cell proliferation of eMP1 
silenced cells and shNSC control cells was monitored over time by MACSQuant flow. Data are presented 
as mean plus seM of three independent experiments (*p<0.05, **p<0.01, ***p<0.001).
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eMP1 silencing increases apoptosis and induces partial cell cycle arrest
to assess the role of eMP1 in prednisolone-resistant aLL, we silenced eMP1 in six 
different prednisolone-resistant leukemic cell lines, i.e. an ETV6-RUNX1+ BCP-aLL, 
a TCF3-PBX1+ BCP-aLL, an t(5;12) BCP-aLL, an MLL-AF4+ BCP-aLL, a tetraploid 
t-aLL and a t-lymphoblast cell line. Robust EMP-1 knockdown was achieved 
following lentiviral transduction to levels varying between 2.3%±0.5% and 
27.7%±20% of those observed in cells transduced with a non-silencing control 
short hairpin (shnsC; p<0.001 figure 1C). available sheMP1 constructs present in 
the sigma-aldrich shRna library were tested and only one construct provided 
sufficient knockdown of EMP1 (supplemental figure s2). Protein levels in eMP1 
silenced cells were reduced up to 20.2%±3.7% (p<0.05) of those observed in 
shnsC-transduced cells after 168 hours (figure 1D, supplemental figure s3). 
silencing of eMP1 decreased cell proliferation in all six cell lines, resulting in a 
proliferation rate down to 16% of that seen for shnsC-transduced cells (p<0.05; 
figure 1e). we were unable to study eMP1 knockdown in primary patients’ aLL 
cells, since these primary cells only survive for 96 hours in ex vivo cultures and 
eMP1 protein knockdown only becomes evident after 168 hours.
Annexin-V/PI staining revealed a significant increase of apoptosis in five out 
of six cell lines, with a maximum increase of 2.4-fold (p<0.05, figure 2a). Brdu 
incorporation assays showed a significant reduction of EMP1-silenced cells in S 
phase in all six cell lines up to 1.7-fold (p<0.05 figure 2B). four out of six cell lines 
demonstrated an increase of eMP1-silenced cells in G0/G1-phase and/or G2/M-
phase, with a maximum increase of 1.5-fold and 2.1-fold, respectively (p<0.01 
figure 2B).
Knockdown of eMP1 sensitizes to prednisolone
we next evaluated whether inhibiting eMP1 expression sensitized leukemic cells 
towards prednisolone-induced apoptosis. silencing of eMP1 expression rendered 
three out of six cell lines more sensitive towards prednisolone-induced apoptosis 
(figure 3, Of note: the cytotoxic effect of prednisolone was corrected for death 
caused by silencing of eMP1 or shnsC.) the cytotoxicity of prednisolone in the 
other 3 cell lines did not change nor did the cells become more resistant to 
prednisolone (figure 3). silencing of eMP1 resulted in a fold-change reduction in 
LC50 values for prednisolone by 4.3-fold in the TCF3-PBX1+ BCP-aLL, by 1.8-fold in 
tetraploid t-aLL and by 8.8-fold in the t-lymphoblast cell lines (all p<0.001).
eMP1 is important for leukemic cell migration and cell adhesion
Recently, the bone marrow microenvironment was demonstrated to contribute 
to resistance of leukemic cells to drugs 21,22. when we co-cultured leukemic cells 
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figure 2. eMP1 silencing increases apoptosis and induces cell cycle arrest.
(a) eMP1 knockdown-induced apoptosis was assessed in six leukemic cell lines 168 hours after transduction 
with the MaCsQuant using an annexinv/PI staining. the percentage of apoptotic cells was calculated 
using the quadrant method. (B) Cell cycle distribution of eMP1-silenced cells and non-silencing control 
cells was analyzed after 1h Brdu incorporation, followed by Brdu-fItC and 7-aaD staining. the percent of 
cells in G0/G1, s and G2/M is presented as means plus seM of three independent experiments (*p<0.05, 
**p<0.01).
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with a human mesenchymal stromal cell layer (hMsC-teRt) (figure 4a), we ob-
served a 4.1-fold increase in EMP1 mRna levels in the fraction of leukemic cells 
that adhered to hMsC-teRt compared to the fraction that remained in suspen-
sion (figure 4B). eMP1 expressions levels returned to normal after the adhered 
aLL fraction was cultured without hMsC-teRt for 72 hours (figure 4B). In five out 
of six cell lines viable EMP1-silenced cells adhered significantly less to hMSC-
teRt, up to 29.3%±4.1% reduction, compared to shnsC-transduced control cells 
(p<0.01, figure 4C).
next, we evaluated migration of eMP1-silenced cells placed in an upper 
compartment of a transwell assay (figure 4e and D). the bottom compartment 
contained either a hMsC-teRt layer that was pre-incubated with aIMv for 
48h or did not contain a hMsC-teRt layer but only the preconditioned aIMv 
medium which had been collected from hMsC-teRt after 48h of incubation. a 
bottom compartment with only plain aIMv was used as negative control. viable 
eMP1-silenced cells migrated less to the bottom compartment containing the 
hMsC-teRt layer or the preconditioned medium in all six cell line models, with a 
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figure 3. Knockdown of eMP1 sensitizes to prednisolone
sensitivity to prednisolone after eMP1 knockdown was measured in a 3-day Mts assay. sensitivity was 
corrected for cell death induced by eMP1 knockdown itself in the absence of prednisolone. Data are 
presented as mean plus seM of three or more independent experiments (repeated measurement one-
way anOva, ***p<0.001).
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maximal reduction in migration by 78.3%±9.0% in eMP1-silenced cells compared 
to shnsC-transduced control cells (p<0.05, figure 4D).
Role of eMP1 in bone marrow microenvironment mediated 
prednisolone resistance
the observation that eMP1 is not only important in prednisolone resistance, but 
also in leukemic cell migration and adherence to hMsC-teRt prompted us to 
investigate the role of eMP1 in bone marrow microenvironment mediated pred-
nisolone resistance. we cultured eMP1-silenced cells with or without hMsC-teRt 
layer and with or without 0.488 µg/ml prednisolone for 3 days. we discovered 
that an hMsC-teRt layer can rescue shnsC-transduced control cells from pred-
nisolone-induced apoptosis (figure 4f). this was not caused by prednisolone-
induced apoptosis of the MsCs, since hMsC-teRt are prednisolone resistant, nor 
by reduced availability of prednisolone in the medium due to consumption by 
hMsC-teRt (supplemental figures s4a and B). Most importantly, eMP1 knock-
down partly prevented hMsC-teRt mediated prednisolone resistance (figure 
4f).
eMP1 signals through the src kinase family and further downstream to 
JnK, sTaT3, sTaT5, CReb and nf-κb
we next determined which signaling pathways are affected by eMP1. we dem-
onstrate that eMP1 silencing in ETV6-RUNX1+ and MLL-AF4+ BCP-aLL and tetraploid 
t-aLL cell lines decreased phosphorylation of several src kinases, i.e. src, Yes, fgr, 
Blk and hck, up to 55% (p<0.05 figure 5a and B). further downstream, eMP1 silenc-
ing resulted in decreased phosphorylation of JnK, stat3, stat5, CReB and nf-kB, 
up to 80% reduction (p<0.05 figure 5a and B). p38 and eRK1/2 phosphorylation 
levels were below detection level in BCP-aLL cell lines (nD = not detectable).
eMP1 status is an independent prognostic factor for clinical outcome 
in bCP-all
EMP1 mRna levels were determined by affymetrix microarrays for 134 BCP-aLL 
and 60 t-aLL patients treated on the German COaLL97-03-protocol, and 239 
BCP-aLL and 56 t-aLL patients treated on the Dutch aLL10 (DCOG) protocol 
(supplemental table s1). EMP1 expression status (i.e. low or high expression 
levels) was based on the median cut-off value of mRna levels detected by 
microarrays among a batch of BCP-aLL and a batch of t-aLL cases.
In the combined analysis of the COALL and DCOG patients stratified for 
treatment protocol, EMP1-high BCP-ALL (n=187) patients had a significantly 
poorer event free survival (efs) compared to EMP1-low BCP-aLL (n=186) patients 
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with 5-year efs rates of 77%±3% and 89%±2%, respectively (p<0.004, figure 6a 
and table 1). Cumulative incidence of relapse (CIR) analysis demonstrated a 
significant higher relapse and non-response risk for EMP1-high than EMP1-low 
cases in BCP-aLL (5-year CIR: 17%±3% vs. 9%±2% p=0.02, figure 6B). efs and 
CIR curves per treatment protocol are depicted in supplemental figure s5. 
to evaluate the independent prognostic value of EMP1, we performed Cox’s 
multivariate regression analysis on all 373 BCP-ALL patients stratified according 
to treatment protocol using white blood cell count, age and EMP1 expression 
status as covariates. We identified EMP1-high expression levels at diagnosis as Figure	  	  5.	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figure 5. eMP1 signals through the src kinase family to activate JnK, sTaT3, sTaT5, CReb and 
nf-κb.
(a-B) Phosphorylation levels of src kinase family members and several key-members of important cellular 
pathways were determined by means of a luminex assay in protein harvested from non-silencing control 
cells and eMP1-silenced cells at 168 hours after infection. Phosphorylation levels in shnsC transduced 
control cells were put to 100% (dashed line). Phosphorylation levels were corrected for protein load by 
GaPDh and β-tubulin levels in the same sample. Data are presented as mean plus seM of Reh and seM 
BCP-aLL cell lines (n=4) (a) and Jurkat t-aLL cell line experiments (n=2) (B) (*p<0.05, **p<0.01, ***p<0.001). 
nD: not detectable, P38 and eRK1/2 measurements in BCP-aLL were below the background level
figure 4. eMP1 is important in leukemic cell migration, adhesion to mesenchymal stromal 
cells and might be important in bone marrow microenvironment mediated prednisolone 
resistance.
(a-B) Maroon labeled ETV6-RUNX1+ leukemic cells were cocultured with hMsC-teRt for 24h. eMP1 mRna levels 
were measured in non-adherent leukemic cells and adherent leukemic cells that were separated from hMsC-
TERT by fluorescence activated cell sorting. Separated adherent leukemic cells were subsequently cultured 
without hMsC-teRt for 72 hours. (C) Leukemic cells were cocultured on an MsC layer overnight, whereafter 
only viable non-adherent and adherent cells were quantified by means of the trypan blue exclusion assay 
and MACSQuant flow cytometer. (D-E) Non-silencing control leukemic cells or EMP1-silenced leukemic cells 
were placed in aIMv medium into an upper compartment of a transwell assay and allowed to migrate to 
a lower compartment containing hMsC-teRt preconditioned for 48h in aIMv, to a lower compartment with 
only preconditioned aIMv medium taken from MsCs or to plain aIMv. Migration of viable cells was assessed 
by trypan blue exclussion assay and MACSQuant flow cytometer. (F) Non-silencing control leukemic cells and 
eMP1-silenced leukemic cells were cultured for three days with or without MsCs and with or without 0.488 
µg/ml prednisolone. hereafter, leukemic cells were harvested and cell survival was assessed by trypan blue 
exclusion assay and MACSQuant flow. Data are presented as mean plus SEM of three or more independent 
experiments (*p<0.05, **p<0.01, ***p<0.001).
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an independent predictor (p<0.01) for poor outcome in BCP-aLL with a hazard-
ratio of 2.36 (95% confidence interval: 1.31–4.25, table 1). the poor prognosis of 
EMP1-high expressing BCP-aLL patients at diagnosis is independent of in vitro 
and in vivo prednisolone response (supplemental table s1) and subtype of aLL 
(supplemental table s2).
although we found a similar functional role for eMP1 in t-aLL cell line models 
and a trend for poorer outcome of EMP1-high cases in the t-aLL cohort, this 
was not statistically significant neither in a treatment-protocol stratified analysis 
(figure 6C/D, table 1B) nor in each of the protocols separately (supplemental 
figure s5, supplemental table s2 and s3).
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figure 6. eMP1 status is an independent prognostic factor in bCP-all.
eMP1 status was based on the median cut-off value of microarray mRna expression levels seen in 373 
BCP-aLL (panel a and B) and 116 t-aLL (panel C and D). event-free survival (efs) (upper panels) and 
cumulative incidence of relapse and non-response (CIR) (lower panels) was calculated. event-free 
survival (efs) was calculated as time to relapse, non-response, secondary malignancy and death using 
Kaplan-Meier analysis and Cox proportional hazard analyses. Cumulative incidence of relapse (CIR) was 
calculated as time to relapse and non-response with death as a competing event using the method of 
fine and Gray 18.
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DIsCussIOn
Prednisolone, a glucocorticoid, regulates transcription of numerous genes even-
tually leading to cell cycle arrest and apoptosis in lymphocytes. these properties 
make glucocorticoids pivotal in the treatment of hematologic malignancies 
and have led to their inclusion in all chemotherapy protocols for lymphoid ma-
lignancies 23. elucidating causes of resistance to prednisolone remains however 
Table 1. Univariate and multivariate analysis of eMP1 status and event-free survival.
Univariate and multivariate analysis of the indicated prognostic factors stratified according to treatment 
protocol (DCOG: Dutch, COaLL: German) were performed by a Cox regression model in BCP-aLL (a) 
and t-aLL (B).
 
	  	   	  A	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   BCP-­‐ALL	   	  	  
	  	   	  	   	  	   	  	   Univariate	  Analysis	   Multivariate	  Analysis	   	  	  
	  	   	  	   Patients	   Events	   HR	  (95%-­‐CI)	   p-­‐value	   HR	  (95%-­‐CI)	   p-­‐value	   	  	  
	  	   EMP1	  expression	  (mRNA)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   <Median	   186	   16	   	  	   	  	   	  	   	  	   	  	  
	  	   ≥Median	   187	   37	   2.42(1.34-­‐4.35)	   <0.01	   2.36(1.31-­‐4.25)	   <0.01	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Age	  at	  diagnosis	  (years)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Low	  <10	   255	   35	   	  	   	  	   	  	   	  	   	  	  
	  	   High	  ≥10	   118	   18	   1.50(0.84-­‐2.67)	   0.17	   1.44(0.80-­‐2.56)	   0.22	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   WBC	  count	  (x	  10
9/	  L)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Low	  <	  50	   288	   37	   	  	   	  	   	  	   	  	   	  	  
	  	   High	  ≥	  50	   85	   16	   1.58(0.88-­‐2.83)	   0.13	   1.46(0.81-­‐2.63	   0.21	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
 
	  	   B	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   T-­‐ALL	   	  	  
	  	   	  	   	  	   	  	   Univariate	  Analysis	   Multivariate	  Analysis	   	  	  
	  	   	  	   Patients	   Events	   HR	  (95%-­‐CI)	   p-­‐value	   HR	  (95%-­‐CI)	   p-­‐value	   	  	  
	  	   EMP1	  expression	  (mRNA)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   <Median	   58	   11	   	  	   	  	   	  	   	  	   	  	  
	  	   ≥Median	   58	   19	   1.75(0.83-­‐3.68)	   0.14	   1.76(0.83-­‐3.71)	   0.14	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Age	  at	  diagnosis	  (years)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Low	  <10	   63	   16	   	  	   	  	   	  	   	  	   	  	  
	  	   High	  >10	   53	   14	   1.09(0.53-­‐2.25)	   0.81	   1.10(0.53-­‐2.25)	   0.80	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   WBC	  count	  (x	  109/	  L)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Low	  <	  50	   36	   8	   	  	   	  	   	  	   	  	   	  	  
	  	   High	  ≥	  50	   79	   22	   1.17(0.52-­‐2.64)	   0.71	   1.09(0.48-­‐2.48)	   0.83	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   BCP-­‐ALL	   	  	  
	  	   	   	  	   	  	   Univariate	  Analysis	   Multivariate	  Analysis	   	  	  
	  	   	  	   Patients	   Events	   HR	  (95%-­‐CI)	   p-­‐value	   HR	  (95%-­‐CI)	   p-­‐value	   	  	  
	  	   EMP1	  expression	  (mRNA)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   <Median	   186	   16	   	  	   	  	   	  	   	  	   	  	  
	  	   ≥Median	   187	   37	   2.42(1.34-­‐4.35)	   <0.01	   2.36(1.31-­‐4.25)	   <0.01	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Age	  at	  diagnosis	  (years)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Low	  <10	   255	   35	   	  	   	  	   	  	   	  	   	  	  
	  	   High	  ≥10	   118	   18	   1.50(0.84-­‐2.67)	   0.17	   1.44(0.80-­‐2.56)	   0.22	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   WBC	  count	  (x	  10
9/	  L)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Low	  <	  50	   288	   37	   	  	   	  	   	  	   	  	   	  	  
	  	   High	  ≥	  50	   85	   16	   1.58(0.88-­‐2.83)	   0.13	   1.46(0.81-­‐2.63	   0.21	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   T-­‐ALL	   	  	  
	  	   	  	   	  	   	  	   Univariate	  Analysis	   Multivariate	  Analysis	   	  	  
	  	   	  	   Patients	   Events	   HR	  (95%-­‐CI)	   p-­‐value	   HR	  (95%-­‐CI)	   p-­‐value	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  expression	  (mRNA)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   <Median	   58	   11	   	  	   	  	   	  	   	  	   	  	  
	  	   ≥Median	   58	   19	   1.75(0.83-­‐3.68)	   0.14	   1.76(0.83-­‐3.71)	   0.14	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Age	  at	  diagnosis	  (years)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Low	  <10	   63	   16	   	  	   	  	   	  	   	  	   	  	  
	  	   High	  >10	   53	   14	   1.09(0.53-­‐2.25)	   0.81	   1.10(0.53-­‐2.25)	   0.80	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   WBC	  count	  (x	  109/	  L)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   Low	  <	  50	   36	   8	   	  	   	  	   	  	   	  	   	  	  
	  	   High	  ≥	  50	   79	   22	   1.17(0.52-­‐2.64)	   0.71	   1.09(0.48-­‐2.48)	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challenging due to the multifactorial processes in which these glucocorticoids 
are involved.
In this study, we identified a significant overexpression of EMP1 mRna in 
leukemic cells taken from prednisolone resistant aLL patients. we show that 
knockdown of eMP1 moderately sensitized leukemic cells to prednisolone. 
Interestingly, a link between glucocorticoids and eMP1 family members has 
been shown before, as glucocorticoids can regulate the promoter activity of 
the homologues family members PMP22 and eMP2 24,25. we show that eMP1 is 
important for leukemic cell survival, as silencing of eMP1 results into cell cycle 
arrest and apoptosis. In line with this are several studies associating EMP1 expres-
sion levels with cell cycle and cell survival 5,26,27. the observed role of eMP1 in 
migration and adhesion of leukemic cells is supported by the notion that eMP1 
regulates cell-cell contact 6,7, and contributes to integrin mediated leukocyte 
migration and adhesion 11. These findings are important in relation to the tumor 
microenvironment, as this plays a significant role in leukemic cell survival and 
in chemotherapy resistance. Chemokines secreted by MsCs, such as stem cell 
factor 1 and CXCL12 stimulate leukemic cell homing and survival 28,29. MsCs 
can also induce leukemic drug resistance through upregulation of the voltage-
dependant channel heRG1 21, or rescue cells from L-asparaginase by secreting 
asparagine 22. furthermore, sequestration of aLL cells by MsCs may provide a 
physical barrier for chemotherapeutics. we show here that MsCs can protect 
leukemic cells against prednisolone-induced apoptosis and, moreover, that si-
lencing of eMP1 reduces the protection by MsCs. these data suggest that eMP1 
contributes to microenvironment-induced prednisolone resistance.
we furthermore determined which signaling pathways underlie eMP1 medi-
ated effects. Recent studies in non-small lung carcinoma suggest that eMP1 
increases eGfR signaling 11 , and showed that eMP1 activates the PI3K/aKt 
pathway 30. We did, however, not find an association between EMP1 and EGFR 
signaling (ariës et al, unpublished data), nor could we demonstrate an effect 
on aKt phosphorylation after eMP1 silencing in aLL (figure 5). In contrast, we 
demonstrated that eMP1 mediates its effect through the src-kinase family, in-
cluding src, fgr, hck, Yes and Blk. this is in line with data showing that the family 
member eMP2 promotes src and faK phosphorylation 31. src kinase family mem-
bers are oncogenes which are essential in B-cell and t-cell receptor signaling 
32,33. silencing of eMP1 also decreased the phosphorylation of CReB, nf-kB, JnK, 
stat3 and stat5 in our study. src kinase activation was previously shown to affect 
the proliferation and migration of cells via these proteins 34. furthermore, JnK 
and stat pathways have proven to be important in cell survival of both BCP-aLL 
and t-aLL35–37. we propose the following model; eMP1 most likely serves together 
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with integrines 11 as an anchor molecule essential for proper function of recep-
tor tyrosine kinases (RtKs). Knockdown of eMP1 probably results in destabilized 
RtKs, impairing src kinase phosphorylation and context-dependent downstream 
signaling to stat5 in BCP-aLL and JnK, stat3, CReB and nf-κB in t-aLL, leading 
to decreased proliferation, migration, adhesion, and a modest decrease in 
prednisolone resistance. Most importantly, in addition to our functional studies, 
we identified that EMP1 expression status is an independent prognostic factor 
for clinical outcome in BCP-aLL. although we showed that eMP1 has a func-
tional role in t-aLL cell line models, the EMP1 expression status was not a strong 
prognostic indicator in t-aLL patients.
taken together, this study substantiates an important pathobiological role for 
eMP1 in aLL. the membrane protein property of eMP1 potentiates it as an inter-
esting candidate for drug-targeting since problems of drug penetration and 
partitioning in the cytoplasm or elimination of the drug by drug-efflux pumps 
can be avoided 38. the development of an eMP1 inhibitory small compound or 
antibody is desirable and may serve as a potential new therapeutic option for 
aLL.
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Figure	  S1.	  
Figure	   S1.	   +i,ere-./0	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   6781	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  2er	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  45	  ?@@.	  Microarray	  expression	  levels	  of	  EMP1	  probeset	  
201324_at	  are	  compared	  between	   in	  vitro	  prednisolone	  sensiCve	  (sens)	  and	  resistant	  
(res)	   	   ETV6-­‐RUNX1+,	   hyperdiploid	   (HD)	   (>50	   chromosomes),	   BCR-­‐ABL1-­‐like,	   B-­‐other	  
BCP-­‐PQQ	   paCents	   and	   T-­‐PQQ	   paCents.	   Sreen	   block	   indicates	   paCents	   with	   an	   EMP1	  
expression	  below	  the	  median.	  The	  median	  expression	  level	  differed	  between	  BCP	  and	  
T-­‐PQQ	   cases	   because	   these	   paCents	   were	   tested	   in	   two	   different	   batches	   of	  
microarrays.	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Figure	  S2.	  
Figure	  S3.	  
Figure	   S2.	   Only	   shEMP1-­‐b	   yields	   sufficient	   EMP1	  
mRNA	  knockdown.	  	  	  
EMP1	   mRNA	   expression	   was	   assessed	   at	   different	  
Cmepoints	   aZer	   transfecCon	   with	   three	   different	  
shEMP1	   constructs	   available	   TRCN0000117943	  
(shEMP1-­‐a),	   TRCN0000117944	   (shEMP1-­‐b)	   and	  
TRCN0000117945	   (shEMP1-­‐c).	   	   Only	   shEMP1-­‐b	  
yielded	  sufficient	  knockdown	  at	  all	  	  Cmepoints.	  
Figure	  S3.	  Knockdown	  of	  EMP1	  protein	  expression	  
bec/me	  /pp/rent	  /Mer	  1NOh.	  
EMP1	   protein	   expression	   in	   NALM6	   was	   assessed	  
aZer	   96h	   and	   168h.	   Knockdown	   of	   EMP1	   protein	  
expression	   became	   apparent	   aZer	   168h.	  _e	  were	  
therefore	  not	   able	   to	   achieve	   EMP1	   knockdown	   in	  
primary	   paCents`	   ALL	   cells,	   since	   these	   cells	   only	  
survive	  for	  96	  hours.	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Figure	  S4.	  
!"#$%&	   (P.	   @&$J&G"F	   F&00	   2%40"5&%/.4-Q	   7(R3	   /-<	   2%&<-"3404-&.	   (A)	   Cell	   survival	   of	   hMSC-­‐TERT	   aZer	   3-­‐day	  
prednisolone	   exposure	   determined	   by	   an	  MTS	   assay.	   (B)	   Leukemic	   cell	   survival	   determined	   by	   a	   3-­‐day	  MTS	  
assay	  with	  either	  fresh	  prednisolone	  in	  RPMI	  medium,	  prednisolone	  that	  was	  incubated	  for	  three	  days	  at	  37	  ◦C	  
in	  RPMI	  medium,	  and	  prednisolone	   in	  RPMI	  medium	  that	  was	  harvested	  from	  hMSC-­‐TERT	  aZer	  three	  days	  of	  
incubaCon	  at	  37	  ◦C	  .	  Data	  are	  presented	  as	  mean	  plus	  SEM	  of	  three	  independent	  experiments	  (***p<0.001).	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Figure	  S5.	  
Figure	   S5.	   EFS	   and	   CIR	   of	   EMP1	   high	   versus	   EMP1	   low	   pa.ents	   per	   treatment	   protocol.	   EMP1	   status	   was	  
determined	  by	  the	  median	  value	  of	  microarray	  mRNA	  expression	  for	  134	  BCP-­‐ALL	  (leZ)	  and	  60	  T-­‐ALL	  paCents	  
(right)	  treated	  on	  the	  German	  COALL97-­‐03-­‐protocol	  (A	  and	  C	  panel),	  and	  249	  BCP-­‐ALL	  (leZ)	  and	  56	  T-­‐ALL	  (right)	  
paCents	  treated	  on	  the	  Dutch	  ALL10	  protocol	   (B	  and	  D	  panel).	  5-­‐year	  event-­‐free	  survival	  were	  analyzed	  using	  
Kaplan-­‐Meier	  staCsCcs.	  CumulaCve	  incidence	  of	  relapse	  was	  calculated	  with	  the	  method	  of	  Fine	  and	  Gray.	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Supplemental	  Table	  S1
EMP1	  microarray	  expression	  of	  512	  patients	  used	  for	  limma	  analysis	  and	  survival	  analysis.
Patient	  Nr.	   Protocol Genetic In	  vitro	  Prednisolone In	  vitro	  Prednisolone2 EMP1 BCP-­‐ALL	  Limma	   Survival	  
COALL/ALL10/other Subtype LC50 Category	   201324_at analysis Analysis
1 COALL HD 0.106 Intermediate 11.09 x x
2 COALL HD 2.287 Intermediate 9.95 x x
3 COALL T 0.051 Sensitive 7.79 x
4 COALL BAL 0.337 Intermediate 11.28 x x
5 COALL BO 0.334 Intermediate 8.15 x x
6 COALL BAL >250 Resistant 12.70 x x
7 COALL ER 0.042 Sensitive 6.74 x x
8 COALL T 0.371 Intermediate 6.91 x
9 COALL BAL >250 Resistant 10.21 x x
10 COALL T 0.412 Intermediate 8.70 x
11 COALL BO 0.225 Intermediate 11.40 x x
12 COALL T 0.310 Intermediate 9.21 x
13 COALL HD 14.8 Intermediate 9.61 x x
14 COALL T >250 Resistant 7.45 x
15 COALL T 3.08 Intermediate 8.12 x
16 COALL MLL 0.283 Intermediate 9.90 x x
17 COALL HD 0.450 Intermediate 12.40 x x
18 COALL T 0.367 Intermediate 7.25 x
19 COALL ER 0.020 Sensitive 8.09 x x
20 COALL T 0.397 Intermediate 5.94 x
21 COALL T 0.082 Sensitive 6.44 x
22 COALL T >250 Resistant 6.27 x
23 COALL T >250 Resistant 6.43 x
24 COALL T 0.048 Sensitive 6.14 x
25 COALL T >250 Resistant 8.40 x
26 COALL T >250 Resistant 5.34 x
27 COALL T 0.098 Sensitive 6.28 x
28 COALL T >250 Resistant 10.57 x
29 COALL HD >250 Resistant 10.83 x x
30 COALL T 0.351 Intermediate 6.66 x
31 COALL BAL >250 Resistant 9.68 x x
32 COALL T 1.95 Intermediate 7.69 x
33 COALL T >250 Resistant 9.21 x
34 COALL BAL >250 Resistant 11.49 x x
35 COALL BAL 195 Resistant 10.30 x x
36 COALL T 29.5 Intermediate 5.32 x
37 COALL T 0.337 Intermediate 7.18 x
38 COALL T 2.36 Intermediate 6.78 x
39 COALL T 0.014 Sensitive 8.85 x
40 COALL T 0.047 Sensitive 8.12 x
41 COALL ER 229 Resistant 9.16 x x
42 COALL T >250 Resistant 7.08 x
43 COALL BO 154 Resistant 11.20 x x
44 COALL T >250 Resistant 8.19 x
45 COALL T 0.038 Sensitive 7.61 x
46 COALL T >250 Resistant 7.89 x
47 COALL T >250 Resistant 7.19 x
48 COALL T >250 Resistant 8.86 x
49 COALL T 0.057 Sensitive 7.13 x
50 COALL T 0.081 Sensitive 6.71 x
51 COALL BAL >250 Resistant 10.16 x x
52 COALL ER >250 Resistant 11.45 x x
53 COALL BO >250 Resistant 11.58 x x
54 COALL T 0.199 Intermediate 5.60 x
55 COALL T 0.037 Sensitive 8.23 x
56 COALL T 0.055 Sensitive 7.74 x
88
57 COALL T >250 Resistant 7.22 x
58 COALL BAL >250 Resistant 10.38 x x
59 COALL T 0.286 Intermediate 5.15 x
60 COALL BO >250 Resistant 11.87 x x
61 COALL T 0.488 Intermediate 6.18 x
62 COALL T 126 Intermediate 6.33 x
63 COALL ER 0.031 Sensitive 8.39 x x
64 COALL BO 0.040 Sensitive 6.90 x x
65 COALL ER 0.068 Sensitive 8.10 x x
66 COALL BAL 27.1 Intermediate 11.73 x x
67 COALL BO 0.014 Sensitive 8.78 x x
68 COALL HD >250 Resistant 12.85 x x
69 COALL BO 0.031 Sensitive 9.07 x x
70 COALL ER >250 Resistant 10.78 x x
71 COALL ER >250 Resistant 8.04 x x
72 COALL T 223 Resistant 11.77 x
73 COALL BO 17.6 Intermediate 10.97 x x
74 COALL ER <0,008 Sensitive 6.21 x x
75 COALL T <0,008 Sensitive 5.58 x
76 COALL T 0.373 Intermediate 6.85 x
77 COALL T 1.42 Intermediate 6.36 x
78 COALL BAL 0.324 Intermediate 9.58 x x
79 COALL E2A 0.030 Sensitive 8.09 x x
80 COALL BAL 0.061 Sensitive 7.86 x x
81 COALL HD 0.026 Sensitive 8.90 x x
82 COALL BA 0.032 Sensitive 11.27 x x
83 COALL T 0.031 Sensitive 4.62 x
84 COALL T 0.045 Sensitive 6.54 x
85 COALL BO 0.024 Sensitive 9.40 x x
86 COALL T 0.043 Sensitive 5.50 x
87 COALL ER 0.040 Sensitive 11.43 x x
88 COALL BO 0.243 Intermediate 9.02 x x
89 COALL ER 0.057 Sensitive 10.00 x x
90 COALL T 0.298 Intermediate 7.01 x
91 COALL HD 0.280 Intermediate 9.73 x x
92 COALL BO 0.028 Sensitive 6.14 x x
93 COALL ER 0.384 Intermediate 9.20 x x
94 COALL BAL 0.275 Intermediate 10.80 x x
95 COALL ER 0.045 Sensitive 8.14 x x
96 COALL BAL 0.553 Intermediate 9.61 x x
97 COALL ER 0.302 Intermediate 6.56 x x
98 COALL T 0.259 Intermediate 7.07 x
99 COALL BAL 0.583 Intermediate 11.80 x x
100 COALL ER 0.247 Intermediate 6.87 x x
101 COALL T 177 Resistant 7.57 x
102 COALL ER 0.091 Sensitive 6.85 x x
103 COALL ER 0.397 Intermediate 6.68 x x
104 COALL BO >250 Resistant 12.26 x x
105 COALL HD 0.306 Intermediate 9.77 x x
106 COALL HD 0.208 Intermediate 6.60 x x
107 COALL NA 0.271 Intermediate 9.31 x x
108 COALL HD 0.421 Intermediate 11.69 x x
109 COALL HD 0.417 Intermediate 8.66 x x
110 COALL BO >250 Resistant 7.76 x x
111 COALL ER 0.050 Sensitive 6.30 x x
112 COALL T >250 Resistant 10.65 x
113 COALL HD 0.253 Intermediate 10.22 x x
114 COALL ER 0.427 Intermediate 9.09 x x
115 COALL BA 3.62 Intermediate 8.98 x x
116 COALL BO 3.87 Intermediate 4.96 x x
117 COALL T 0.027 Sensitive 7.87 x
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118 COALL T 0.061 Sensitive 6.56 x
119 COALL BO 0.074 Sensitive 8.28 x x
120 COALL BO 0.179 Intermediate 9.71 x x
121 COALL ER 155 Resistant 6.91 x x
122 COALL ER 0.133 Intermediate 6.07 x x
123 COALL BAL 0.039 Sensitive 8.64 x x
124 COALL HD >250 Resistant 11.94 x x
125 COALL BO 0.023 Sensitive 4.90 x x
126 COALL ER <0,008 Sensitive 5.44 x x
127 COALL HD 0.034 Sensitive 8.84 x x
128 COALL ER >250 Resistant 9.12 x x
129 COALL BO >250 Resistant 12.29 x x
130 COALL BO 0.009 Sensitive 4.36 x x
131 COALL HD 0.025 Sensitive 10.18 x x
132 COALL HD 0.058 Sensitive 8.82 x x
133 COALL BO <0,008 Sensitive 10.76 x x
134 COALL HD <0,008 Sensitive 11.11 x x
135 COALL ER 0.346 Intermediate 8.54 x x
136 COALL HD 0.199 Intermediate 9.44 x x
137 COALL HD 0.049 Sensitive 9.36 x x
138 COALL HD 0.059 Sensitive 10.94 x x
139 COALL HD >250 Resistant 10.04 x x
140 COALL HD 0.040 Sensitive 11.72 x x
141 COALL ER 0.053 Sensitive 9.01 x x
142 COALL BAL 0.338 Intermediate 9.15 x x
143 COALL HD 0.057 Sensitive 11.91 x x
144 COALL BAL 0.034 Sensitive 11.15 x x
145 COALL BO >250 Resistant 12.24 x x
146 COALL T 0.021 Sensitive 4.79 x
147 COALL ER 0.026 Sensitive 5.52 x x
148 COALL BO 0.046 Sensitive 5.21 x x
149 COALL HD 211 Resistant 11.76 x x
150 COALL ER 0.025 Sensitive 9.37 x x
151 COALL BO 2.77 Intermediate 6.69 x x
152 COALL BO >250 Resistant 7.77 x x
153 COALL BO 0.429 Intermediate 5.95 x x
154 COALL T 0.488 Intermediate 5.15 x
155 COALL BO 2.20 Intermediate 8.69 x x
156 COALL T >250 Resistant 6.49 x
157 COALL HD 0.129 Intermediate 9.49 x x
158 COALL T 0.032 Sensitive 7.54 x
159 COALL BAL 172 Resistant 10.84 x x
160 COALL ER <0,008 Sensitive 7.83 x x
161 COALL ER 0.025 Sensitive 8.82 x x
162 COALL HD 0.015 Sensitive 11.89 x x
163 COALL BAL 0.106 Intermediate 7.86 x x
164 COALL HD 0.011 Sensitive 10.13 x x
165 COALL E2A >250 Resistant 9.49 x x
166 COALL BO <0,008 Sensitive 6.96 x x
167 COALL HD 0.050 Sensitive 11.83 x x
168 COALL BAL 0.027 Sensitive 9.23 x x
169 COALL BAL 0.054 Sensitive 10.19 x x
170 COALL HD 206 Resistant 9.17 x x
171 COALL ER 0.465 Intermediate 8.88 x x
172 COALL ER >250 Resistant 9.68 x x
173 COALL BO 0.045 Sensitive 8.77 x x
174 COALL BAL 2.61 Intermediate 8.07 x x
175 COALL HD 0.186 Intermediate 9.07 x x
176 COALL T 0.055 Sensitive 6.48 x
177 COALL ER 0.049 Sensitive 8.51 x x
178 COALL T 0.046 Sensitive 8.57 x
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179 COALL HD 0.028 Sensitive 9.90 x x
180 COALL HD 0.049 Sensitive 9.69 x x
181 COALL BO 0.042 Sensitive 7.25 x x
182 COALL T 0.221 Intermediate 6.87 x
183 COALL HD 0.038 Sensitive 7.05 x x
184 COALL BO >250 Resistant 11.45 x x
185 COALL HD >250 Resistant 10.88 x x
186 COALL BAL 0.409 Intermediate 7.24 x x
187 COALL HD >250 Resistant 10.40 x x
188 COALL ER 0.131 Intermediate 6.96 x x
189 COALL ER 0.054 Sensitive 5.07 x x
190 COALL ER 0.173 Intermediate 6.26 x x
191 COALL T 0.312 Intermediate 4.74 x
192 COALL ER 0.032 Sensitive 6.09 x x
193 COALL ER 0.396 Intermediate 11.32 x x
194 COALL ER 0.175 Intermediate 8.82 x x
195 ALL10 ER 0.040 Sensitive 8.80 x x
196 ALL10 ER 0.060 Sensitive 8.50 x x
197 ALL10 ER NA NA 9.84 x
198 ALL10 MLL >250 Resistant 8.87 x x
199 ALL10 T 0.055 Sensitive 5.86 x
200 ALL10 BO 0.036 Sensitive 4.54 x x
201 ALL10 T NA NA 5.20 x
202 ALL10 T 0.163 Intermediate 6.97 x
203 ALL10 HD 0.363 Intermediate 8.59 x x
204 ALL10 ER 0.219 Intermediate 5.93 x x
205 ALL10 HD NA NA 8.21 x
206 ALL10 HD 0.357 Intermediate 8.92 x x
207 ALL10 ER 0.090 Sensitive 5.79 x x
208 ALL10 ER >250 Resistant 5.48 x x
209 ALL10 HD NA NA 8.00 x
210 ALL10 ER NA NA 5.67 x
211 ALL10 ER >250 Resistant 11.50 x x
212 ALL10 BO >250 Resistant 6.85 x x
213 ALL10 ER 0.159 Intermediate 5.16 x x
214 ALL10 ER >250 Resistant 7.48 x x
215 ALL10 ER <0,008 Sensitive 5.84 x x
216 ALL10 HD 0.208 Intermediate 10.67 x x
217 ALL10 BO NA NA 7.79 x
218 ALL10 ER 0.061 Sensitive 6.37 x x
219 ALL10 BAL >250 Resistant 10.57 x x
220 ALL10 ER NA NA 9.97 x
221 ALL10 BAL NA NA 5.22 x
222 ALL10 BO NA NA 8.81 x
223 ALL10 BAL 0.284 Intermediate 10.11 x x
224 ALL10 HD 0.330 Intermediate 7.49 x x
225 ALL10 HD NA NA 10.73 x
226 ALL10 E2A <0,008 Sensitive 4.64 x x
227 ALL10 HD <0,008 Sensitive 8.84 x x
228 ALL10 HD >250 Resistant 10.80 x x
229 ALL10 BAL 0.053 Sensitive 9.22 x x
230 ALL10 HD NA NA 10.55 x
231 ALL10 HD 0.151 Intermediate 10.59 x x
232 ALL10 E2A 0.087 Sensitive 10.75 x x
233 ALL10 T NA NA 7.28 x
234 ALL10 ER 0.102 Intermediate 6.95 x x
235 ALL10 ER >250 Resistant 6.15 x x
236 ALL10 T 0.334 Intermediate 6.02 x
237 ALL10 ER 0.047 Sensitive 8.14 x x
238 ALL10 T 0.040 Sensitive 5.02 x
239 ALL10 HD 0.041 Sensitive 6.53 x x
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240 ALL10 BO <0,008 Sensitive 6.59 x x
241 ALL10 T 0.051 Sensitive 5.16 x
242 ALL10 T 0.348 Intermediate 6.78 x
243 ALL10 ER 0.041 Sensitive 8.53 x x
244 ALL10 BAL NA NA 8.94 x
245 ALL10 HD NA NA 8.55 x
246 ALL10 BAL NA NA 8.68 x
247 ALL10 BO NA NA 9.75 x
248 ALL10 BO NA NA 8.13 x
249 ALL10 ER 0.343 Intermediate 9.85 x x
250 ALL10 HD 0.216 Intermediate 10.48 x x
251 ALL10 HD NA NA 9.31 x
252 ALL10 BAL NA NA 8.89 x
253 ALL10 ER NA NA 6.17 x
254 ALL10 ER NA NA 8.36 x
255 ALL10 ER NA NA 7.51 x
256 ALL10 BO NA NA 9.00 x
257 ALL10 T NA NA 5.91 x
258 ALL10 E2A NA NA 7.63 x
259 ALL10 HD NA NA 10.36 x
260 ALL10 HD NA NA 10.01 x
261 ALL10 ER NA NA 7.08 x
262 ALL10 T NA NA 6.35 x
263 ALL10 T NA NA 5.86 x
264 ALL10 ER NA NA 6.52 x
265 ALL10 HD NA NA 10.42 x
266 ALL10 ER NA NA 7.75 x
267 ALL10 T NA NA 8.41 x
268 ALL10 HD NA NA 10.29 x
269 ALL10 E2A NA NA 7.38 x
270 ALL10 HD NA NA 9.28 x
271 ALL10 HD NA NA 11.54 x
272 ALL10 HD NA NA 13.06 x
273 ALL10 HD NA NA 10.59 x
274 ALL10 MLL NA NA 11.33 x
275 ALL10 HD NA NA 12.26 x
276 ALL10 T NA NA 7.01 x
277 ALL10 HD NA NA 11.31 x
278 ALL10 HD NA NA 9.98 x
279 ALL10 HD NA NA 10.33 x
280 ALL10 HD NA NA 11.29 x
281 ALL10 ER NA NA 8.21 x
282 ALL10 E2A NA NA 9.00 x
283 ALL10 ER NA NA 9.13 x
284 ALL10 BO NA NA 10.81 x
285 ALL10 BO NA NA 9.99 x
286 ALL10 ER NA NA 7.31 x
287 ALL10 ER NA NA 7.96 x
288 ALL10 BAL NA NA 8.36 x
289 ALL10 HD NA NA 11.57 x
290 ALL10 T NA NA 8.04 x
291 ALL10 ER NA NA 8.10 x
292 ALL10 T NA NA 12.32 x
293 ALL10 HD NA NA 12.36 x
294 ALL10 T NA NA 5.15 x
295 ALL10 T NA NA 6.73 x
296 ALL10 ER NA NA 6.38 x
297 ALL10 E2A NA NA 6.05 x
298 ALL10 HD NA NA 10.44 x
299 ALL10 HD NA NA 9.67 x
300 ALL10 HD NA NA 10.05 x
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301 ALL10 ER NA NA 8.23 x
302 ALL10 ER NA NA 7.66 x
303 ALL10 BO NA NA 6.74 x
304 ALL10 E2A NA NA 5.97 x
305 ALL10 T NA NA 6.94 x
306 ALL10 ER NA NA 7.31 x
307 ALL10 HD NA NA 11.53 x
308 ALL10 BAL NA NA 10.28 x
309 ALL10 HD NA NA 12.03 x
310 ALL10 HD NA NA 11.28 x
311 ALL10 HD NA NA 11.47 x
312 ALL10 ER NA NA 8.59 x
313 ALL10 ER NA NA 7.91 x
314 ALL10 HD NA NA 10.47 x
315 ALL10 ER NA NA 7.92 x
316 ALL10 ER NA NA 8.78 x
317 ALL10 ER NA NA 10.34 x
318 ALL10 HD NA NA 11.26 x
319 ALL10 T NA NA 5.76 x
320 ALL10 MLL NA NA 6.07 x
321 ALL10 ER NA NA 6.18 x
322 ALL10 E2A NA NA 6.24 x
323 ALL10 BO NA NA 7.96 x
324 ALL10 ER NA NA 9.93 x
325 ALL10 HD NA NA 10.69 x
326 ALL10 BO NA NA 10.76 x
327 ALL10 HD NA NA 11.69 x
328 ALL10 ER NA NA 5.28 x
329 ALL10 BAL NA NA 7.53 x
330 ALL10 HD NA NA 11.53 x
331 ALL10 ER NA NA 6.39 x
332 ALL10 BAL NA NA 5.94 x
333 ALL10 BAL NA NA 7.92 x
334 ALL10 ER NA NA 7.03 x
335 ALL10 T NA NA 5.83 x
336 ALL10 ER NA NA 7.35 x
337 ALL10 ER NA NA 7.21 x
338 ALL10 HD NA NA 8.89 x
339 ALL10 BAL NA NA 8.72 x
340 ALL10 ER NA NA 10.60 x
341 ALL10 T NA NA 6.52 x
342 ALL10 BAL NA NA 10.02 x
343 ALL10 ER NA NA 6.68 x
344 ALL10 ER NA NA 7.77 x
345 ALL10 T NA NA 5.97 x
346 ALL10 BAL NA NA 9.09 x
347 ALL10 HD NA NA 12.31 x
348 ALL10 T NA NA 8.12 x
349 ALL10 T NA NA 4.85 x
350 ALL10 ER NA NA 8.83 x
351 ALL10 T NA NA 6.88 x
352 ALL10 BO NA NA 6.94 x
353 ALL10 T NA NA 6.02 x
354 ALL10 ER NA NA 6.70 x
355 ALL10 BAL NA NA 10.58 x
356 ALL10 BO NA NA 11.20 x
357 ALL10 BO NA NA 7.08 x
358 ALL10 ER NA NA 6.34 x
359 ALL10 BAL NA NA 8.65 x
360 ALL10 BO NA NA 5.72 x
361 ALL10 BAL NA NA 8.43 x
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362 ALL10 HD NA NA 11.17 x
363 ALL10 BAL NA NA 6.85 x
364 ALL10 HD NA NA 10.42 x
365 ALL10 BAL NA NA 9.63 x
366 ALL10 ER NA NA 7.58 x
367 ALL10 HD NA NA 9.64 x
368 ALL10 HD NA NA 10.22 x
369 ALL10 E2A NA NA 5.96 x
370 ALL10 HD NA NA 9.35 x
371 ALL10 T NA NA 9.11 x
372 ALL10 T NA NA 6.77 x
373 ALL10 ER NA NA 7.86 x
374 ALL10 T NA NA 6.26 x
375 ALL10 BO NA NA 10.60 x
376 ALL10 T NA NA 7.25 x
377 ALL10 T NA NA 5.64 x
378 ALL10 HD NA NA 10.88 x
379 ALL10 ER NA NA 7.39 x
380 ALL10 ER NA NA 9.69 x
381 ALL10 T NA NA 7.67 x
382 ALL10 ER NA NA 8.23 x
383 ALL10 MLL NA NA 8.65 x
384 ALL10 T NA NA 9.33 x
385 ALL10 T NA NA 7.99 x
386 ALL10 E2A NA NA 5.78 x
387 ALL10 ER NA NA 6.66 x
388 ALL10 ER NA NA 5.63 x
389 ALL10 HD NA NA 11.35 x
390 ALL10 T NA NA 8.12 x
391 ALL10 HD NA NA 11.49 x
392 ALL10 T NA NA 7.06 x
393 ALL10 BAL NA NA 10.01 x
394 ALL10 BO NA NA 10.49 x
395 ALL10 T NA NA 8.34 x
396 ALL10 MLL NA NA 10.48 x
397 ALL10 T NA NA 8.17 x
398 ALL10 ER NA NA 8.70 x
399 ALL10 BAL NA NA 10.05 x
400 ALL10 T NA NA 5.72 x
401 ALL10 T NA NA 7.01 x
402 ALL10 HD NA NA 10.95 x
403 ALL10 ER NA NA 7.96 x
404 ALL10 BO NA NA 7.90 x
405 ALL10 BAL NA NA 10.76 x
406 ALL10 MLL NA NA 6.39 x
407 ALL10 BAL NA NA 6.31 x
408 ALL10 T NA NA 7.61 x
409 ALL10 HD NA NA 11.01 x
410 ALL10 T NA NA 8.09 x
411 ALL10 ER NA NA 8.67 x
412 ALL10 ER NA NA 8.10 x
413 ALL10 HD NA NA 10.15 x
414 ALL10 HD NA NA 11.34 x
415 ALL10 HD NA NA 12.10 x
416 ALL10 BO NA NA 9.35 x
417 ALL10 HD NA NA 11.40 x
418 ALL10 BO NA NA 7.77 x
419 ALL10 ER NA NA 9.58 x
420 ALL10 BO NA NA 11.13 x
421 ALL10 HD NA NA 11.40 x
422 ALL10 T NA NA 6.44 x
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423 ALL10 T NA NA 7.67 x
424 ALL10 HD NA NA 11.54 x
425 ALL10 T NA NA 8.76 x
426 ALL10 ER NA NA 7.05 x
427 ALL10 HD NA NA 11.23 x
428 ALL10 T NA NA 9.18 x
429 ALL10 HD NA NA 10.99 x
430 ALL10 BO NA NA 8.61 x
431 ALL10 T NA NA 7.52 x
432 ALL10 HD NA NA 9.09 x
433 ALL10 BO NA NA 7.08 x
434 ALL10 ER NA NA 7.99 x
435 ALL10 T NA NA 7.45 x
436 ALL10 HD NA NA 9.51 x
437 ALL10 HD NA NA 11.98 x
438 ALL10 T NA NA 10.99 x
439 ALL10 HD NA NA 9.96 x
440 ALL10 ER NA NA 7.59 x
441 ALL10 BAL NA NA 9.64 x
442 ALL10 BO NA NA 10.98 x
443 ALL10 ER NA NA 8.75 x
444 ALL10 T NA NA 9.36 x
445 ALL10 BO NA NA 10.81 x
446 ALL10 HD NA NA 10.30 x
447 ALL10 HD NA NA 11.38 x
448 ALL10 HD NA NA 10.98 x
449 ALL10 BAL NA NA 9.64 x
450 ALL10 HD NA NA 10.25 x
451 ALL10 ER NA NA 6.64 x
452 ALL10 ER NA NA 7.42 x
453 ALL10 E2A NA NA 8.65 x
454 ALL10 T NA NA 5.58 x
455 ALL10 ER NA NA 5.94 x
456 ALL10 ER NA NA 10.17 x
457 ALL10 BO NA NA 6.97 x
458 ALL10 HD NA NA 10.04 x
459 ALL10 T NA NA 6.59 x
460 ALL10 ER NA NA 9.56 x
461 ALL10 HD NA NA 10.17 x
462 ALL10 BAL NA NA 8.25 x
463 ALL10 ER NA NA 6.02 x
464 ALL10 E2A NA NA 8.47 x
465 ALL10 BAL NA NA 8.99 x
466 ALL10 BAL NA NA 8.45 x
467 ALL10 T NA NA 11.66 x
468 ALL10 T NA NA 8.88 x
469 ALL10 E2A NA NA 8.72 x
470 ALL10 ER NA NA 6.59 x
471 ALL10 BO NA NA 7.83 x
472 ALL10 ER NA NA 7.65 x
473 ALL10 BO NA NA 6.00 x
474 ALL10 BO NA NA 6.99 x
475 ALL10 HD NA NA 10.63 x
476 ALL10 T NA NA 7.94 x
477 ALL10 ER NA NA 8.46 x
478 ALL10 BO NA NA 7.56 x
479 ALL10 T NA NA 6.66 x
480 ALL10 ER NA NA 9.76 x
481 ALL10 HD NA NA 11.44 x
482 ALL10 ER NA NA 5.79 x
483 ALL10 HD NA NA 9.85 x
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484 ALL10 BA NA NA 9.26 x
485 ALL10 BA NA NA 11.11 x
486 ALL10 BA NA NA 10.24 x
487 ALL10 BA NA NA 10.14 x
488 ALL10 BA NA NA 11.39 x
489 ALL10 BA NA NA 9.61 x
490 other T 0.148 Intermediate 7.25
491 other T 0.444 Intermediate 7.14
492 other T 0.060 Sensitive 4.36
493 other T 75.0 Intermediate 6.26
494 other T 0.387 Intermediate 5.28
495 other T >250 Resistant 6.64
496 other T 0.305 Intermediate 7.14
497 other BO 0.054 Sensitive 9.39 x
498 other BO 12.6 Intermediate 5.05 x
499 other E2A <0,008 Sensitive 6.33 x
500 other HD 0.052 Sensitive 10.86 x
501 other BA 0.048 Sensitive 7.91 x
502 other HD 0.050 Sensitive 12.12 x
503 other HD 133 Intermediate 12.32 x
504 other ER >250 Resistant 10.18 x
505 other NA 0.061 Sensitive 6.63 x
506 other T <0,008 Sensitive 6.60
507 other T 0.397 Intermediate 8.01
508 other T 0.278 Intermediate 6.97
509 other T 0.056 Sensitive 7.22
510 other T 0.158 Intermediate 4.75
511 other T 0.171 Intermediate 6.35
512 other T >250 Resistant 4.69
Genetic	  Subtype:	  HD=hyperdiploid,	  ER=ETV6-­‐RUNX1+,	  BA=BCR-­‐ABL1+,	  BAL=	  BCR-­‐ABL1-­‐Like,	  E2A=TCF3-­‐PBX1+,	  MLL=MLL	  rearranged,
BO=	  B-­‐other,	  negative	  for	  aforementioned	  lesions,	  T=T-­‐ALL,	  NA=not	  available
Prednisolone	  category:	  sensitive	  =	  ≤0.1	  μg/ml,	  intermediate=	  >0.1-­‐<150	  μg/ml,	  resistant	  =≥150	  μg/ml,	  see	  also	  reference	  2	  and	  11.
Only	  BCP-­‐ALL	  patients	  with	   in	  vitro	  prednisolone	  cytotoxicity	  data	  were	  used	  for	  limma-­‐analysis,	  indicated	  by	  X	  in	  column	  7,	  
as	  we	  compare	  in	  vitro	  resistant	  to	  sensitive	  patients.
Only	  BCP-­‐ALL	  and	  T-­‐ALL	  patients	  of	  COALL97-­‐03	  and	  DCOG-­‐ALL10	  protocol,	  indicated	  by	  X	  in	  column	  8,	  were	  used	  for	  survival	  analysis,	  
as	  the	  analysis	  was	  stratified	  for	  treatment	  protocol.	  
Remaining	  patients	  belonged	  either	  to	  DCOG-­‐ALL8	  or	  -­‐ALL9	  protocols.	  EMP1	  expression	  values	  of	  these	  patients	  were	  only
	  used	  in	  Supplemental	  Figure	  S1.
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Table S2. 
Table S2. Univariate and multivariate analysis of EMP1 status, age, white blood cell count and in vitro and in 
vivo prednisolone resistance and prognosis. Univariate and multivariate analysis of the indicated prognostic 
factors were performed by a Cox regression model based on event-free survival and with riskgroup as stratum. 
In vitro prednisolone response data are only available of COALL-97/03 patients, in contrast in vivo prednisolone 
response data are only available  of DCOG-ALL10 patients. 
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 30 9 1 1
≥ Median 30 11 1.19(0.49-2.86) 0.70 1.39(0.54-3.53) 0.49
Age at diagnosis (years)
Low <10 34 11 1 1
High ≥10 26 9 1.09(0.45-2.64) 0.85 1.13(0.46-2.80) 0.79
WBC count (x 109/ L)
Low < 50 15 4 1 1
High ≥ 50 45 16 1.45(0.49-4.34) 0.51 1.17(0.35-3.87) 0.80
In vitro  Prednisolone  response
Good 21 7 1 1
Intermediate 22 9 1.37(0.51-3.68) 0.533 1.36(0.48-3.85) 0.56
Poor 17 4 0.72(0.21-2.48) 0.61 0.66(0.19-2.37) 0.53
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 28 2 1 1
≥ Median 28 8 4.40(0.93-20.73) 0.06 6.27(1.18-3.29) 0.03
Age at diagnosis (years)
Low <10 29 5 1 1
High ≥10 27 5 1.10(0.32-3.80) 0.88 1.80(0.43-7.45) 0.42
WBC count (x 109/ L)
Low < 50 21 4 1 1
High ≥ 50 34 6 0.85(0.24-3.01) 0.80 0.44(0.11-1.74) 0.24
In vivo  Prednisolone  response
Good 39 5 1 1
Poor 16 5 2.54(0.74-8.79) 0.14 3.23(0.80-13.01) 0.10
T-ALL
 COALL-97/03 protocol
Univariate Analysis Multivariate Analysis
 DCOG-ALL10 protocol
Univariate Analysis Multivariate Analysis
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 67 9 1 1
≥ Median 67 19 2.09(0.94-4.64) 0.07 1.81(0.77-4.25) 0.17
Age at diagnosis (years)
Low <10 103 20 1 1
High ≥10 31 8 1.23(0.54-2.79) 0.62 1.22(0.51-2.95) 0.66
WBC count (x 109/ L)
Low < 50 100 16 1 1
High ≥ 50 34 12 2.64(1.25-5.57) 0.01 2.66(1.12-6.35) 0.03
In vitro  Prednisolone  response
Good 54 8 1 1
Intermediate 47 12 1.95(0.80-4.78) 0.14 1.57(0.62-3.94) 0.34
Poor 33 8 1.61(0.60-4.30) 0.34 1.38(0.47-4.05) 0.56
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 119 7 1 1
≥ Median 120 18 2.842(1.186-6.812) 0.02 3.172(1.123-8.958) 0.03
Age at diagnosis (years)
Low <10 152 15 1 1
High ≥10 87 10 1.857(0.813-4.243) 0.14 1.402(0.501-3.918) 0.52
WBC count (x 109/ L)
Low < 50 188 21 1 1
High ≥ 50 51 4 0.724(0.248-2.109) 0.55 0.563(0.176-1.802) 0.33
In vivo Prednisolone  response
Good 223 23 1 1
Poor 7 2 2.749(0.647-11.689) 0.17 0.864(0.160-4.651) 0.87
DCOG-ALL10 protocol
Univariate Analysis Multivariate Analysis
BCP-ALL
 COALL-97/03 protocol
Univariate Analysis Multivariate Analysis
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Good 21 7 1 1
Intermediate 22 9 1.37(0.51-3.68) 0.533 1.36(0.48-3.85) 0.56
Poor 17 4 0.72(0.21-2.48) 0.61 0.66(0.19-2.37) 0.53
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 28 2 1 1
≥ Median 28 8 4.40(0.93-20.73) 0.06 6.27(1.18-3.29) 0.03
Age at diagnosis (years)
Low <10 29 5 1 1
High ≥10 27 5 1.10(0.32-3.80) 0.88 1.80(0.43-7.45) 0.42
WBC count (x 109/ L)
Low < 50 21 4 1 1
High ≥ 50 34 6 0.85(0.24-3.01) 0.80 0.44(0.11-1.74) 0.24
In vivo  Prednisolone  response
Good 39 5 1 1
Poor 16 5 2.54(0.74-8.79) 0.14 3.23(0.80-13.01) 0.10
T-ALL
 COALL-97/03 protocol
Univariate Analysis Multivariate Analysis
 DCOG-ALL10 protocol
Univariate Analysis Multivariate Analysis
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 67 9 1 1
≥ Median 67 19 2.09(0.94-4.64) 0.07 1.81(0.77-4.25) 0.17
Age at diagnosis (years)
Low <10 103 20 1 1
High ≥10 31 8 1.23(0.54-2.79) 0.62 1.22(0.51-2.95) 0.66
WBC count (x 109/ L)
Low < 50 100 16 1 1
High ≥ 50 34 12 2.64(1.25-5.57) 0.01 2.66(1.12-6.35) 0.03
In vitro  Prednisolone  response
Good 54 8 1 1
Intermediate 47 12 1.95(0.80-4.78) 0.14 1.57(0.62-3.94) 0.34
Poor 33 8 1.61(0.60-4.30) 0.34 1.38(0.47-4.05) 0.56
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 119 7 1 1
≥ Median 120 18 2.842(1.186-6.812) 0.02 3.172(1.123-8.958) 0.03
Age at diagnosis (years)
Low <10 152 15 1 1
High ≥10 87 10 1.857(0.813-4.243) 0.14 1.402(0.501-3.918) 0.52
WBC count (x 109/ L)
Low < 50 188 21 1 1
High ≥ 50 51 4 0.724(0.248-2.109) 0.55 0.563(0.176-1.802) 0.33
In vivo Prednisolone  response
Good 223 23 1 1
Poor 7 2 2.749(0.647-11.689) 0.17 0.864(0.160-4.651) 0.87
DCOG-ALL10 protocol
Univariate Analysis Multivariate Analysis
BCP-ALL
 COALL-97/03 protocol
Univariate Analysis Multivariate AnalysisTable S2. 
Table S2. Univariate and multivariate nalysis of EMP1 statu , ge, white blood cell count and i  vitro a d in 
vivo prednisolone resistance and prognosis. Univariate and multivariate analysis of the indicated prognostic 
factors were performed by a Cox regression model based on event-free survival and with riskgroup as stratum. 
In vitro prednisolone response data are only available of COALL-97/03 patients, in contrast in vivo prednisolone 
response data are only available  of DCOG-ALL10 patients. 
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 30 9 1 1
≥ Median 30 11 1.19(0.49-2.86) 0.70 1.39(0.54-3.53) 0.49
Age at diagnosis (years)
Low <10 34 11 1 1
High ≥10 26 9 1.09(0.45-2.64) 0.85 1.13(0.46-2.80) 0.79
WBC count (x 109/ L)
Low < 50 15 4 1 1
High ≥ 50 45 16 1.45(0.49-4.34) 0.51 1.17(0.35-3.87) 0.80
In vitro  Prednisolone  response
Good 21 7 1 1
Intermediate 22 9 1.37(0.51-3.68) 0.533 1.36(0.48-3.85) 0.56
Poor 17 4 0.72(0.21-2.48) 0.61 0.66(0.19-2.37) 0.53
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 28 2 1 1
≥ Median 28 8 4.40(0.93-20.73) 0.06 6.27(1.18-3.29) 0.03
Age at diagnosis (years)
Low <10 29 5 1 1
High ≥10 27 5 1.10(0.32-3.80) 0.88 1.80(0.43-7.45) 0.42
WBC count (x 109/ L)
Low < 50 21 4 1 1
High ≥ 50 34 6 0.85(0.24-3.01) 0.80 0.44(0.11-1.74) 0.24
In vivo  Prednisolone  response
Good 39 5 1 1
Poor 16 5 2.54(0.74-8.79) 0.14 3.23(0.80-13.01) 0.10
T-ALL
 COALL-97/03 protocol
Univariate Analysis Multivariate Analysis
 DCOG-ALL10 protocol
Univariate Analysis Multivariate Analysis
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expression (mRNA)
< Median 67 9 1 1
≥ Median 67 19 2.09(0.94-4.64) 0.07 1.81(0.77-4.25) 0.17
Age at diagnosis (years)
Low <10 103 20 1 1
High ≥10 31 8 1.23(0.54-2.79) 0.62 1.22(0.51-2.95) 0.66
WBC count (x 109/ L)
Low < 50 100 16 1 1
High ≥ 50 34 12 2.64(1.25-5.57) 0.01 2.66(1.12-6.35) 0.03
In vitro  Prednisolone  response
Good 54 8 1 1
Intermediate 47 12 1.95(0.80-4.78) 0.14 1.57(0.62-3.94) 0.34
Poor 33 8 1.61(0.60-4.30) 0.34 1.38(0.47-4.05) 0.56
Patients Events HR (95%-CI) p -value HR (95%-CI) p -value
EMP1 expr ssion (mRNA)
< Median 119 7 1 1
≥ Median 120 18 2.842(1.186-6.812) 0.02 3.172(1.123-8.958) 0.03
Age at diagnosis (years)
Low <10 152 15 1 1
High ≥10 87 10 1.857(0.813-4.243) 0.14 1.402(0.501-3.918) 0.52
WBC count (x 109/ L)
Low < 50 188 21 1 1
High ≥ 50 51 4 0.724(0.248-2.109) 0.55 0.563(0.176-1.802) 0.33
In vivo Prednisolone  response
Good 223 23 1 1
Poor 7 2 2.749(0.647-11.689) 0.17 0.864(0.160-4.651) 0.87
DCOG-ALL10 protocol
Univariate Analysis Multivariate Analysis
BCP-ALL
 COALL-97/03 protocol
Univariate Analysis Multivariate Analysis
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Table	  S3.	  
Table	  S3.	  Univariate	  an<	  G$l.variate	  anal>3i3	  45	  67P)	  3tat$3Q	  a#eQ	  ;Cite	  bl44<	  Fell	   F4$nt	  an<	  3$bt>2e3	   in	  
BCP-­‐ALL.	  Univariate	   and	   mulCvariate	   analysis	   o6	   the	   indi,ated	   prognosC,	   6a,tors	   were	   per6ormed	   by	   a	   Co0	  
regression	  model	  straCied	  6or	  treatment	  proto,ol	  DCOALLhDCOSE	  based	  on	  event-­‐6ree	  survival.	  The	  per,ent	  o6	  
K-­‐year	  event-­‐6ree	   survival	  was	  analyfed	  using	  ^aplan-­‐Meier	   staCsC,s.	  _BC=white	  blood	   ,ell	   ,ountk	   ER=ETlW-­‐
RUNX1+,	   HD=hyperdiploid,	   E2A=TCF3-­‐PBX1+,	   BO=B-­‐other,	   BA=BCR-­‐ABL1+,	   BAL=BCR-­‐ABL1-­‐like,	   MLL=MLL-­‐
rearranged.	  ER	  and	  HD	  belong	  to	  the	   low-­‐risk	  group,	  E2A	  and	  BO	  to	   intermediate-­‐risk	  group	  and	  BA,	  BAL	  and	  
MLL	  to	  high-­‐risk	  group.	  
Patients Events HR	  (95%-­‐CI) p -­‐value HR	  (95%-­‐CI) p -­‐value
EMP1	  expression	  (mRNA)
<	  Median 186 16 1 1
≥	  Median 187 37 2.42(1.34-­‐4.35) <0.01 2.41(1.32-­‐4.39) <0.01
Age	  at	  diagnosis	  (years)
Low	  <10 255 35 1 1
High	  ≥10 118 18 1.50(0.84-­‐2.67) 0.17 0.89(0.485-­‐1.635) 0.71
WBC	  count	  (x	  10^9/	  L)
Low	  <	  50 288 37 1 1
High	  ≥	  50 85 16 1.58(0.88-­‐2.83) 0.13 1.22(0.665-­‐2.249 0.52
Subtype	  (risk)
ER	  HD 227 17 1 1
	  E2A	  BO 66 16 3.25(1.69-­‐6.28) <0.01 3.69(1.86-­‐7.31) <0.01
BA	  BAL	  MLL	   67 20 3.84(1.96-­‐7.54) <0.01 3.35(1.61-­‐6.98) <0.01
BCP-­‐ALL
Univariate	  Analysis Multivariate	  Analysis
COALL-­‐97/03	  protocol	  and	  DCOG-­‐ALL10	  cohort
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the nR4a ORPhan nuCLeaR ReCePtORs DO 
nOt COnfeR PReDnIsOLOne ResIstanCe In 
PeDIatRIC aCute LYMPhOBLastIC LeuKeMIa
I.M. ariës 1, e.s.R. van den Dungen1 , R. Pieters 1, M.L. den Boer 1
1 Department of Pediatric Oncology/hematology, erasmus Medical Center-sophia 
Children’s hospital, Rotterdam.
Leukemia 2013; [epub ahead of print]
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aBstRaCt
Resistance of leukemic cells to prednisolone is an obstacle for effective treat-
ment of pediatric precursor B-cell acute lymphoblastic leukemia (BCP-aLL) at 
initial diagnosis and even more at relapse. In this study we demonstrate that in 
primary BCP-aLL cells obtained from 176 children NR4A1 (nur77), NR4A2 (nurr1) 
and NR4A3 (nor1) mRna and (protein) levels were up to 3-fold (p<0.007) higher 
in in vitro prednisolone-resistant compared to sensitive cases. the nR4a family 
members are nuclear receptors which can antagonize the glucocorticoid re-
ceptor. we hypothesized that the nR4a family members may cause prednisolone 
resistance in BCP-aLL. Due to observed compensatory mechanisms between 
the nR4a members, we simultaneously silenced all three members in primary 
cells of BCP-aLL pediatric patients. simultaneous knockdown did not sensitize to 
prednisolone whereas a modest significant decrease of 25.4±11.1% in cell viabil-
ity was observed (p=0.029). In conclusion, although the nR4a family members 
are higher expressed in prednisolone-resistant BCP-aLL cells, these genes do not 
functionally contribute to prednisolone resistance. targeting the nR4a receptors 
modestly reduces leukemic cell viability. nevertheless, the requisite to target all 
three family members simultaneously due to compensatory mechanisms makes 
these genes unlikely candidates for a targeted drug approach to improve clini-
cal outcome in children with BCP-aLL.
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IntRODuCtIOn
Prednisolone is one of the principal chemotherapeutic drugs used to treat 
children with acute lymphoblastic leukemia (aLL). Resistance to prednisolone, 
both in vitro and in vivo, was shown to be of unfavorable prognostic value and 
has been used as a risk parameter in German COaLL and BfM protocols as 
well as Dutch DCOG treatment protocols 1–3. In addition, aLL cells often acquire 
resistance to prednisolone at the time the leukemia relapses 4. therapeutic inter-
vention to overcome prednisolone resistance is therefore desirable.
Prednisolone serves as ligand for the cytosolic glucocorticoid receptor (GR, 
also known as nR3C1). Binding of prednisolone conformationally changes the 
GR dispersing inactivating cochaperones, leading to homodimerization (figure 
1). hereafter, active GR orchestrates transcriptional regulation by binding to spe-
cific palindromic negative or positive glucocorticoid response elements (GRE) 
in the Dna, leading to gene repression or activation, respectively. active GR 
can also sequester other transcription factors, such as aP-1 and nf-κB, thereby 
diminishing the transcriptional activation of aP-1 and nf-κB responsive genes.
to study prednisolone resistance in more detail, we generated gene expression 
profiles of in vitro prednisolone sensitive and resistant precursor B-aLL (BCP-aLL) 
cells of newly diagnosed patients. Limma analysis revealed increased expression 
of all NR4A1, NR4A2 and NR4A3 probesets in in vitro prednisolone resistant BCP-
PREDNISOLONE
1 2 3
INACTIVE
GR
ACTIVE
AP-1 / NF-KB / NR4A
AP-1 / NF-KB / NR4A
CYTOSOL
NUCLEUS
COCHA-
PERONES
ACTIVE 
GR
AP-1
NF-KB
TRANSACTIVATION/
TRANSREPRESSIONTRANSREPRESSION
GRE
RNA
DNA
ACTIVE 
GR
NR4A
figure 1. Prednisolone; mechanisms of action and counteraction by nR4a family.
Prednisolone binds the cytosolic glucocorticoid receptor (GR), which dissociates inactivating 
cochaperones leading to homodimerization. Hereafter, GR binds specific palindromic negative or 
positive glucocorticoid response elements (GRe) in the Dna leading to gene repression or activation, 
respectively. active GR can also scavenge other transcription factors, such as aP-1 and nf-kB, inducing 
transrepression. nR4a family members can bind the GR as well, after which not only nR4a-dependent 
transcription but also GR-dependent transcription is diminished.
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aLL cells (see results). Interestingly, NR4A1 (protein name: nur77), NR4A2 (protein 
name: nurr1), and NR4A3 (protein name: nor1) are orphan nuclear receptors 
which belong to the same steroid hormone receptor superfamily as GR5. In con-
trast to the GR, nR4a family receptors are constitutively active without need for 
ligand binding 6. nur77, nurr1, and nor1 bind the nerve growth factor-induced 
B and nur Dna response element thereby transcriptionally regulating glucose 
and fatty acid metabolism, inflammation, central nervous system development, 
proliferation, differentiation and apoptosis7. a direct protein-protein interaction 
between GR and the nR4a family members has been demonstrated which was 
independent of GR homodimerization 8,9. Remarkably, it has been shown that 
the direct interaction between nR4a family members and the GR represses GR-
dependent transcription 8,9. Based on this literature and our microarray data, we 
hypothesized that the upregulated expression of nR4a family members may be 
responsible for prednisolone resistance in aLL by direct repression of predniso-
lone induced transcription (figure 1). In this study we aimed to silence the nR4a 
family members to evaluate the potential modulating effects on prednisolone 
resistance in primary BCP-aLL cells of pediatric patients.
MateRIaLs anD MethODs
Processing of patients’ leukemic cells
Bone marrow and peripheral blood samples were collected from children sus-
pected to suffer from newly diagnosed aLL (before initial therapy) as approved by 
the institutional review board and after written informed consent was obtained. 
Mononuclear cells were isolated by lymphoprep density gradient centrifugation, 
as previously described1. If necessary, immunomagnetic beads were used to 
enrich for leukemic blasts, as only leukemic samples with ≥ 90% leukemic blasts 
were used in the present study. the subtype of each patient, i.e. hyperdiploid 
(>50 chromosomes), ETV6-RUNX1+ , TCF3-PBX1+, MLL-rearrangement, BCR-ABL1+, 
BCR-aBL1+-like, or B-other (negative for aforementioned genomic lesions), was 
determined by means of FISH, PCR and by utilizing the 110-probeset classifier 10. 
Mononuclear cells were isolated from bone marrow (nBM) and peripheral blood 
(nPB) of children who were suspected for a malignancy but who turned out to 
be negative for a hematological disorder. Cells were cultured in RPMI Dutch 
modification (Gibco) supplemented with 0.1% insulin- transferrin- sodium selenite 
(sigma), 0.4 mM glutamine (Invitrogen), 0.25 µg/ml gentamycine (Gibco), 100 
Iu/ml penicillin (Gibco), 100 µg/ml streptomycin (Gibco), 0.125 µg/ml fungizone 
(Gibco) and 20% fetal calf serum (Integro) at 37°C in humidified air containing 
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5% CO2. Cell viability and cell counts were determined by trypan blue exclusion 
staining assays (Miltenyi Biotec).
Gene expression Microarrays
Total RNA was extracted from leukemic blasts (≥ 90% purity) by means of Trizol 
isolation (Invitrogen) according to the manufacturer’s protocol. Rna quality and 
integrity was determined with the 2100 Bioanalyzer (agilent). the One-Cycle 
cDna synthesis kit and the GeneChip Ivt Labeling kit (affymetrix) were used to 
synthesize cRna. Processing and hybridization of cRna to the affymetrix u133 
Plus 2.0 GeneChip oligonucleotide microarray was performed according to the 
manufacturer’s protocol. Gene-expression values were calculated with the af-
fymetrix Microarray suite version 5.0. expression signals were scaled to the target 
intensity of 500 and log-transformed. Only arrays with a scaling factor <10 and 
GaPDh cRna integrity (3’/5’) <3 were used for subsequent analyses. next, array 
data were normalized using the affy R Package to calculate the Robust Mul-
tichip average (RMa) and using the variance stabilization and normalization 2 
(vsn2) package 11. Differentially expressed genes between in vitro prednisolone 
resistant and sensitive BCP-ALL patients were identified with Limma R Package 
using subtype as a confounder in the statistical environment R, version 2.15.0. 
Correction for multiple tests was performed according to the false discovery 
rate (fDR) method 12. all NR4A1, NR4A2 and NR4A3 probesets were statistically 
differentially expressed between in vitro prednisolone sensitive and resistant pa-
tients. Probesets 202340_x_at NR4A1, 204621_s_at NR4A2, 209959_at NR4A3 were 
used for further analysis, as these probesets showed the most reliable differential 
expression between in vitro prednisolone sensitive and resistant patients.
Reverse Phase Protein array
Proteins from primary leukemic cells were isolated with protein lysis buffer con-
taining 25 mM tris ph 7.4, 150 mM naCl, 5 mM eDta ph 8.0, 1% triton X-100, 10% 
Glycerol, 10 mM sodium-pyrophosphate, 1 mM sodium-orthovanadate, 10 mM 
Glycerolphosphate, Dtt, Phenylmethylsulfonyl fluoride, aprotinin and sodium-
Fluoride. Protein concentration was quantified according to the BCA assay 
(Pierce). Lysates were spotted twice in triplicate on glass-backed nitrocellulose-
coated array slides by the facility of Dr. e. f. Petricoin, George Mason university, 
Manassas, USA. Slides were stained with specific antibodies, incubated with 
a biotinylated secondary antibody and scanned using the novaRay scanner. 
Protein levels were calculated relative to the total amount of protein per sample 
using Microvigene software. antibodies used were: nur77 antibody (Cell signal-
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ling #3960), nurr1 (sigma #n6413), nor1 (kindly provided by Prof C. de vries, 
aMC, the netherlands 13) (supplemental table 1).
siRna
siRnas (sigma) were designed utilizing rnaidesigner (Invitrogen) considering a 
maximum GC amount of 40-55% and tagged with an appropriate label (supple-
mental table 2). 2.0x106/ml leukemic patients’ cells were transfected with all 
three sinR4as simultaneously, 0.1 µM/106 cells each, or with the same amount 
of siscrl, 0.3 µM/106 cells using the transfection reagent Dharmafect 4 (thermo 
Scientific). Transfection efficiency was verified with the Accuri (BD Biosciences). 
viability of transfected cells was assessed by a trypan blue exclusion assay. Cells 
were harvested for Rna and protein isolation after 72 hours of culture.
Quantitative RT-PCR
Rna was extracted using a Rneasy microkit (Qiagen) according to the manu-
facturer’s protocol. cDna was synthesized from 1 µg Rna by 8 Iu/µl MMLv (Pro-
mega), 20nM oligodt primers, 1µM random hexamer primers (Invitrogen), 200 
µM dntPs and 1 Iu/µl Rnasin in MMLv-buffer (Promega). NR4A1, NR4A2 and 
NR4A3 mRNA levels were quantified by incorporation of SYBR Green (Thermo 
Scientific) by quantitative real-time (qRT) PCR (Applied Biosystems 7900HT). 
Primer sequences see supplemental table 3.
Western blot analysis
25 µg protein was loaded on Bio-Rad Mini-Protean tGX pre-cast anyKD and 
transferred to nitrocellulose membranes (trans-Blot turbo Mini nitrocellulose 
transfer Packs, Bio-Rad). Blots were blocked and probed with antibody 
according to supplemental table 1. Hereafter, protein levels were quantified 
using the Odyssey 3.0 application software (Li-COR).
In vitro MTT drug-resistance assay
Cytotoxicity of prednisolone (Bufa Pharmaceutical Products) in primary 
patients’ cells was determined by the in vitro 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (Mtt) drug-resistance assay after 4-days of 
exposure, as previously described 1. Optical density values were measured on a 
versamax (Molecular Devices) at λ=562 nm and λ=720nm. In vitro prednisolone 
sensitivity was defined by a concentration of prednisolone lethal to 50% of the 
cells (LC50) below 0.1 μg/mL and prednisolone resistance was defined by a LC50 
value above 150 µg/mL as shown previously to be predictive for clinical outcome 
in pediatric aLL1. Prednisolone response after siRna treatment was determined 
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by the Mtt drug-resistance assay after 3-days of exposure and prednisolone-
response curves of nR4a-silenced cells were corrected for loss of cell viability 
caused by the silencing procedure itself.
statistical analysis
Spearman’s rank correlation coefficient was calculated to compare microarray 
gene expression results to qRt-PCR results. Data from other experiments were 
compared with Mann-whitney u tests. a p-value below 0.05 was considered 
statistically significant.
ResuLts
nR4a1, nR4a2 and nR4a3 mRna expression levels are higher in 
prednisolone resistant leukemic cells
Microarray analysis of 176 primary BCP-aLL patients revealed that NR4A1, NR4A2 
and NR4A3 mRna levels were 3.0-fold (fDR=0.007), 2.6-fold (fDR=0.01) and 
2.0-fold (fDR=0.01) respectively higher in leukemic cells of in vitro prednisolone 
resistant compared to sensitive patients (Microarray data are provided in sup-
plemental table 4). validation of microarray data by qRt-PCR indicated that the 
NR4A mRNA levels measured in 23 cases were significantly correlated (Rs=0.94, 
Rs=0.87 and Rs=0.91, respectively p<0.0001, figure 2). NR4A1, NR4A2 and NR4A3 
mRna levels were 13.2-fold, 4.8-fold and 13.8-fold higher, respectively in BCP-aLL 
cells compared to normal bone marrow samples (p<0.05, figure 2).
nur77 and nurr1 protein levels are higher in prednisolone resistant 
leukemic patients´ cells and are overall increased in leukemic cells 
compared to normal cells
Reverse phase protein array analysis revealed a 2.7-fold higher nur77 (encoded 
by NR4A1) and 1.2-fold higher nurr1 (encoded by NR4A2) protein level in in 
vitro prednisolone resistant compared to sensitive aLL patients’ samples (figure 
3, p<0.01). Protein levels of nor1 (encoded by NR4A3) did not differ (figure 3). 
Nur77 and Nurr1 levels were significantly higher in BCP-ALL compared to normal 
BM, overall 5-fold (p<0.0001, figure 3). a high expression of nur77 was especially 
seen in hyperdiploid aLL patients (7.4-fold , p<0.0001), BCR-ABL1-like aLL patients 
(6.3-fold, p<0.0001), ETV6-RUNX1+ aLL patients (3.9-fold, p<0.0001) and B-other aLL 
patients (3.3-fold p<0.0001) compared to normal bone marow samples. notably, 
patients with the highest nur77 expression were all in vitro intermediate resistant or 
resistant to prednisolone, with the exception of two patients (figure 3).
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figure 2. nR4a1, nR4a2 and nR4a3 mRna expression is increased in prednisolone resistant 
leukemic patients´ cells.
nR4a1, nR4a2 and nR4a3 mRna expression levels are higher in prednisolone resistant leukemic primary 
patient cell samples compared to sensitive samples as detected by microarrays. nR4a1, nR4a2 and nR4a3 
mRna levels detected by microarrays were correlated with those detected by qRt-PCR as shown for 12 in 
vitro prednisolone sensitive patients and 11 in vitro prednisolone resistant patients. qRt-PCR revealed that 
nR4a mRna levels in 11 prednisolone resistant BCP-aLL cases were higher than those of 3 normal bone 
marrow samples (*p<0.05, **p<0.01, ***p<0.001)
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figure 3. nur77 and nurr1 protein expression levels are higher in prednisolone resistant 
leukemic patients´ cells and are increased in leukemic cells compared to normal cells.
Protein levels of nur77 (nR4a1 gene), nurr1 (nR4a2 gene), nor1 (nR4a3 gene) were analyzed by reverse 
phase protein arrays. each dot represents a leukemic patient sample. Patient samples above the dashed 
line have high nur77 expression levels and are intermediate resistant and resistant to prednisolone except 
for two sensitive patients who are indicated by white symbols. (**p<0.01, ***p<0.001). a.u. arbitrary units 
normalized for total protein.
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Figure 4. Knockdown of Nur77, Nurr1 and Nor1 in primary ALL cells affects cell survival.
Pediatric BCP-ALL cells were transfected simultaneously with siNR4A1-Flc, siNR4A2-Cy3 and siNR4A3-Cy5 (siNR4A-all), 
or with siScrl-Cy5. (A)Transfection efficiency at 72 hours after transfection was assessed by means of flow cytometry. 
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mined 72 hours after transfection by qRT-PCR and calculated relative to siScrl after correcting for the housekeeping 
gene RPS20. (C) Western Blot analysis was used to determine Nur77, Nurr1 and Nor1 expression 72 hours after trans-
fection relative to the housekeeping protein β-actin. (D) Protein expression levels were calculated with the Odyssey 
software and corrected for β-actin and are relative to the levels detected in siScrl treated cells. (E) Leukemic cell 
survival 72 hours after transfection was evaluated with a trypan blue exclusion assay.  Data are presented as mean 
plus SEM of four different BCP-ALL patients’ leukemic cell samples with the following subtype, two ETV6-RUNX1+, one 
hyperdiploid and one sample with no known genetic aberration, i.e. B-other (*p<0.05).
Figure 4. Knockdown of Nur77, Nurr1 and Nor1 in primary ALL cells affects cell survival.
Pediatric BCP-ALL cells were transfected simultaneously with siNR4A1-Flc, siNR4A2-Cy3 and siNR4A3-Cy5 
(siNR4A-all), or with siScrl-Cy5. (A)Transfection efficiency at 72 hours after transfection was assessed by 
means of flow cytometry. (Mo k; green line, siScrl; purple line, siNR4A- ll; pink line) (B) NR4A1, NR4A2 and 
NR4A3 mRNA levels were determined 72 hours after transfection by qRT-PCR and calculated relative to 
siScrl after correcting for the housekeeping gene RPS20. (C) Western Blot analysis was used to determine 
Nur77, Nurr1 and Nor1 expression 72 hours after transfection relative to the housekeeping protein β-actin. 
(D) Protein expression levels were calculated with the Odyssey software and corrected for β-actin and are 
r lative to the l v ls detected in siScrl treated cells. (E) Leukemic c ll survival 72 hours after transfection 
was evaluated with a trypan blu  exclusion assay. Data are presented as mean plus SEM of four different 
BCP-ALL patients’ leukemic cell samples with the following subtype, two ETV6-RUNX1+, one hyperdiploid 
and one sample with no known genetic aberration, i.e. B-other (*p<0.05).
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Knockdown of nur77, nurr1 and nor1 in primary bCP-all cells does 
not sensitize to prednisolone but does reduce cell viability
to test our hypothesis that increased expression of nR4a receptors antagonize 
the functionality of the GR and as such causes prednisolone resistance, we 
silenced the expression of these genes and assessed changes in the cytotoxicity 
of prednisolone. we observed that NR4A1, NR4A2 and NR4A3 expression 
levels are lower in a prednisolone resistant cell line than in patients’ leukemic 
cells (supplementary figure 1). Moreover, knockdown of one NR4A led to an 
extreme upregulation in expression levels of the other NR4A family members 
(supplementary figure 1). we therefore simultaneously silenced all three nR4a 
family members in leukemic cells of in vitro prednisolone resistant BCP-aLL 
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figure 5. Knockdown of nur77, nurr1 and nor1 in primary all cells does not sensitize to 
prednisolone.
Response to prednisolone was assessed in a three day Mtt assay directly after transfection with either 
siscrl or co-transfection of sinR4a1, sinR4a2 and sinR4a3 (sinR4a-all). sensitivity was corrected for cell 
death induced by nR4a1, nR4a2 and nR4a3 knockdown without co-exposure to prednisolone. Data are 
presented as mean plus seM of a duplicate experiment.
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patients who had high basal expression of NRA41, NR4A2 and NR4A3 mRna. 
all primary patients’ cells were 100% positive for the labeled siRnas directed 
against the three nR4a-family members (figure 4a). Co-transfection of all three 
siRnas (sinR4a-all) reduced the mRna levels by 57.1±14.5% for NR4A1, 47.7±27.5% 
for NR4A2 and 57.8±35.0% for NR4A3, compared to the levels seen in equally 
dosed non-silencing scrambled control (siscrl) treated cells (n=4, p<0.05, figure 
4B). nur77, nurr1 and nor1 protein levels were decreased to 51.4%, 51.2% and 
35.4% respectively, compared to those observed in the siscrl cells (figure 4C-D). 
silencing of all three nR4as simultaneously decreased the viability of primary 
BCP-aLL patients’ cells by 25.4±11.1% (p<0.05, figure 4e). however, silencing of 
these three nR4as did not sensitize to prednisolone (figure 5).
DIsCussIOn
Resistance of leukemic cells to prednisolone is linked to an unfavorable clinical 
outcome in children with newly diagnosed aLL. Leukemic cells even become 
more resistant to prednisolone at the time of relapse 4,14. up to now the mo-
lecular mechanisms which denotes prednisolone resistance in leukemic cells 
are unclear. In this study we demonstrated increased NR4A1 (nur77), NR4A2 
(nurr1) and NR4A3 (nor1) mRna and protein levels in in vitro prednisolone re-
sistant compared to sensitive patients. nur77, nurr1 and nor1 directly bind the 
GR via their Dna binding domain, independent of GR homodimerization, and 
subsequently antagonize glucocorticoid induced transcriptional activation 8,9. 
we hypothesized that upregulated nR4a family expression may be responsible 
for prednisolone resistance in aLL. nur77, nurr1 and nor1 are highly homologues, 
the Dna binding and C-terminal ligand binding domains exhibit ~91-95% and 
~60% homology, respectively whereas their n-terminal domains are highly di-
vergent 15. nor1 can take over the function of nur77, as NR4A1-/- mice appear 
normal due to compensation by NR4A3 16. this compensation process most likely 
explains the upregulation of NR4A2 and NR4A3, after NR4A1 knockdown in BCP-
aLL cells as shown in the present study (supplemental figure 1).
we therefore developed a system in which we could knockdown all three 
NR4As in primary pediatric aLL patients’ cells. we were able to achieve ~50% 
knockdown of all three NR4As simultaneously. however, knockdown of the 
nR4a family did not result in prednisolone sensitization in primary aLL patient 
cell samples. Our results suggest that prednisolone resistance is not caused by 
impaired functioning of GR at the receptor level. In correspondence, previous 
studies showed that there was no correlation between baseline GR mRna levels 
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and prednisolone resistance 17,18. Prednisolone resistance has been correlated 
with aberrant function of apoptosis genes and increased glycolytic activity 19,20. 
Impaired downregulation of anti-apoptotic MCL1 by prednisolone has been ob-
served in prednisolone resistant patients 21,22. together these data suggest that 
resistance to prednisolone more likely is caused by mechanisms affecting the 
downstream intracellular signaling than by mechanisms affecting the effective 
GR receptor levels.
although knockdown of the nR4a family did not result into prednisolone sensi-
tization, we did see a decline in cell survival. Reported effects of the nR4a family 
on cell survival are context dependent. nuclear export of nur77 and nor1 to 
the mitochondria activates pro-apoptotic Bcl-2 family members 23, which occurs 
in acute myeloid leukemia 24. In contrast, nur77, nurr1 and nor1 transcription 
regulation conveys an anti-apoptotic environment 25–27, as is the case in for 
example B cell lymphoma, melanoma, colon cancer 24,28, and as we show here, 
in BCP-aLL.
In conclusion, the nR4a family members are higher expressed in prednisolone 
resistant aLL cells, but do not functionally contribute to resistance in these cells. 
BCP-aLL is characterized by overall higher expression of the nR4a family com-
pared to normal BM cells. targeting of nR4a genes impairs leukemic cell survival, 
but compensatory mechanisms designate that all three nR4a members need 
to be targeted simultaneously to diminish cell survival. these data therefore 
show that nR4a genes are not suitable to reverse prednisolone resistance nor to 
induce cell death by targeted drugs.
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 siRNA Sense Antisense Label 
siNR4A1 GAGGGAGAGAGCUAUUCCAUGCCUA UAGGCAUGGAAUAGCUCUCUCCCUC 5’ Fluorescein 
siNR4A2 CCCUGGAAAUAACUGAGCACUUUGA UCAAAGUGCUCAGUUAUUUCCAGGG 5’ Cy3 
siNR4A3 ACUCAACACCCAGAGAUCUUGAUUA UAAUCAAGAUCUCUGGGUGUUGAGU 5’Cy5 
siScrl GGACAAGGCCAUGCAAUUGGUACAA UUGUACCAAUUGCAUGGCCUUGUCC 5’ Cy5 
 
Supplemental Table 2. siRNA sequences
Gene Forward (5’ – 3’) Reverse (5’ – 3’) 
NR4A1 GGG GAG GGA GAG AGC TAT TTA GCC AGG CAG ATG TAC TT 
NR4A2 GCG AAC CCT GAC TAT CAA AGG AGA AGG CAG AAA TGT C 
NR4A3 ACG TCG AAA CCG ATG TCA GTA GGC TGA GAA GGT TCC TGT TGT A 
RPS20 AAG GGC TGA GGA TTT TTG CGT TGC GGC TTG TTA G 
 
Supplemental Table 3. Primer sequences
Supplemental Table 1. Antibodies RPPA and Western Blot
Supplemental Tables.
Antigen Manufacturer (#) Blocking, Dilution, Conditions 
β-Actin Abcam #ab8226 5% BSA or 5% milk in TBST, 1:20000, 1 hour room temperature 
Nur77 Cell Signaling #3960 5% BSA in TBST, 1:500 , 2 hour room temperature 
Nurr1 Sigma #N6413 5% milk in TBST, 1:1000, overnight 4 °C 
Nor1 Provided by Prof C. de Vries 11 5% BSA in TBST, 1:1000, overnight 4 °C 
Secondary 
antibodies 
Li-COR, #926-32210, 
#926-32211, #926-32220 
1:5000 – 1:10000 in same solution as primary antibody,                         
1 hour room temperature 
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Supplemental Table 4. 
NR4A1, NR4A2, NR4A3 microarray expression and patient characteristics of 176 pediatric BCP-ALL patients.
Patient Treatment Genetic LC50 Score NR4A1 NR4A2 NR4A3
Number  Protocol Subtype Prednisolone µg/ml Prednisolone 202340_x_at 204621_s_at 209959_at
1 COALL HD 0,106 2 11,30 11,20 9,59
2 COALL HD 2,287 2 11,47 11,18 8,13
3 COALL BAL 0,337 2 11,30 11,13 9,97
4 COALL BO 0,334 2 11,08 11,52 9,61
5 COALL BAL 250,000 3 10,95 10,84 8,25
6 COALL TA 0,042 1 10,09 10,48 9,87
7 COALL BAL 250,000 3 10,62 11,70 12,34
8 COALL BO 0,225 2 11,77 11,36 10,06
9 COALL HD 14,844 2 10,01 10,63 10,01
10 COALL MLL 0,283 2 10,55 11,33 11,17
11 COALL HD 0,450 2 11,89 12,18 11,26
12 COALL TA 0,020 1 9,36 8,48 8,35
13 COALL HD 250,000 3 10,65 10,90 9,65
14 COALL BAL 250,000 3 9,08 9,77 7,39
15 COALL BAL 250,000 3 12,47 12,74 12,01
16 COALL BAL 195,313 3 10,46 10,27 9,48
17 COALL TA 228,966 3 11,37 9,92 10,49
18 COALL BO 154,018 3 10,10 11,06 8,76
19 COALL BAL 250,000 3 10,83 9,85 8,96
20 COALL TA 250,000 3 10,82 9,97 10,88
21 COALL BO 250,000 3 10,49 10,97 9,62
22 COALL BAL 250,000 3 11,33 10,91 8,55
23 COALL BO 250,000 3 11,72 11,12 11,90
24 COALL TA 0,031 1 9,32 8,91 8,49
25 COALL BO 0,040 1 10,12 8,05 8,35
26 COALL TA 0,068 1 10,94 10,43 10,75
27 COALL BAL 27,107 2 10,30 9,76 10,18
28 COALL BO 0,014 1 9,59 8,84 11,53
29 COALL HD 250,000 3 11,28 11,48 10,93
30 COALL BO 0,031 1 11,18 9,57 7,03
31 COALL TA 250,000 3 12,43 11,41 12,22
32 COALL TA 250,000 3 9,43 9,41 8,86
33 COALL BO 17,578 2 10,97 8,93 7,32
34 COALL TA 0,008 1 9,22 8,71 7,70
35 COALL BAL 0,324 2 11,66 11,26 10,46
36 COALL E2A 0,030 1 10,88 9,27 10,20
37 COALL BAL 0,061 1 9,25 8,96 8,78
38 COALL HD 0,026 1 9,00 9,51 7,65
39 COALL BA 0,032 1 11,46 12,07 8,67
40 COALL BO 0,024 1 9,39 10,36 7,61
41 COALL TA 0,040 1 10,47 10,50 8,89
42 COALL BO 0,243 2 10,69 9,87 10,53
43 COALL TA 0,057 1 10,51 10,34 11,12
44 COALL HD 0,280 2 9,50 9,58 8,42
45 COALL BO 0,028 1 8,35 8,91 7,02
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46 COALL TA 0,384 2 9,70 9,30 9,62
47 COALL BAL 0,275 2 10,12 9,63 8,13
48 COALL TA 0,045 1 10,06 9,23 9,24
49 COALL BAL 0,553 2 11,39 11,59 10,64
50 COALL TA 0,302 2 8,94 8,94 7,87
51 COALL BAL 0,583 2 11,46 11,88 9,92
52 COALL TA 0,247 2 9,77 9,67 9,69
53 COALL TA 0,091 1 8,94 7,06 6,55
54 COALL TA 0,397 2 9,61 7,78 9,56
55 COALL BO 250,000 3 11,49 12,05 10,79
56 COALL HD 0,306 2 10,49 11,00 9,97
57 COALL HD 0,208 2 8,08 8,33 8,29
58 COALL NA 0,271 2 10,39 10,28 9,12
59 COALL HD 0,421 2 10,89 11,25 7,87
60 COALL HD 0,417 2 10,07 9,68 9,13
61 COALL BO 250,000 3 10,53 9,87 8,61
62 COALL TA 0,050 1 8,59 7,97 8,15
63 COALL HD 0,253 2 11,08 9,99 8,29
64 COALL TA 0,427 2 11,65 9,73 9,44
65 COALL BA 3,621 2 7,87 9,06 6,94
66 COALL BO 3,871 2 11,31 10,17 9,18
67 COALL BO 0,074 1 8,63 9,52 8,58
68 COALL BO 0,179 2 11,68 11,66 11,47
69 COALL TA 154,891 3 8,92 8,80 8,40
70 COALL TA 0,133 2 9,28 8,98 8,15
71 COALL BAL 0,039 1 7,14 8,20 6,28
72 COALL HD 250,000 3 10,92 12,03 11,45
73 COALL BO 0,023 1 8,02 8,29 9,01
74 COALL TA 0,008 1 8,08 8,49 7,22
75 COALL HD 0,034 1 10,23 10,07 7,95
76 COALL TA 250,000 3 10,30 9,59 10,24
77 COALL BO 250,000 3 10,26 11,14 10,56
78 COALL BO 0,009 1 8,53 6,82 8,50
79 COALL HD 0,025 1 11,77 11,56 10,76
80 COALL HD 0,058 1 10,11 9,06 8,55
81 COALL BO 0,008 1 10,92 11,92 11,87
82 COALL HD 0,008 1 10,39 9,78 7,88
83 COALL TA 0,346 2 10,17 10,44 10,30
84 COALL HD 0,199 2 10,49 10,40 7,27
85 COALL HD 0,049 1 9,75 10,70 7,02
86 COALL HD 0,059 1 11,63 11,44 9,98
87 COALL HD 250,000 3 9,30 9,09 7,95
88 COALL HD 0,040 1 10,67 9,84 8,38
89 COALL TA 0,053 1 10,28 9,25 10,32
90 COALL BAL 0,338 2 10,67 11,10 10,75
91 COALL HD 0,057 1 10,49 9,67 9,10
92 COALL BAL 0,034 1 11,35 11,45 8,88
93 COALL BO 250,000 3 10,21 10,91 9,83
94 COALL TA 0,026 1 9,75 7,31 7,34
95 COALL BO 0,046 1 7,41 6,70 7,01
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96 COALL HD 210,938 3 11,69 11,76 11,13
97 COALL TA 0,025 1 11,63 10,86 12,34
98 COALL BO 2,767 2 10,82 11,14 9,91
99 COALL BO 250,000 3 7,26 7,52 6,86
100 COALL BO 0,429 2 9,12 9,67 9,70
101 COALL BO 2,197 2 9,78 10,77 7,13
102 COALL HD 0,129 2 9,31 9,55 6,86
103 COALL BAL 172,176 3 9,37 9,77 8,08
104 COALL TA 0,008 1 7,61 8,53 6,67
105 COALL TA 0,025 1 11,27 9,35 11,33
106 COALL HD 0,015 1 10,87 10,83 11,22
107 COALL BAL 0,106 2 10,20 10,57 7,68
108 COALL HD 0,011 1 11,60 11,59 9,59
109 COALL E2A 250,000 3 9,84 9,69 10,16
110 COALL BO 0,008 1 8,97 8,73 10,52
111 COALL HD 0,050 1 9,92 10,46 9,24
112 COALL BAL 0,027 1 9,37 9,51 8,22
113 COALL BAL 0,054 1 10,42 10,10 6,91
114 COALL HD 206,250 3 10,90 11,78 10,47
115 COALL TA 0,465 2 10,76 9,04 10,87
116 COALL TA 250,000 3 10,93 9,90 12,32
117 COALL BO 0,045 1 7,68 9,82 7,77
118 COALL BAL 2,608 2 11,55 11,23 11,60
119 COALL HD 0,186 2 10,57 10,90 8,02
120 COALL TA 0,049 1 11,35 11,84 12,26
121 COALL HD 0,028 1 9,06 9,61 7,16
122 COALL HD 0,049 1 10,82 11,76 8,73
123 COALL BO 0,042 1 9,99 10,50 6,45
124 COALL HD 0,038 1 10,12 10,75 8,37
125 COALL BO 250,000 3 11,22 11,20 12,08
126 COALL HD 250,000 3 11,71 9,92 10,09
127 COALL BAL 0,409 2 10,72 11,05 12,01
128 COALL HD 250,000 3 11,12 11,32 8,47
129 COALL TA 0,131 2 9,24 8,86 8,65
130 COALL TA 0,054 1 9,01 8,72 8,00
131 COALL TA 0,173 2 9,13 9,04 9,45
132 COALL TA 0,032 1 8,96 8,59 7,43
133 COALL TA 0,396 2 11,23 9,66 10,80
134 COALL TA 0,175 2 7,19 6,84 5,97
135 DCOG E2A 0,008 1 9,68 6,95 8,31
136 DCOG HD 0,052 1 10,47 10,74 8,38
137 DCOG TA 0,040 1 11,40 8,58 9,81
138 DCOG TA 0,060 1 8,70 7,84 6,29
139 DCOG BO 0,054 1 8,01 8,12 7,53
140 DCOG MLL 250,000 3 10,01 8,49 7,91
141 DCOG BO 0,036 1 8,58 7,30 8,08
142 DCOG HD 3,626 2 7,66 7,60 5,86
143 DCOG TA 0,219 2 7,44 5,72 6,36
144 DCOG HD 0,357 2 9,14 8,76 7,08
145 DCOG TA 0,090 1 7,15 6,94 6,05
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146 DCOG TA 250,000 3 8,87 7,63 7,49
147 DCOG TA 250,000 3 11,58 11,85 12,41
148 DCOG BO 250,000 3 8,74 8,26 6,59
149 DCOG TA 0,159 2 7,74 7,28 6,30
150 DCOG TA 250,000 3 12,40 12,04 13,31
151 DCOG TA 0,008 1 8,27 7,48 6,44
152 DCOG HD 0,208 2 11,31 11,41 10,04
153 DCOG TA 0,061 1 7,04 5,03 6,25
154 DCOG BA 0,048 1 10,77 10,29 10,80
155 DCOG BAL 250,000 3 12,47 13,08 12,89
156 DCOG BAL 2,846 2 12,00 12,11 10,26
157 DCOG HD 0,330 2 10,58 9,77 7,29
158 DCOG E2A 0,008 1 6,96 5,40 5,91
159 DCOG HD 0,008 1 10,41 10,93 8,52
160 DCOG HD 250,000 3 10,38 10,46 9,03
161 DCOG HD 0,151 2 9,69 9,25 7,75
162 DCOG E2A 0,087 1 9,47 10,21 8,02
163 DCOG TA 0,102 2 10,50 9,40 9,39
164 DCOG TA 250,000 3 10,13 8,49 8,34
165 DCOG TA 0,047 1 10,39 9,54 8,94
166 DCOG HD 0,050 1 11,14 11,60 10,15
167 DCOG HD 132,523 2 11,21 11,18 9,20
168 DCOG HD 0,041 1 8,55 8,25 6,07
169 DCOG TA 250,000 3 11,14 11,21 10,61
170 DCOG NA 0,061 1 11,34 7,88 9,13
171 DCOG BO 0,008 1 8,30 7,03 6,52
172 DCOG TA 0,041 1 10,87 10,37 11,21
173 DCOG HD 0,427 2 9,05 8,97 7,58
174 DCOG TA 0,343 2 11,26 9,74 9,84
175 DCOG BO 12,600 2 7,87 6,75 6,77
176 DCOG HD 2,158 2 10,04 9,34 9,28
Genetic Subtype: HD=hyperdiploid, TA=ETV6-RUNX1+, BA=BCR-ABL1+, BAL= BCR-ABLLike, E2A=TCF3-PBX1+, MLL=MLL rearranged,  
BO= B-other,  negative for aforementioned lesions
Prednisolone score: 1 sensitive = ≤0.1 µg/ml, 2 intermediate=<0.1-<150 µg/ml, 3 resistant =≥150 µg/ml
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Supplemental Figure 1.
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Supplemental Figure 1. 
Knockdown of NR4A1 induces strong upregulation of NR4A2 and NR4A3.
A-C. NR4A1, NR4A2 and NR4A3 mRNA expression was evaluated by qRT-PCR in 12 in vitro
prednisolone sensitive patients, 11 in vitro prednisolone resistant patients’ and several
timepoints of an in vitro prednisolone resistant BCP-ALL cell line Reh (ETV6-RUNX1+). D.
mRNA expression of NR4A1, NR4A2 and NR4A3 was assessed 96 hours after lentiviral
shNR4A1 knockdown, corrected for RPS20 expression and relative to a non-silencing
control short hairpin (NSC). Data are presented as mean plus SEM of two independent
experiments.
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aBstRaCt
the 5-year event-free survival of pediatric precursor-B acute lymphoblastic leu-
kemia (BCP-aLL) has currently reached 80-90%. targeted drugs are warranted 
to cure the remaining 10-20%. Prednisolone has been shown a pivotal drug and 
resistance remains an adverse prognostic factor in BCP-aLL. In this study we 
demonstrate that prednisolone downregulated the activity of the Ras-Raf-MeK 
pathway and stat6 in prednisolone sensitive patients cells, but was not capable 
to do so in prednisolone resistant patients. In addition, we identified activating 
Ras-pathway-mutations (nRas, KRas, PtPn11 and fLt3) in 10 out of 26 patients 
(38%) of which 6 cases harboured ≥ 2 RAS-mutations predominantly associated 
with presence of minor clones (<30%). exposure of primary patients’ aLL samples 
to Trametinib (MEK-inhibitor), Sorafinib (BRAF-inhibitor), AS1517499 (STAT6-
inhibitor) or Crizotinib (cMet-inhibitor) as single agents did not affect leukemic 
cell survival. however, trametinib was impressively potent when combined with 
prednisolone eradicating all leukemic cells of the nRas/KRas-mutated BCP-
aLL patients. In one nRas/KRas-mutated case sorafenib but not trametinib 
sensitized to prednisolone significantly. In conclusion, our data implicate that 
BCP-aLL patients should be screened for Ras-activating-mutations as these 
patients may benefit from treatment with Trametinib/Sorafenib combined with 
prednisolone. we furthermore advise to perform in vitro inhibitor assays in Ras-
mutated BCP-aLL patients’ cells to elucidate which inhibitor may be the most 
effective in individual patients.
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IntRODuCtIOn
Optimization of treatment protocols and improved risk stratification have en-
hanced event-free survival rates in pediatric precursor-B acute lymphoblastic 
leukemia (BCP-aLL) up to 80-90% 1. Remarkably, these results are obtained 
without changing the core chemotherapeutic drugs that have been used for 
decades, including prednisolone, L-asparaginase and vincristine. to cure the 
remaining 20% of patients and to reduce long-term side effects in survivors, 
more personalized targeted therapy is warranted. the remarkable improvement 
of survival in BCR-ABL1-positive pediatric BCP-aLL with the addition of the aBL1 
tyrosine kinase inhibitor dasatinib and imatinib 2–4 to current treatment protocols 
is a key-example and encourages further investigation of targeted therapy. Op-
timized high-throughput screening has brought tailored therapy a step closer. 
Recently, high-throughput sequencing in 187 high-risk BCP-ALL cases identified 
a high frequency of recurrent alterations in crucial signaling pathways, including 
B-cell development/differentiation (68% of cases), the tP53/RB tumor suppres-
sor pathway (54%), Ras signaling (50%), and Janus kinases (11%) 5. these results 
are remarkable, although the clinical and biologic significance has yet to be 
investigated.
novel targeted drugs will most likely serve as adjuvants to current 
chemotherapy regimens. Prednisolone has been shown to be the most pivotal 
in treating pediatric BCP-aLL, as in vivo and in vitro response to prednisolone 
is an important predictor for long-term clinical outcome6. Moreover, relapsed 
leukemic cells gain prednisolone resistance 7. hence, to improve clinical 
outcome drugs need to be found which reverse resistance to prednisolone. 
Prednisolone is a glucocorticoid that binds the glucocorticoid receptor, which 
acts as a transcription factor regulating the expression of numerous genes 
eventually leading to apoptosis. eight hours of prednisolone exposure of sensitive 
BCP-aLL cells already results in differential expression of 51 genes 8. In this study 
we hypothesized that prednisolone resistance in BCP-aLL may be caused by 
dysregulation of prednisolone responsive survival proteins. we aimed to target 
these unresponsive proteins in vitro with targeted inhibitors to increase sensitivity 
to prednisolone leading to cytotoxicity of otherwise resistant leukemic cells.
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MateRIaLs anD MethODs
Processing of patients’ leukemic cells
Bone marrow samples were collected from children with newly diagnosed aLL 
after written consent as approved by the institutional review board. Mononuclear 
cells were isolated by lymphoprep density gradient centrifugation, as previously 
described 9. Only leukemic samples with ≥ 90% leukemic blasts were used in the 
present study. If applicable, enrichment of leukemic blasts was achieved with 
immunomagnetic beads. each patient was examined for the following genomic 
lesions, i.e. hyperdiploid (>50 chromosomes), ETV6-RUNX1+, TCF3-PBX1+, MLL-rear-
rangement, BCR-ABL1+ and BCR-ABL1+-like by means of fIsh, PCR and by utilizing 
the 110-probeset classifier 10. Patients negative for aforementioned genomic 
abberations or signature were named B-other. Cells were cultured in RPMI Dutch 
modification (Gibco) supplemented with 0.1% insulin- transferrin- sodium selenite 
(sigma), 0.4 mM glutamine (Invitrogen), 0.25 µg/ml gentamycine (Gibco), 100 Iu/ml 
penicillin (Gibco), 100 µg/ml streptomycin (Gibco), 0.125 µg/ml fungizone (Gibco) 
and 20% fetal calf serum (Integro) at 37°C in humidified air containing 5% CO2.
Reverse Phase Protein array
Proteins were isolated from 1) unexposed primary BCP-aLL cells obtained at 
initial diagnosis 2) normal mononuclear cells obtained from non-leukemic pedi-
atric bone marrow samples and 3) primary BCP-aLL cells that were exposed for 
48h to 0 µg/ml, 1 µg/ml or 250 µg/ml prednisolone. Proteins were isolated with 
protein lysis buffer containing 25 mM tris ph 7.4, 150 mM naCl, 5 mM eDta ph 
8.0, 1% triton X-100, 10% glycerol, 10 mM sodium-pyrophosphate, 1 mM sodium-
orthovanadate, 10 mM glycerolphosphate, DTT, phenylmethylsulfonyl fluoride, 
aprotinin and sodium-fluoride. Protein concentration was quantified by means 
of the BCa assay (Pierce). hereafter, lysates were spotted twice in triplicate on 
glass-backed nitrocellulose-coated array slides by the facility of Dr. e. f. Petricoin, 
George Mason university, Manassas, usa. slides were subsequently stained with 
indicated antibodies, incubated with a biotinylated secondary antibody and 
scanned using the novaRay scanner. the Microvigene software was used to 
calculate protein levels relative to the total amount of protein per sample. an-
tibodies used were: phospho-stat6(Y641) (Cell signaling (Cs) #9361), phospho-
Met(Y1234-1235) (Cs #3126), phospho Ras-GRf1(s916) (Cs #3321), phospho-
aRaf(s299) (Cs #4431), phospho-BRaf(s455) (Cs #2696), phospho-CRaf(s338) 
(Cs #9427), phospho-MeK1/2(s217-221) (Cs #9121), phospho-aKt(s473) (Cs 
#9271), phospho-nfκB(s536) (Cs #3031), phospho-p38MaPK(t180-Y182) (Cs 
#9211), phospho-saPK-JnK(t183-Y185) (Cs #9251), phospho-JaK2(Y1007) (Cs 
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#3771), phospho-tYK2(Y1054/55) (Cs #9321), phospho-stat5(Y694) (Cs #9351), 
phospho-P70s6K(t389) (Cs #9208), phospho-CReB(s133) (Cs #9191) and phos-
pho-PLCgamma2(Y759) (Cs #3874).
Western blot
Proteins were isolated (see reverse phase protein array for method) from primary 
patients’ cells treated for 4 days with the indicated inhibitor. there were only 
enough leukemic cells of one patient (patient D) for extensive western blotting 
studies. Protein samples (total 25 µg) were loaded on pre-cast gels and trans-
ferred to nitrocellulose membranes (Bio-Rad). Blots were blocked and probed 
with the following antibodies; phospho-MeK1/2(s217-221) (Cs #9121), phospho-
eRK1/2(thr202/tyr204) (Cs #9101), phospho-aKt(s473) (Cs #9271), phospho-
BRaf(s455) (Cs #2696), and β-actin (abcam, ab6276). hereafter, protein levels 
were quantified using the Odyssey 3.0 application software (Li-COR).
Ion Torrent deep sequencing
DNA was extracted from leukemic blasts (≥ 90% purity) by means of Trizol isolation 
according to the manufacturer’s protocol (Invitrogen). Dna concentration was 
determined by the Quant-it picogreen method (Invitrogen). Deep sequencing 
was performed on the Ion PGM using the Ion ampliseq Library Kit 2.0, the Ion 
ampliseq Cancer Panel Primer Pool and Ion Xpress Barcode adapters 1-32 
(Life technologies). the multiplexed PCR covered several hotspot mutations in 
BRaf, nRas, hRas, KRas, PtPn11, fLt3 and cMet, as was reported in the Cosmic 
database (supplemental table 1). a maximum of 16 indexed samples were 
pooled in equimolar fashion and sequenced on an Ion torrent 318B chip using the 
200bp sequencing chemistry according to manufacturer’s protocol. sequences 
were analyzed using the torrent_suite 3.4.2 software (variant caller v3.4.51874). 
variants were annotated using an in-house developed pipeline using the 
ensembl databases (www.ensembl.org).
MTT assay
Cytotoxicity of prednisolone (Bufa Pharmaceutical Products) in primary patients’ 
cells (as indicated in table 1) was determined by the in vitro 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (Mtt) drug-resistance assay after 4-days of 
exposure, as previously described9. Optical density values were measured on the 
versamax (Molecular Devices) at λ=562 nm and λ=720nm. In vitro prednisolone 
sensitivity was defined by a concentration of prednisolone lethal to 50% of the cells 
(LC50) below 0.1 μg/mL and prednisolone resistance was defined by a LC50 value 
above 150 µg/mL as shown previously to be predictive for clinical outcome in 
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pediatric aLL 9,11,12. Cytotoxicity to trametinib, sorafenib, Crizotinib (selleckchem) 
and as1517499 (axon Medchem) in primary patients’ cells was determined by 
the Mtt assay after 4-days of exposure. these inhibitors were dissolved in 100% 
DMsO and were tested in a serial dilution ranging between 0.0002 and 20 µM. 
Cytotoxicity of these inhibitors together with prednisolone was determined after 4 
days by the Mtt assay. Prednisolone dose-response curves were corrected for loss 
of cell viability caused by the inhibitors and the solvent itself.
statistical analysis
Prednisolone-induced changes in protein expression were analyzed with a 
Kruskal-wallis test. a t-test was used to compare data obtained in resistant and 
sensitive patients, and to test the prednisolone sensitizing effects of inhibitors on 
cell viability compared to vehicle control. the dose-response curves of pred-
nisolone in combination with an inhibitor was analyzed by two-way anOva, 
testing the interaction between inhibitor*prednisolone. a p-value below 0.05 
was considered statistically significant.
ResuLts
Prednisolone-responsive survival proteins are dysregulated in 
prednisolone resistant primary patients’ cells
to study our hypothesis that prednisolone resistance is caused by dysregulation 
of prednisolone-responsive survival proteins, we analyzed phosphorylation levels 
of 17 key-signaling proteins in leukemic cells obtained from in vitro prednisolone 
sensitive and resistant aLL patients (table 1, column 2). we observed that basal 
phosphorylation levels of these 17 proteins did not differ between prednisolone 
resistant and sensitive patients’ cells (supplemental figure 1a). exposure to 
prednisolone for 48h induced discrepant phosphorylation changes in 6 out of 
17 proteins between prednisolone resistant and sensitive cases. Prednisolone 
downregulated the activity of the Ras-Raf-MeK pathway in prednisolone sen-
sitive patients cells but not in resistant patients (figure 1a-D). Phosphorylation 
levels of Ras, aRaf, BRaf, MeK1/2 and also stat6 were 2.5-fold, 8.1-fold, 2.3-fold, 
2.9-fold and 3.1-fold (p<0.01), respectively higher in prednisolone resistant com-
pared to sensitive patients’ cells after prednisolone exposure (figure 1a-e). In 
contrast, a 3.8-fold induction of cMet phosphorylation was observed in resistant 
patients’ cells after prednisolone exposure, whereas no change was observed in 
sensitive cells (figure 1f). In summary, we observed a dysregulation of Ras-Raf-
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MEK, STAT6 and cMET phosphorylation upon prednisolone exposure specifically 
in leukemic cells of prednisolone resistant patients.
Ras pathway mutations in pediatric bCP-all and in vitro prednisolone 
resistance
The finding that prednisolone is incapable of downregulating the activity of RAS-
Raf-MeK pathway in prednisolone resistant patients, prompted us to investigate 
the presence of Ras-pathway activating mutations. these mutations are known to 
induce constitutive Ras signaling which results in a survival advantage of cancer 
cells 13. we investigated hotspot regions of mutations in the protein coding domains 
of BRaf, nRas, hRas, KRas, PtPn11 and fLt3 as documented in the COsMIC 
database (supplemental table 1) with Ion torrent deep-sequencing (~1000x read 
depth) in 26 pediatric BCP-aLL patients with known genetic subtype and in vitro 
prednisolone response (table 1). In addition, we examined in previously described 
Figure 1. 
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figure 1. Prednisolone mediated dysregulation of pivotal survival proteins is impaired in 
prednisolone resistant primary patient cells.
(a-f) Protein phosphorylation was analyzed by means of reverse phase protein array in three pediatric 
BCP-aLL cases with in vitro prednisolone sensitive and three cases with in vitro resistant leukemic cells. 
samples were exposed for 48h to 0 µg/ml, 1 µg/ml prednisolone or 250 µg/ml prednisolone. Data are 
presented as mean plus seM of three independent patients’ samples. (a Kruskal-wallis test was used to 
compare 0, 1, 250 μg/ml data points indicated by ∏–∏ and a T-test was used to compare data between 
sensitive and resistant patients indicated by |–| *p<0.05, **p<0.01, ***p<0.001, ns=not significant, A.U. 
arbitrary units.)
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hotspot regions the presence of mutations in cMet (supplemental table 1) but no 
cMet mutations were found. 10 out of 26 patients (38%, table 1) carried activating 
nRas and/or KRas mutations or additional mutations in the fLt3 receptor or 
regulatory PtPn11 (shP2) known to trigger Ras-MeK pathways in hematopoietic 
cells 14,15. single heterozygous nRas/KRas-mutations were found in four cases with 
one dominant clone, representing 50-100% of cells (table 1, patient 3, 5, 6 and 8). 
two or more Ras-pathway mutations were found in six cases (table 1, patient 1, 2, 
4, 7, 9 and 10). Of interest, these mutations were often found in subclones as small 
as 5%. We identified 9 activating point mutations in NRAS, of which 6 in exon 1 (4 
in codon 12 and 2 in codon 13) and 3 in exon 2 (2 in codon 61 and 1 in codon 64). 
In KRas we found 8 activating point mutations in exon 1 (codon 12 and 13) and 
none in exon 2 (codon 61). the activating mutations found in PtPn11 comprised 
codon 69 and FLT3 codon 835. We did not find mutations in BRAF and HRAS. 
Interestingly, we detected more often Ras activating mutations in prednisolone 
resistant compared to sensitive patients (54% vs. 23% table 2). this difference was 
not statistically different (fisher’s exact test: p=0.2), this might be due to limited 
sample size (n=13 vs. n=13). furthermore, the mutations did not present in one 
specific genetic subtype (table 2) nor did the two patients that relapsed in this 
small cohort harbour a Ras-mutation (table 1). Collectively, we have found a 
high frequency (38%) of Ras-mutations in BCP-aLL cells taken at initial diagnosis, 
60% consisted of several subclones and the presence of these mutations seems 
associated with prednisolone resistance of leukemic cells.
Inhibitors against MeK1/2, bRaf, sTaT6, cMeT do not reduce viability of 
patients’ leukemic cells
We studied the effect of specific inhibitors directed against MEK1/2 (Trametinib), 
BRaf (sorafenib), stat6 (as1517499) and cMet (Crizotinib) (supplemental table 
2) in five in vitro prednisolone resistant BCP-aLL patients’ samples (table 1, column 
3) expressing high levels of the targeted proteins in leukemic cells compared 
to normal mononuclear bone marrow cells (figure 2a). trametinib, sorafenib, 
as1517499 or Crizotinib did not induce substantial cell death in prednisolone 
resistant leukemic patients’ cells (fig. 2B-E). Western blot analysis verified that 
Trametinib specifically decreased phospho-ERK and Sorafenib decreased phos-
pho-BRaf (figure 2F). Western blot analysis also verified that AS1517499 specifi-
cally decreased phospho-aKt and Crizotinib decreased phospho-MeK1/2 and 
phospho-aKt, which are known downstream targets of stat616–18 and cMet19,20, 
respectively (figure 2f).
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Trametinib (MeK inhibitor) and sorafenib (bRaf inhibitor) restore 
prednisolone sensitivity in Ras mutated patients
we next evaluated the prednisolone sensitizing properties of these inhibitors in 
primary BCP-aLL patients’ cells (figure 3, supplemental figure 2, tabel 1). Re-
markably, we observed a complete sensitization to prednisolone after trametinib 
treatment in patient 2 and 3 (figure 3B1-C2 p<0.01). 100% of the leukemic cells 
of patient 2 harboured a G12R mutated KRas and 70% and 16% of leukemic 
cells of patient 3 had a G12v nRas and G12s KRas mutation, respectively 
(table 1). trametinib was not effective in patient 1 of which 27% of the cells 
harboured a G13D KRas activating mutation, and 14% and 5% of leukemic cells 
harboured G12D and Q61R nRas mutations, respectively (figure 3a1 and table 
1). Interestingly, this patient was the only patient in which sorafenib sensitized 
cells to prednisolone up to 61% compared to prednisolone and vehicle control 
(figure a1-a2, p=0.001). trametinib also had prednisolone sensitizing effects in 
the Ras-wildtype patients, although less pronounced compared to the effects 
seen in Ras-mutated cases. (figure 3D1-e2, p=0.01).
these highly prednisolone sensitizing effects were not seen for as1517499 (stat6 
inhibitor) and Crizotinib (cMet inhibitor). the stat6 inhibitor as1517499 modestly 
sensitized 1 out of 5 patient cell samples (p=0.01, figure 3C1, supplemental fig-
ure 2). however, in 3 out of 5 patient cell samples inhibition of stat6 had an 
opposite effect and even moderately increased prednisolone resistance (figure 
3, supplemental figure 2). Crizotinib modestly sensitized leukemic cells in 2 out 
of 5 patient cell samples (p<0.05, figure 3D1-e1, supplemental figure 2). there 
was no specific association between the prednisolone sensitizing effects of 
these inhibitors and Ras-mutation status. Overall, trametinib and sorafenib were 
impressively potent when combined with prednisolone eradicating especially 
leukemic cells of Ras-mutated patients.
DIsCussIOn
Prednisolone is able to target a wide range of genes eventually leading to 
apoptosis of leukemic cells 8. To our knowledge this is the first study showing 
Table 2. frequency of Ras mutations in relation to prednisolone sensitivity.
In vitro  prednisolone response
 B-other BCR-ABL1 -like ETV6-RUNX1+ Total
Sensitive 0% (0/4 patients)  25%  (1/4 patients) 40% (2/5 patients) 23% (3/13 patients)
Resistant 80% (4/5 patients) 33% (1/3 patients) 40% (2/5 patients) 54% (7/13 patients)
Total 44% (4/9 patients) 29% (2/7patients) 40% (4/10 patients) 38% (10/26 patients)
RAS-mutations
133
R
a
s M
u
ta
tIO
n
s a
n
D
 PR
eD
n
IsO
LO
n
e R
esIsta
n
C
e In
 a
LL
5
0
20
40
60
80
100
0.001 0.01 0.1 1 10 100
Patient D
Patient A
Patient C
Patient B
Patient E
AS1517499 - STAT6 (µM)
C
el
l s
ur
vi
va
l (
%
)
0
20
40
60
80
100
0.001 0.01 0.1 1 10 100
Patient D
Patient A
Patient C
Patient B
Patient E
Crizotinib - cMet (µM)
C
el
l s
ur
vi
va
l (
%
)
0
20
40
60
80
100
120
0.001 0.01 0.1 1 10 100
Patient D
Patient A
Patient C
Patient B
Patient E
Sorafenib - BRAF (µM)
C
el
l s
ur
vi
va
l (
%
)
0
20
40
60
80
100
0.001 0.01 0.1 1 10 100
Patient D
Patient A
Patient C
Patient B
Patient E
Trametinib - MEK1/2 (µM)
C
el
l s
ur
vi
va
l (
%
)
Figure  2.  
pM
EK
1/2
pB
RA
F
pS
TA
T6
pc
ME
T
0
2
4
6
8
10
20
30
40
nBM
Patient A
Patient B
Patient C
Patient D
Patient E
R
el
at
iv
e 
pr
ot
ei
n 
ex
pr
es
si
on
 (f
ol
d-
ch
an
ge
) A B C 
D E 
pMEK1/2 
pERK1/2 
pAkt 
β-actin 
β-actin 
pBRAF 
Patient D F 
figure 2. Inhibitors against MeK, bRaf, sTaT6, cMeT do not reduce viability of patients’ 
leukemic cells.
(A) Protein phosphorylation levels of MEK1/2, BRAF, STAT6 and cMET was analyzed in leukemic cells of five 
prednisolone resistant BCP-aLL samples by reverse phase protein array. Phosphorylated protein levels in 
patients were compared to the levels observed in normal bone marrow mononuclear cells (dashed line 
set at 1). (B-e) five prednisolone resistant BCP-aLL patients were treated for 4-days with the indicated 
inhibitor in a concentration range between 0.0002-20 µM, whereafter leukemic cell survival was analyzed 
by Mtt-assay and corrected for effects caused by vehicle itself. (f) MeK1/2(s217-221), eRK1/2(thr202/
tyr204), aKt(s473) and BRaf(s455) phosphorylation of patient D treated for 4 days with 5µM of the 
indicated inhibitors or 5µM of the vehicle DMsO was analyzed by western blot. β-actin expression was 
used as a loading control. Data are presented as mean plus seM.
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figure 3. Trametinib (MeK inhibitor) and sorafenib (bRaf inhibitor) restore prednisolone 
sensitivity in Ras-mutated patients
(a1-e1) Sensitivity to 3.9 μg/ml prednisolone of five distinct pediatric BCP-ALL patients’ cell samples 
co-incubated with 2.5 µM trametinib (MeK1/2 inhibitor), sorafenib (BRaf inhibitor), as1517499 (stat6 
inhibitor), Crizotinib (cMet inhibitor) or vehicle (DMsO) control measured in a 4-day Mtt assay. Data are 
presented as mean plus seM of a duplicate experiment (t-test *p<0.05, **p<0.01, ***p<0.001). (a2-e2) 
Dose-response curve of prednisolone combined with the inhibitor giving the most prominent effect in a1-
e1. Graphs represent 2.5 or 5.0 µM sorafenib (BRaf inhibitor), trametinib (MeK inhibitor) or vehicle control 
(DMsO). Data are presented as mean plus seM of a duplicate experiment ( two-way anOva, interaction 
inhibitor*prednisolone *p<0.05, **p<0.01, ***p<0.001). sensitivity was corrected for cell death induced by 
the inhibitor/vehicle itself in the absence of prednisolone to facilitate assessment of pure prednisolone 
sensitizing effects. the upper three patients have Ras-mutations, the lower two patients are Ras-wildtype.
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that prednisolone downregulates the Ras-Raf-MeK pathway and stat6 protein 
phosphorylation in prednisolone sensitive patients’ aLL cells which is blocked in 
prednisolone resistant aLL cells, whereas an active upregulation of the proto-
oncogene cMet was observed in prednisolone resistant cells. Inhibitors directed 
against either MeK1/2, BRaf, stat6 or cMet did not induce substantial cell death 
in prednisolone resistant aLL patients’ cells despite the presence of relative high 
targeted phosphorylated protein levels. this suggests that the expression level 
of phosphorylated proteins is not sufficient to guide the choice of an inhibitor 
for targeted treatment. Remarkably, highly resistant leukemic patients’ cells 
harbouring KRas/nRas mutations were completely sensitized to prednisolone in 
the presence of the MeK1/2 inhibitor trametinib or the BRaf inhibitor sorafenib. 
these sensitizing effects were not seen for as1517499 (stat6 inhibitor) and Crizo-
tinib (cMet inhibitor). Collectively, these results suggest that MeK/BRaf inhibitors 
are mainly indicated for Ras-mutated BCP-aLL cases and only when used in 
combination with prednisolone.
the synergy between prednisolone and MeK/BRaf inhibitors in Ras-mutated 
patients might be explained by the following three mechanisms: 1) the MeK/
BRaf inhibitors mostly target Ras-mutant signaling 21,22. the limited effect of MeK/
BRaf inhibitors as single agents on viability of BCP-aLL cells might be explained 
by recent findings that targeted RAS-mutant signaling resensitizes to tyrosine 
kinase signaling via wildtype Ras 21,22. Prednisolone targets wildtype Ras as is 
evident by the presence of a glucocorticoid response element in Ras 23 and our 
finding that prednisolone decreases RAS phosphorylation levels in prednisolone 
sensitive cells. the synergy between MeK/BRaf inhibitors and prednisolone might 
therefore be explained by a prednisolone-mediated decrease of Ras-wildtype 
signaling and MeK/BRaf targeted decrease of Ras-mutant signaling. 2) Ras mu-
tations might inhibit glucocorticoid-dependent inhibition of the survival protein 
aP1, as was shown in lung and epithelial cell lines 24,25. targeting the mutated 
Ras-pathway genes may enable prednisolone to inhibit aP1, thereby reducing 
cell viability. 3) It is known that Ras activating mutations generate an anti-
apoptotic environment by decreasing pro-apoptotic BIM levels 26 , increasing 
anti-apoptotic BCL2 27 and MCL1 28 levels. we previously showed that predniso-
lone downregulates MCL1 in sensitive but not in prednisolone resistant BCP-aLL 
cells 29. targeting MeK/BRaf may therefore synergistically act with prednisolone 
on the balance between pro- and anti-apoptotic proteins.
In this study we observed a relative high frequency of Ras-pathway mutated 
patients (38%) and these mutations seem to be overrepresented in prednisolone 
resistant compared to sensitive patients. Prednisolone resistance has recently 
been associated with Ras mutations in major clones of infant aLL 30. Remarkably, 
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deep-sequencing of BCP-aLL cases in the present study revealed multiple minor 
clones in 60% of mutated cases. Different hRas and nRas activating mutations 
as well as mutations in genes inducing the Ras-pathway (fLt3 and PtPn11) were 
found. In contrast, other studies hardly detected concomitant mutations 30–32 
and only one study in high-risk BCP-ALL leukemias identified multiple NRAS/KRAS 
mutations in 3% of patients 5. Our finding that RAS-mutations are not mutually 
exclusive in most leukemic patients, not only encourages for future mutation 
analysis by means of deep-sequencing instead of sanger-sequencing, but also 
signifies the importance of these mutations in leukemia. This is further supported 
by our discovery of co-occurrence of minor clones with different Ras-pathway 
mutations and the finding that RAS mutations predominating at relapse could 
be retrospectively demonstrated in minor clones at initial diagnosis of the cor-
responding patients 33,34.
Collectively, our results indicate that as1517499 (stat6 inhibitor) and Crizotinib 
(cMet inhibitor) are not suitable as therapeutic options to resensitize leukemic 
patients’ cells to prednisolone. Potential therapeutic effectiveness of MeK/BRaf 
inhibitors is mainly indicated for nRas/KRas mutated cases when combined with 
prednisolone. Potential inhibitors of choice in BCP-aLL are trametinib (reviewed 
in 35) and sorafenib, since both inhibitors have been approved by the fDa for 
use in other cancers (supplemental table 2). In addition, sorafenib was shown to 
be well tolerated and effective in fLt3 internal tandem duplicate acute myeloid 
leukemia36–38. Our data indicate that trametinib and sorafenib should not be 
given as a monotherapy in nRas/KRas mutated patients, but are mainly effec-
tive in combination with prednisolone. furthermore, we advise that leukemic 
cells of children in which Ras-pathway mutations have been detected should 
be first in vitro tested for sensitivity to trametinib and sorafenib inhibitors (com-
bined with prednisolone) to guide the choice which inhibitor is most benificial 
for the patiënt.
In conclusion, Ras mutations are frequently found in leukemic cells of children 
with BCP-aLL. targeting Ras-signaling with trametinib and sorafenib could serve 
as a novel therapeutic option to modulate prednisolone resistance and may 
provide a way to further improve the clinical outcome of childhood BCP-aLL.
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Supplemental Figure 1. A 
Supplemental Figure 1. Prednisolone mediated dysregulation of pivotal survival proteins is impaired in 
prednisolone resistant primary patients’ cells. 
(A) Phosphorylation levels  of 17 proteins were analyzed by means of reverse phase protein array (relative to 
total protein) of 31 in vitro prednisolone sensitive and 15 prednisolone resistant unexposed samples taken from 
BCP-ALL patients’ at initial diagnosis. P-value was not significant for all proteins. Data are presented as mean plus 
SEM of three patients (T-test, *p<0.05, **p<0.01, ***p<0.00 , a.u. Arbitrary Units) 
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Supplemental Figure 2. 
Supplemental Figure 2. Trametinib (MEK inhibitor) and Sorafenib (BRAF inhibitor) restored prednisolone 
sensitivity in RAS-mutated patients Dose-response curves of five pediatric BCP-ALL patients’ cell samples exposed 
to prednisolone together with 2.5 or 5.0 µM of inhibitor or vehicle (DMSO). Data are presented as mean plus SEM 
of a duplicate experiment (repeated measurement two-way ANOVA, *p<0.05, **p<0.01, ***p<0.001). To facilitate 
assessment of cellular sensitization to prednisolone by the inhibitors,  cell survival was corrected for the cell death 
induced by the inhibitor. The upper three patients have RAS-mutations, the lower two patients are RAS-wildtype 
(see also Table 1).  
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Supplemental Table 1. 
Supplemental Table 2. 
Gene
BRAF
NRAS
HRAS
KRAS
PTPN11
FLT3
cMET
60, 61, 69, 72, 73,76, 502 and 503
451,572, 592,597, 599, 601, 602, 603, 834, 835, 836 and 842
168, 375, 1010,1112, 1248,1253 and 1268
Cosmic hotspot codons examined
444, 464, 466, 469, 471, 581, 587, 592, 594, 595, 596, 597, 599, 600, 601 and 605
12, 13, 18, 61 and 64
12, 13 and 61
12,13,19,22,59,61 and 146
Inhibitor Main Target
Trametinib MEK1-2
Sorafenib BRAF
AS1517499 STAT6
Crizotinib cMET
and hepatocellular carcinoma
FDA approval
No clinical trial data
FDA approved for non-small lung carcinoma
FDA approved for melanoma
FDA approved for renal cell carcinoma
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Better risk stratification and continuous optimization of treatment protocols, 
without changing the primary chemotherapeutic drugs that have been used for 
decades, have improved pediatric precursor-B acute lymphoblastic (BCP-aLL) 
leukemia event-free survival rates up to 80-90% 1. targeted drugs adjuvating cur-
rent chemotherapy regimens are warranted to cure the remaining 10-20%. sixty 
years after the first discovery of its anti-leukemic competences, prednisolone is 
still the primary drug used in the treatment of BCP-aLL and t-aLL. In vivo and in 
vitro resistance against prednisolone remains an adverse prognostic factor in 
pediatric BCP-aLL 2,3. Moreover, relapsed leukemic cells acquire prednisolone 
resistance disproportionally to other chemotherapeutic drugs 4. to eventually 
cure the remaining 10%-20% of aLL patients it is essential to unravel prednisolone 
resistance and find targeted drugs that modulate prednisolone resistance.
PReDnIsOLOne InDuCeD aPOPtOsIs: MuLtIfaCtORIaL aPPROaCh
Recent investigations indicated that prednisolone resistant cells have defects in 
drug-induced apoptosis mechanisms, such as caspase-3 activation and PaRP 5. 
additionally, it was discovered that the pro-apoptotic BCL-2-interacting media-
tor of cell death (BIM) expression is increased upon prednisolone treatment in 
sensitive, but not in resistant cells 6,7. In fact, knockdown of BIM induced pred-
nisolone resistance in a sensitive cell line 8. Microarray analysis of in vitro pred-
nisolone resistant and sensitive patients’ BCP-ALL cells showed that specifically 
anti-apoptotic MCL1 and DaPK1 are associated with prednisolone resistance 
9. Indeed, down-regulation of MCL1 in prednisolone resistant MLL-rearranged 
leukemia cell lines by Rna interference led to prednisolone sensitization 10. In 
addition, rapamycin, a mtOR inhibitor, was shown to sensitize leukemic cell 
lines to prednisolone by downregulating MCL1 11. analysis of apoptotic protein 
expression levels in prednisolone sensitive and resistant primary patient BCP-aLL 
samples after in vitro exposure to prednisolone pointed to MCL1 as the key 
apoptotic protein associated with prednisolone resistance (Chapter 2). Locked-
nucleic-acid (Lna) oligonucleotides were therefore developed, which were 
shown to specifically knockdown MCL1 and sensitized leukemic cell lines to 
prednisolone (Chapter 2). Lnas are currently investigated in phase I early clinical 
trials (www.Clinicaltrials.gov, nCt01186328, nCt01337518, nCt00466583), as they 
are conformationally structured to prevent most of the current hurdles in siRna 
treatment 12. MCL1 LNA antisense may therefore offer a more specific way of 
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silencing MCL1 than the current BCL-2 family inhibitors R-(-)-gossypol (at101) and 
obatoclax (GX-15-070), which aspecifically block several members of the BCL-2 
family 13,14. however, silencing of MCL1 also promoted the glycolytic route in cells 
thereby providing a rescue mechanism for these cells (Chapter 2). these results 
might be explained by the finding that MCL1 was recently shown to facilitate 
atP production by activating the respiratory complexes in mitochondria 15. 
Knockdown of MCL1 may therefore impair oxidative phosphorylation and forces 
cells to produce atP by glycolysis to ensure survival. we previously observed 
that prednisolone resistance is associated with increased glucose consumption 
in leukemic cells. Inhibition of glycolysis with 2-DG sensitized both leukemic cell 
lines and primary BCP-aLL cells to prednisolone 16. Co-exposure of leukemic cell 
lines with MCL1 Lna and 2-DG synergistically inhibited leukemic cell survival 
and promoted sensitization to prednisolone (Chapter 2). In addition to Lnas, 
2-DG is also currently studied in phase I clinical trials (www.Clinicaltrials.gov, 
nCt00096707).
Overall, MCL1 is most likely the key apoptotic protein associated with pred-
nisolone resistance. treatment with MCL1 Lna antisense and 2-DG provides a 
promising approach to decrease leukemic cell survival and to sensitize aLL pa-
tients’ cells to prednisolone. Most importantly, different mechanisms of survival 
and resistance co-exist and therefore warrant investigation of multifactorial 
approaches to sensitize aLL cells to prednisolone in clinics.
PReDnIsOLOne ResIstanCe anD MICROenvIROnMent 
InteRaCtIOn
Prednisolone binds the glucocorticoid receptor, which in turn transcriptionally 
regulates the expression of numerous genes eventually leading to apoptosis. 
eight hours of prednisolone exposure of sensitive BCP-aLL cells already results in 
differential expression of 51 genes 17. to examine the gene expression pattern 
that might cause prednisolone resistance in more detail, microarray gene ex-
pression profiles of 256 children with newly diagnosed prednisolone sensitive or 
resistant BCP-aLL or t-aLL were analyzed. epithelial membrane protein 1 (eMP1) 
was identified as one of the most discriminative genes (Chapter 3). eMP1 is a 
small hydrophobic four-transmembrane glycoprotein 18. Knockdown of eMP1 
not only reduced leukemic BCP-aLL and t-aLL cell viability and sensitized to 
prednisolone, but also abrogated migration and adhesion of leukemic cells to 
mesenchymal stromal cells (MsCs) (Chapter 3). Only recently, the bone mar-
row microenvironment was demonstrated to be an important contributor to 
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resistance of leukemic cells to drugs 19,20. Chemokines secreted by MsCs, such 
as stem cell factor 1 and CXCL12, can for example stimulate leukemic cell hom-
ing and survival 21,22. MsCs can rescue cells from L-asparaginase by secreting 
asparagine 20 or induce leukemic drug resistance through upregulation of the 
voltage-dependent channel heRG1 19. MsC-based sheltering of aLL cells may 
also provide a physical barrier for chemotherapeutics. Indeed, MsCs potentially 
protect leukemic cells against prednisolone-induced apoptosis (Chapter 3). 
Moreover, silencing of eMP1 reduced in part the protection by MsCs (Chapter 
3).
Overall, eMP1 was shown to play an important pathobiological role in aLL 
and the development of an eMP1 inhibitory small compound may serve as 
a potential new therapeutic option for ALL. These findings have shed light to 
an entire new dimension of drug resistance research and potentiate the im-
portance to study drug resistance in relation to the microenvironment in more 
depth. the current set-up of in vitro assays used to determine drug resistance in 
leukemic cells does not consider the influence of the microenvironment on drug 
resistance. Most certainly, improved in vitro bone marrow models and xenograft 
mouse models are necessary to study the microenvironment and leukemic inter-
action and importance for cellular drug resistance in more detail. In addition, a 
new high throughput technique should be developed that enables detection of 
microenvironment induced drug resistance in patients’ leukemic cells.
GLuCOCORtICOID ReCePtOR antaGOnIzInG MeChanIsMs
Analysis of mRNA and protein array profiles obtained from BCP-ALL cells of newly 
diagnosed patients, revealed an increased mRna and protein expression of the 
nR4a transcription factor family (NR4A1, NR4A2 and NR4A3) in prednisolone re-
sistant compared to sensitive patients (Chapter 4). Interestingly, NR4A1 (protein 
name: nur77), NR4A2 (protein name: nurr1), and NR4A3 (protein name: nor1) 
are orphan nuclear receptors which belong to the same steroid hormone recep-
tor superfamily as the glucocorticoid receptor (GR) 23. a direct protein-protein 
interaction between GR and the nR4a family members exists, which represses 
GR-dependent transcription 24,25. although there is a strong association between 
nR4a expression and prednisolone resistance, functional studies in primary pa-
tients’ cells did not indicate that nR4a genes are causally related to resistance 
in primary patients´ cells (Chapter 4). the role of other GR binding transcription 
factors, such as aP-1 and nf-κB 26 in prednisolone resistance are contradictory 
as well. while some studies showed that overexpression of nf-κB or aP-1 might 
150
contribute to prednisolone resistance 10,27–29, others did not 30. these results sug-
gest that impaired functioning of GR at the receptor level most likely does not 
cause prednisolone resistance. In line with this are previous studies showing that 
there was no correlation between baseline GR mRna levels 31,32, polymorphisms 
or mutations in the GR gene 31 or mRna expression levels of chochaperones 33 
and prednisolone resistance.
Overall, nR4a genes are not suitable targets to reverse prednisolone resis-
tance. Most importantly, resistance to prednisolone is more likely caused by 
mechanisms affecting the downstream intracellular signaling than by mecha-
nisms affecting the effective prednisolone or GR receptor levels.
PReDnIsOLOne ResIstanCe MutatIOns anD PeRsOnaLIzeD 
theRaPY
In addition to apoptotic molecules, also several pro-survival mechanisms have 
been associated with the failure of prednisolone to induce apoptosis. Inhibition 
of the important survival proteins JnK and eRK 34, PI3 kinase and aKt 35,36 and src 
kinase37 sensitized aLL cell lines to prednisolone. examination of survival protein 
levels in prednisolone sensitive and resistant BCP-aLL patients’ samples after ex-
posure to prednisolone revealed that prednisolone downregulated the activity 
of the Ras-Raf-MeK pathway and stat6 in prednisolone sensitive patients cells, 
but was not capable to do so in prednisolone resistant patients (Chapter 5). In 
addition, an active upregulation of the proto-oncogene cMet in prednisolone 
resistant cells became evident that was not present in prednisolone sensitive 
cells. Other studies also indicated that prednisolone targets the MaPK pathway 
17,38, although a direct link between Ras, Raf, stat6 and cMet protein phos-
phorylation and prednisolone resistance has not been made before. we also 
identified a higher frequency of RAS activating mutations in prednisolone resis-
tant compared to sensitive patients (Chapter 5). an association between Ras-
mutations in major clones and prednisolone resistance was recently shown in 
infant aLL 39. we detected a Ras mutation frequency of 38% in newly diagnosed 
BCP-aLL patients and in 60% of the mutated patients multiple minor clones with 
different hRas and nRas activating mutations and mutations in genes inducing 
the RAS-pathway (FLT3 and PTPN11) were identified, signifying the importance 
of these mutations in leukemia (Chapter 5). In contrast, other studies hardly 
detected co-existence of different mutations in the same patients 39–41 and only 
one study in high-risk BCP-ALL leukemias identified multiple NRAS/KRAS muta-
tions in 3% of patients 42. Remarkably, highly resistant leukemic patients cells 
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harbouring KRas/nRas mutations were completely sensitized to prednisolone 
in the presence of the MeK1/2 inhibitor trametinib (Chapter 5). In another KRas/
nRas mutated patient sorafenib (BRaf inhibitor) but not trametinib sensitized to 
prednisolone significantly (Chapter 5). these highly sensitizing effects were not 
seen for as1517499 (stat6 inhibitor) and Crizotinib (cMet inhibitor) (Chapter 5).
Overall, BCP-aLL patients should be screened for Ras mutations, as these 
patients could benefit from treatment with Trametinib or Sorafenib combined 
with prednisolone. Most importantly, our results highlight the heterogeneous 
aspect of prednisolone resistance and encourages for further investigation of 
mutation-based prednisolone resistance combined with personalized targeted 
therapy. Leukemia often consists of multiple subclones with sometimes different 
genetic abnormalities, as we showed for Ras mutations. these minor clones 
can be responsible for later relapses 43. It has also been shown that relapsed 
leukemic cells gain prednisolone resistance 4. fundamental in future research 
will therefore be investigations of prednisolone resistance in relapsed leukemias 
and how to treat (minor) subclones more effectively, preferably at the time of 
initial diagnosis of aLL.
In conclusion, this thesis indicates the multifactoriality of prednisolone resistance 
in pediatric aLL. Our results point out that MCL1 Lnas , 2-DG, an eMP1 inhibitor, 
trametinib (MeK inhibitor) and sorafenib (BRaf inhibitor) may be of therapeutic 
value to reverse prednisolone resistance in childhood aLL. we also show that 
the causes of resistance differ between patients supporting a more personalized 
approach to improve outcome for those children who are not cured with current 
regimens.
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20% of aLL patients relapse on or after current treatment strategies. treatment 
failure has been associated with cellular resistance to prednisolone, the leading 
drug in multi-drug treatment of aLL. the molecular mechanisms behind pred-
nisolone resistance in pediatric ALL are poorly defined. This thesis aimed to find 
new druggable targets that may modulate prednisolone resistance.
Recent investigations indicated that prednisolone resistant cells have defects 
in drug-induced apoptosis mechanisms. analysis of apoptotic protein expression 
levels (Chapter 2) in prednisolone sensitive and resistant primary patient precur-
sor-B acute lymphoblastic leukemia (BCP-aLL) samples after in vitro exposure 
to prednisolone pointed to MCL1 as the key apoptotic protein associated with 
prednisolone resistance. Clinically relevant locked-nucleic-acid (Lna) oligonu-
cleotides were developed, which were shown to specifically silence the expres-
sion of MCL1 and induced apoptosis of leukemic cell lines. however, silencing of 
MCL1 appeared to increase glycolysis of leukemic cells thereby rescuing these 
cells from prednisolone-induced apoptosis. targeting both MCL1 with MCL1 Lna 
and glycolysis with 2-deoxyglucose (2-DG) synergistically inhibited leukemic cell 
survival and in part mutually sensitized leukemic cells to prednisolone. Our results 
indicate that MCL1 Lna antisense and 2-DG provide a promising therapeutic 
approach to decrease leukemic cell survival and sensitize aLL patients’ cells to 
prednisolone. These findings also illustrate that investigation of multifactorial and 
combined ways to sensitize leukemic cells to prednisolone are warranted. 
to examine prednisolone resistance in more detail, we generated microarray 
gene expression profiles of 256 children with newly diagnosed ALL. Epithelial 
membrane protein 1 (EMP1) was identified as one of the most discriminative 
genes for prednisolone resistance (Chapter 3). eMP1 is a small hydrophobic 
four-transmembrane glycoprotein of which the biological function is largely un-
known. we discovered that knockdown of eMP1 in leukemic cell lines increased 
apoptosis and induced cell cycle arrest leading to large reductions in leukemic 
cell survival. Moreover, eMP1 knockdown sensitized three out of six cell lines to 
prednisolone. silencing of eMP1 also abrogated migration and adhesion of 
leukemic cell lines to mesenchymal stromal cells. notably, we also discovered 
that eMP1 contributes to MsC-mediated prednisolone resistance, as predniso-
lone resistance triggered during leukemic MsC coculture was partially reversed 
after eMP1 knockdown. Pathway analysis indicated that eMP1 signals through 
src kinase family phosphorylation to activate amongst others JnK, stat3, stat5, 
CReB and nf-κB. finally, we discovered that high expression of EMP1 is a novel 
poor prognostic factor in BCP-aLL. Overall, our results indicate that eMP1 plays 
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an important pathobiological role in aLL. the development of an eMP1 inhibitory 
small compound may serve as a potential new therapeutic option for aLL. Most 
importantly, first insights in the role of the microenvironment in drug resistance 
have become evident which encourages further investigations.
Next to microarray gene expression profiles, we also generated protein ar-
ray profiles of in vitro prednisolone sensitive and resistant BCP-aLL cells of 123 
newly diagnosed patients. an increased mRna and protein expression of the 
nR4a transcription factor family (NR4A1, NR4A2 and NR4A3) was detected in 
prednisolone resistant patients compared to sensitive patients (Chapter 4). the 
nR4a family are orphan nuclear receptors, which antagonize the glucocor-
ticoid receptor. we hypothesized that upregulated nR4a family expression is 
responsible for prednisolone resistance in BCP-aLL. simultaneous siRna medi-
ated knockdown of nur77 (NR4A1), nurr1 (NR4A2) and nor1 (NR4A3) protein in 
pediatric leukemic patients’ aLL cells did, however, not sensitize these cells to 
prednisolone. We observed a significant, albeit modest, decrease in leukemic 
cell survival. Overall our data implicate that the nR4a genes are not suitable tar-
gets to reverse prednisolone resistance. these data also suggest that resistance 
to prednisolone is more likely caused by mechanisms affecting the downstream 
intracellular signaling than by mechanisms affecting the effective GR receptor 
levels.
In addition to apoptotic molecules, also several pro-survival mechanisms have 
been associated with prednisolone resistance which was therefore examined 
further in Chapter 5. although basal protein expression in resistant and sensitive 
patients appeared similar, differences became strikingly evident after exposure 
to prednisolone. Remarkably, prednisolone downregulated the activity of the 
Ras-Raf-MeK pathway and stat6 in prednisolone sensitive patients cells, but 
was not capable to do so in prednisolone resistant cases. In addition, an active 
upregulation of the proto-oncogene cMet was found in prednisolone resistant 
compared to prednisolone sensitive cells. The finding that prednisolone is inca-
pable of downregulating the activity of Ras-Raf-MeK pathway in prednisolone 
resistant patients, prompted us to investigate the presence of Ras-pathway 
activating mutations. we discovered activating nRas and KRas mutations in 
38% of patients. In 60% of mutated patients we even found multiple subclones 
with different mutations. we also detected a tendency of more Ras activating 
mutations in prednisolone resistant compared to sensitive patients. Inhibitors 
against MeK (trametinib), BRaf (sorafenib), stat6 (as1517499), or cMet (Crizo-
tinib) did not induce substantial cell death in vitro in BCP-aLL patient samples. 
however, trametinib was impressively potent when combined with prednisolone 
eradicating especially all nRas/KRas-mutated leukemic cells. In one nRas/
160
KRas-mutated case sorafenib but not trametinib sensitized the leukemic cells 
to prednisolone significantly. Our data implicate that BCP-ALL patients should 
be screened for RAS-mutations as these patients could benefit from treatment 
with trametinib/sorafenib combined with prednisolone. we furthermore advise 
analysis of the in vitro response of Ras mutated BCP-aLL patients’ cells to tra-
metinib and sorafenib. Our results illustrate the heterogeneity among causes 
of prednisolone resistance and encourages the investigation of Ras-activating 
mutations with high read-depth to select patients who may be eligible for more 
targeted drugs.
Overall, the results in this thesis point out that MCL1 Lnas , 2-DG, an eMP1 in-
hibitor, trametinib (MeK inhibitor) and sorafenib (BRaf inhibitor) belong to the 
therapeutic options to reverse prednisolone resistance which may contribute to 
cure the remaining 10-20% of aLL patients. future investigations should focus on 
multifactorial approaches to completely sensitize aLL cells to prednisolone and 
on further in depth investigations of microenvironment induced prednisolone 
resistance and personalized mutation-based therapies to revert prednisolone 
resistance.
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van kinderen met acute lymfatische leukemie (aLL) recidiveert 20% tijdens of 
na de huidige behandelingsstrategieën. het falen van de huidige behandeling 
is geassocieerd met cellulaire resistentie tegen prednisolon, het voornaamste 
medicijn dat gebruikt wordt in de huidige combinatie-chemotherapie. De 
moleculaire mechanismen betrokken bij prednisolon resistentie in kinder aLL zijn 
niet volledig bekend. het doel van dit proefschrift was om nieuwe aanknopings-
punten te vinden waarmee we prednisolon resistentie kunnen opheffen.
Recente bevindingen tonen aan dat prednisolon resistente cellen een defect 
hebben in medicijn-geïnduceerde celdood mechanismen. wij hebben daarom 
celdood eiwitten in leukemiecellen van kinderen met aLL geanalyseerd 
(Hoofdstuk 2). hieruit bleek dat een hoge eiwit expressie van MCL1 waarschijn-
lijk prednisolon resistentie veroorzaakt. we hebben daartoe klinisch relevante 
locked-nucleic-acid (Lna) oligonucleotiden ontwikkeld die de expressie van 
MCL1 omlaag bracht. De verlaging van MCL1 induceerde celdood en maakte 
de leukemiecellen gevoeliger voor prednisolon. echter niet alle leukemiecellen 
konden hiermee gedood worden. we hebben ontdekt dat deze cellen zichzelf 
weer gedeeltelijk konden redden door hun energieaanmaak te verhogen. toen 
we daarom tegelijkertijd de MCL1 eiwit expressie verlaagde met MCL1 Lnas 
en de energieaanmaak verlaagde met 2-deoxyglucose (2-DG) doodde dit 
gezamenlijk de leukemiecellen en werden ze gevoeliger voor prednisolon. Onze 
resultaten laten daarmee zien dat MCL1 Lna en 2-DG nieuwe therapeutische 
mogelijkheden kunnen bieden. Deze bevindingen laten ook zien dat meer 
onderzoek nodig is naar multifactoriële oorzaken van prednisolon resistentie en 
combinatietherapie om leukemiecellen gevoeliger te maken voor prednisolon.
Om prednisolon resistentie verder te bestuderen hebben we gekeken naar de 
expressie van duizenden genen in leukemiecellen van 256 kinderen met nieuw 
gediagnosticeerde aLL. Met behulp van deze informatie hebben we epitheliaal 
membraan proteïne 1 (EMP1) geïdentificeerd als een mogelijk betrokken gen bij 
prednisolon resistentie (Hoofdstuk 3). eMP1 is een eiwit dat op het celmembraan 
zit en waarvan de biologische functie niet bekend is. we hebben ontdekt dat 
het uitzetten van eMP1 expressie de leukemiecellen doodt en ze gevoeliger 
maakt voor prednisolon. het uitzetten van eMP1 inhibeerde tevens de beweging 
en aanhechting van leukemiecellen aan mesenchymale stroma cellen (MsCs). 
Mesenchymale stroma cellen zijn belangrijke cellen in het beenmerg die ervoor 
kunnen zorgen dat leukemiecellen overleven. we hebben ontdekt dat deze 
MsCs leukemiecellen resistenter kunnen maken voor prednisolon en dat het 
uitzetten van eMP1 dit verhinderd. verder hebben we ontdekt dat kinderen met 
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een hoge expressie van eMP1 een slechtere overleving hebben dan kinderen 
met een lage expressie van eMP1. samengevat laten onze resultaten zien dat 
eMP1 een belangrijke pathobiologische rol speelt in leukemie. het ontwikkelen 
van een eMP1 inhiberend medicijn zou kunnen dienen als een mogelijke nieuwe 
therapeutische behandelingsoptie voor kinderen met leukemie. verder laten 
onze resultaten eerste inzichten zien in de rol van het micromilieu in medicijn 
resistentie dat verder onderzoek naar dit fenomeen aanmoedigt.
naast het bestuderen van duizenden genen, hebben we ook zo’n 250 eiwit-
ten bestudeerd van 123 nieuw gediagnosticeerde kinderen met aLL. we heb-
ben daarbij een verhoogde gen en eiwit expressie gevonden van de nR4a 
transcriptiefactor familie (NR4A1, NR4A2 en NR4A3) in prednisolon resistente 
patiënten vergeleken met prednisolon sensitieve patiënten (Hoofdstuk 4). De 
nR4a familie zijn eiwitten die de werking van prednisolon tegen kunnen werken. 
het tegelijkertijd uitzetten van het nur77 (NR4A1), nurr1 (NR4A2) en nor1 (NR4A3) 
eiwit in leukemiecellen van kinderen maakte deze cellen echter niet gevoeliger 
voor prednisolon. We zagen wel een significant maar bescheiden verlaging 
van celoverleving. samengevat impliceren onze resultaten dat de nR4a genen 
geen geschikte targets zijn om prednisolon resistentie op te heffen. Deze data 
suggereren ook dat resistentie voor prednisolon waarschijnlijk veroorzaakt wordt 
door mechanismen die voornamelijk de ondergelegen intracellulaire signale-
ring beïnvloeden dan door mechanismen die het effectieve actieve prenisolon 
receptor niveau beïnvloeden.
naast celdood mechanismen zijn ook andere overlevings mechanismen ge-
associeerd met prednisolon resistentie, deze zijn verder onderzocht in Hoofdstuk 
5. we zagen dat prednisolon de activiteit van het Ras-overlevingspad en stat6 
verlaagde in prednisolon sensitieve aLL cellen van kinderen, maar niet in staat 
was dit te doen in de resistente cellen. tevens vonden we een actieve opre-
gulatie van het proto-oncogen cMet in prednisolon resistente leukemiecellen 
vergeleken met sensitieve leukemiecellen. De bevinding dat prednisolon niet 
in staat is de activiteit van het Ras-overlevingspad te verlagen in prednisolon 
resistente patiënten, spoorde ons aan om de aanwezigheid van Ras-pad 
activerende afwijkingen te onderzoeken. we hebben afwijkingen in nRas en 
KRas gevonden in 38% van de patiënten. In 60% van deze patiënten vonden 
we afwijkingen in kleine groepen cellen (subklonen). Medicijnen tegen MeK 
(trametinib), BRaf (sorafenib), stat6 (as1517499) of cMet (Crizotinib) waren niet 
in staat de leukemiecellen in vitro te doden. echter, trametinib was indrukwek-
kend potent in combinatie met prednisolon en alle afwijkende nRas/KRas 
leukemiecellen werden hiermee volledig gedood. In één patient met nRas/
KRas-afwijkende leukemiecellen sensitiseerde sorafenib, maar niet trametinib 
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de cellen voor prednisolon. Onze data impliceert dat leukemiepatiënten 
gescreend zouden moeten worden op Ras-afwijkingen, daar deze patiënten 
wellicht voordeel kunnen hebben bij behandeling met trametinib/sorafenib in 
combinatie met prednisolon. Onze resultaten illustreren de heterogeniteit van 
prednisolon resistentie en moedigen aan om Ras-activerende afwijkingen ver-
der te onderzoeken om zodoende patiënten te selecteren die geschikt zijn voor 
deze leukemiecel-specifieke medicijnen.
samengevat, dit proefschrift toont aan dat MCL1 Lnas, 2-DG, een eMP1 inhi-
bitor, trametinib en sorafenib behoren tot de mogelijke therapeutische opties 
om prednisolon resistentie op te heffen en zouden zo kunnen bijdragen aan de 
genezing van de resterende 10-20% kinderen met aLL. toekomstig onderzoek 
zou zich moeten richten op een multifactoriële benadering om aLL cellen vol-
ledig gevoelig te maken voor prednisolon, op verder diepteonderzoek naar 
de invloed van het micromilieu op prednisolon resistentie en op individuele 
afwijking-gebaseerde therapieën om prednisolon resistentie tegen te gaan.
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CuRRICuLuM vItae - enGLIsh
 
Ingrid ariës was born on april 8th 1986 in Maastricht, the netherlands. she passed 
her Gymnasium exam at trichter College Maastricht in 2004. her thesis was on 
“the effects of chloorhexidinedigluconaat and triclosan on Streptococcus Mu-
tans”. In the same year she started with the Bachelor Molecular Life sciences at 
Maastricht university and graduated Cum Laude in 2007. hereafter, she started 
the Master Clinical Molecular sciences at Maastricht university. During her 6 
month junior internship she studied the effects of exogenous galectin-1 on tu-
mour angiogenesis at the department of Pathology, Research school for Growth 
and Development Maastricht, which resulted in an authorship. she obtained 
an erasmus exchange Grant and Dutch Cancer society Grant to continue this 
study during her 9-month senior internship in Milan Italy. at the Istituto europeo di 
Oncologia Milano Italy, department of hematology/Oncology, she studied the 
role of galectin-1 during tumour vasculogenesis in galectin-1 knockout mice. 
she obtained her Masters of science degree Cum Laude in 2009. she moved to 
Rotterdam in september 2009 to start her PhD thesis in the research group of Prof. 
Dr. Rob Pieters and Dr. M.L. den Boer at the department of Pediatric Oncology/
hematology, sophia Children’s hospital – erasmus MC. the research performed 
during this period is presented in this thesis. In October 2013 she started a new 
research project under the supervision of Prof.dr. Rob Pieters and Dr. M.L. den 
Boer named clonal evolution and personalized targeted therapy in pediatric 
acute lymphoblastic leukemia. she will move to Boston, usa, in the summer of 
2014. In the researchgroup of Dr. a. Gutierrez, Children’s hospital Boston-harvard, 
she will investigate chemotherapy/apoptosis resistance in pediatric t-cell acute 
lymphoblastic leukemia.
168
CuRRICuLuM vItae - neDeRLanDs
 
Ingrid ariës is geboren op 8 april 1986 te Maastricht. In 2004 behaalde ze haar 
Gymnasium diploma aan het trichter College te Maastricht. voor haar eindthe-
sis onderzocht ze de effecten van chloorhexidinedigluconaat en triclosan op 
de streptococcus Mutans. In datzelfde jaar startte ze met de bachelor oplei-
ding Molecular Life sciences aan de universiteit Maastricht en in 2007 slaagde 
ze Cum Laude. hierna begon ze met de Master Clinical Molecular sciences 
aan de universiteit Maastricht. tijdens haar 6 maanden durende junior stage 
onderzocht ze de effecten van exogeen galectine-1 op tumor angiogenese 
(afdeling Pathologie, Research school for Growth and Development Maas-
tricht), dat een auteurschap opleverde. ze behaalde een erasmus exchange 
Beurs en Kwf studenten Beurs om dit onderzoek te vervolgen tijdens haar 
9 maanden durende senior stage in Milaan Italië. aan de Istituto europeo di 
Oncologia Milano Italy, afdeling hematologie/Oncologie bestudeerde ze de 
rol van galectin-1 tijdens tumour vasculogensis in galectin-1 knockout muizen. 
ze behaalde haar Masterof science diploma Cum Laude in 2009. In september 
2009 verhuisde ze naar Rotterdam om te beginnen aan haar promotieproject 
in de onderzoeksgroep van Prof.dr. Rob Pieters and Dr. M.L. den Boer op de 
afdeling hematologie/Oncologie , sophia kinderziekenhuis – erasmus MC. het 
onderzoek uitgevoerd tijdens deze periode is beschreven in dit proefschrift. In 
Oktober 2013 is ze begonnen aan een nieuw project onder de supervisie van 
Prof.dr. Rob Pieters en Dr. M.L. den Boer genaamd klonale evolutie en op maat 
gemaakte therapie in acute lymfatische kinderleukemie. In de zomer van 2014 
zal ze verhuizen naar Boston, verenigde staten. In de onderzoeksgroep van Dr. 
a. Gutierrez, Kinderziekenhuis Boston-harvard, zal ze chemotherapie/apoptosis 
resistentie in t-cell acute lymfatische kinderleukemie onderzoeken.
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PhD PORtfOLIOPhD Portfolio
Summary of PhD Training and Teaching Activities
Name: Ingrid M.A.A. Ariës
Erasmus Mc department: Pediatric Oncology/Hematology
Research School: Molecular Medicine
PhD period: Sept 2009 - Sept 2013
Promotor: Prof.dr. R. Pieters
Co-promotor: Dr. M.L. den Boer
Seminars/Courses/Workshops Year ECTS
Biobase knowledge Library and ExPlain Analysis, Postgraduate School Molecular Medicine, 2009 0.4
Erasmuc Medical Center, Rotterdam, The Netherlands, Oct 2009
Biomedical Research Techniques VIII, Postgraduate School Molecular Medicine, 2009 1.5
Erasmuc Medical Center, Rotterdam, The Netherlands, Oct 2009
Basic and Translational Oncology, Postgraduate School Molecular Medicine, 2009 1.8
Erasmuc Medical Center, Rotterdam, The Netherlands, Nov 2009
Basic Oncology Course, Dutch Oncology Association, 2010 2
Seminar Estate Avegoor, Ellecom, The Netherlands, March 2010
Basic Course on "R", Postgraduate School Molecular Medicine, 2010 1.4
Erasmuc Medical Center, Rotterdam, The Netherlands, June 2010
Analysis of Microarray Gene Expression Data, Center for Human and Clinical Genetics 2010 2
Leiden University Medical Center, The Netherlands, June 2010
Photoshop CS3 Workshop, Postgraduate School Molecular Medicine 2010 0.3
Erasmuc Medical Center, Rotterdam, The Netherlands, June 2010
Statistics for Genomics Data-Analysis , Department of Epidemiology and Biostatistics, 2010 2
VU University Medical Center, Amsterdam, The Netherlands, Nov 2010
The Ensembl Workshop, Postgraduate School Molecular Medicine, 2010 0.6
Erasmuc Medical Center, Rotterdam, The Netherlands, Sept 2010
English Biomedical Writing and Communication, Postgraduate School Molecular Medicine, 2011/2012 4
Erasmuc Medical Center, Rotterdam, The Netherlands, Dec 2011 - March 2012
Classical Methods for Data Analysis (CC02), Netherlands Institute for Health Sciences, 2012 5.7
Rotterdam, The Netherlands, Sept - Oct 2012
Indesign CS5 Workshop, Postgraduate School Molecular Medicine, 2013 0.15
Erasmuc Medical Center, Rotterdam, The Netherlands, June 2013
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International and National Conferences and Presentations Year ECTS
Erasmus Postgraduate school Molecular Medicine Day 2011, Rotterdam, 2011 0.6
The Netherlands, Feb 2011, poster presentation
American Association for Cancer Research (AACR) Annual Meeting 2012, Chicago, 2012 1.6
Illinois, USA, April 2012, poster presentation
The International BFM Study group (IBFM) Annual Meeting 2012, Santiago, 2012 1.6
Chili, April 2012, poster presentation, 1st price poster award
European Hematology Association (EHA) Annual Meeting 2012, Amsterdam, 2012 1.6
The Netherlands, June 2012, poster presentation
International Society of Paediatric Oncology (SIOP) Annual Meeting 2012, London, 2012 2
United Kingdom, Oct 2012, oral presentation
American Society of Hematology (ASH) Annual Meeting 2012, Atlanta 2012 1.6
Georgia, USA, Dec 2012, poster presentation
Erasmus MC Daniel den Hoed Day 2013, Rotterdam 2013 2
The Netherlands, Oct 2013, oral and poster presentation
American Society of Hematology (ASH) Annual Meeting 2013, New Orleans, 2013 2
Louisiana, USA, Dec 2013, oral and poster presentation, abstract achievement award 
Other Presentations
Research Meetings Laboratory of Pediatrics and Pediatric Oncology 2009-2013 4
Reviewing Year ECTS
Reviewer for Leukemia Research and Treatment, a peer-reviewed open access journal 2012 3
that publishes original research articles, review articles, and clinical studies related to all 
aspects of leukemia.
Teaching Year ECTS
Supervising Ms. Isabel Jerchel during her final year MSc Molecular Medicine, 2011-2012 10
Rotterdam University, The Netherlands, Master Thesis 12-month Internship on 
"Unraveling prednisolone resistance in Acute Lymphoblastic Leukemia" 
Supervising Ms. Giulia Pellizari during part of her final year MSc Medicina Molecolare, 2012 4
University of Trieste, Italy, Master Thesis Internship on
"The role of TPMT and ITPA in Thiopurine resistance"
Supervising Rotterdam University Medicine Students 2012 and 2013 4
during their Minor Pediatric Oncology/Hematology Laboratory Techniques
Total 60
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“Appreciation is a wonderful thing. It makes what is excellent in others belong 
to us as well.” - Voltaire
na 10.000 uren in het lab, 9000 Mtts, 4500 lentivirale knockdown experimenten, 
200 microarrays, 1 RsI pipetteerduim, 1 gebroken pols, 20 presentaties, 5 inter-
nationale congressen, 6 lasergame wedstrijden, 4 kerstpartijtjes en de zomerse 
lab-day out, 100 gezellige etentjes, bioscoopavondjes of stapavondjes en veel 
nieuwe vrienden verder is het na 4 jaar dan eindelijk zover, ik ga promoveren 
yeahhh!! natuurlijk was dit allemaal nooit gelukt zonder de hulp van mijn promo-
tor, co-promoter, collega’s, vrienden en familie die ik ontzettend dankbaar ben.
“Never, never, never give up.”  - Winston Churchill
allereerst bedank ik alle patiënten en hun ouders. Jullie maken het mogelijk om 
de behandeling en overlevingskans van acute lymfatische leukemie nog verder 
te verbeteren!
“The mediocre teacher tells. The good teacher explains. The superior teacher 
demonstrates. The great teacher inspires.” - William Arthur Ward
Rob, bedankt dat ik de kans heb gekregen om onderzoek te mogen doen in 
het kinderoncologisch laboratorium Rotterdam. Op elk internationaal congres 
werd ik wel een paar keer aangesproken met “Ow, you are in the lab of Rob 
Pieters”, waar uit de intonatie en het verdere gesprek duidelijk de internationale 
waardering voor ons onderzoek naar voren kwam. Bedankt voor de leuke en 
interessante discussies die we de afgelopen jaren hebben gevoerd over mijn 
onderzoek, waar interessante nieuwe ideeën en tips uit voortkwamen. Bedankt 
ook voor het zorgvuldig verbeteren van al mijn manuscripten. veel succes met 
je nieuwe baan in het Prinses Maxima Centrum.
Monique, bedankt dat je vier jaar geleden potentie in me zag en ik mocht be-
ginnen met mijn onderzoek naar prednisolon resistentie. Ik kon me geen leuker 
en interessanter project voorstellen! De afgelopen jaren heb je samen met Rob, 
Jules, Ronald, Marry en Michel ons lab opgebouwd, waarin we als onderzoeker 
worden verwend met een database van duizenden patiëntensampels, met 
daarnaast kennis, apparaten en mogelijkheden tot ontzettend veel moleculaire 
technieken. Bedankt voor de vrijheid die je me hebt gegeven om me als een 
zelfstandige onderzoeker te ontwikkelen en bedankt voor alles dat ik van je heb 
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geleerd. Mijn manuscripten keek je altijd zorgvuldig en snel na, vaak nog in de 
late avonduurtjes, ontzettend bedankt!
Jules en Ronald, bedankt voor jullie input de afgelopen jaren! Ronald, heel 
leuk dat je in mijn promotiecommissie plaats wil nemen. allebei veel succes de 
komende jaren met het verder uitbreiden van jullie onderzoeksgroep, op naar 
de volgende geweldige wetenschappelijke ontdekkingen en publicaties.
Marry, Michel veel succes met jullie onderzoeksgroepen! Janneke en Kees be-
dankt voor jullie suggesties tijdens research meetings en veel succes met jullie 
onderzoeksgroep of nieuwe baan.
verder gaat mijn dank uit naar Prof.dr. Bob Löwenberg, Prof.dr. Gertjan Kaspers, 
Prof.dr. Yves Benoit die als leden van de kleine commissie mijn proefschrift met 
aandacht hebben doorgenomen. Bedankt ook de overige leden, Dr. frank van 
Leeuwen, Dr. Ronald stam, Prof.dr. stefan sleijer voor hun deelname in de com-
missie.
“Alone we can do so little; together we can do so much” - Helen Keller
Rosanna, na twee jaar alleen ploeteren, kwam jij me versterken, dat was gewel-
dig. Ik vond het ontzettend leuk om je alle technieken te leren. zeker het laatste 
jaar ben je uitgegroeid tot een echte research analist! Bedankt voor al je hulp, 
voor het samen pipetteren, soms van 7h tot 23h ‘s avonds. Bedankt!
Isabel, you are the kind of master-student everyone wishes for! from the start you 
were really enthusiastic about research and eager to learn as much as possible. 
thank you for your contribution and I wish you all the luck in your PhD-project 
which I am sure will lead to beautiful publications!
Ik wil graag alle analisten in ons lab bedanken: aurelie, Carla, Clarissa, ellen, 
femke, Jessica, Lonneke, Marije, Marieke, Merel, Myrte, Pauline, Rosanna, 
sandra, susan en wilco. Jullie zijn degene die tijdens de “patiëntendienst” 
een ontzettend grote en waardevolle patiëntensample database hebben 
opgebouwd. Ontzettend bedankt voor jullie inzet en harde werk dat zeer ge-
waardeerd wordt! Ook dank aan alle artsen en verpleegkundigen die verant 
woordelijk waren voor het afnemen van het materiaal en dank aan het lab 
specieel voor het doorsturen van de sampels naar de 15e! furthermore, I would 
like to thank sKIOn and COaLL study group for sending us patient sampels and 
follow-up data.
ellen, Mirjam, Pauline, Jessica en susan als zijnde “laboudsten” kon ik bij jullie 
terecht met elke vraag, waar ik altijd een zorgvuldig antwoord op kreeg, ontzet-
tend bedankt!
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Judith, in mijn tweede jaar werd jij aangenomen als biostatisticus. Hoe fijn was 
het om iemand in onze groep te hebben die zowel veel verstand had van de 
biologie als van bioinformatica. helaas had ik net mijn hele R microarray ana-
lyse afgerond, maar gelukkig kwam jouw zorgvuldige analyse op hetzelfde uit, 
pjiew. Je hebt daarna nog talloze analyses voor me gedaan, waarvoor heel 
veel dank!
Bedankt ook mijn collega’s in de “B-aLL” groep, Mirjam, ellen, Diana, Leila, ste-
fanie, farhad, arian, Marieke, Marije, Janet, Carla, Lieke (bedankt voor alle MsC 
kennis), João, Judith, Myrte, Rosanna, Isabel, Bob, Lieneke, Cesca, Roel, femke 
en aurelie. veel succes de komende jaren met jullie onderzoek, promoties of 
nieuwe baan!
Jammergenoeg is er niet genoeg ruimte om iedereen individueel te bedanken.
ad, andrica, astrid, Dicky, Dirk, Dominique, eddy, elnaz, emiel, emma, eva, eva 
B., floor, Irene, Iris, Janneke B, Kirsten, Lidija, Lilian, Lisette, Maarten, Maartje, 
Mahban, Malou, Marieke vdL, Marieke vL, Marjolein, Mark, Monique v, nicola, 
nicole, noori, Peng, Pieter, Rolien, silvia, sharon, theo, trudy, wilco, wing, Ytje, 
Yunlei. Bedankt voor jullie bijdrage en voor de gezelligheid de afgelopen jaren. 
veel succes met jullie onderzoek of nieuwe baan.
Ingrid, Marcel en Ram, bedankt voor alle bestellingen, alle administratieve za-
ken, alle puntjes die gevuld zijn, al het glaswerk dat geautoclaveerd is, bedankt! 
Jeanine, Jacqueline en anita, bedankt voor al het geregel!
“New journeys invite new friends.”
Jasmijn, mijn paranimf, ik heb ontzettend veel goede en leuke herinneringen 
aan onze tijd in atlanta, Boston, new Orleans en onze dates in nederland! fijn 
dat jij aan mijn zijde wilt staan als paranimf om me te steunen! heel veel suc-
ces met je promotie de komende tijd! voor een tijdje waren we samen met 
Jenny en Daria the 4 musketeers. wat hadden we een lol in onze aiO-kamer en 
daarbuiten! Ook onze onderzoeksfrustraties konden we bij elkaar kwijt. Jenny 
en Daria, heel bijzonder en speciaal dat ik op jullie beide huwelijken aanwezig 
mocht zijn! Jenny heel veel success met je co-schappen en de laatste loodjes 
van je PhD! Daria, jij zit nu all the way in new York, we missen je hoor! we zien 
elkaar snel in new York of Boston!
Jill, allebei werkten we aan prednisolon resistentie en allebei komen we uit zuid-
Limburg, dat schept natuurlijk een hele goede band. Bedaank veur al dien hölp, 
mèt eedere vraog kos iech bij diech terech! Bedankt dat je er altijd voor me 
was! Ik heb erg genoten van de heerlijke diners bij jouw thuis met Leon en Lisa! 
Onze diners samen met Linda en Jenny waren ook altijd weer supergezellig. 
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Linda, ook jij bent helaas alweer een tijdje uit het lab. Je hebt samen met Mark 
een wondertje op de wereld gebracht, tamo. Geniet van deze prachtige tijd!
anna, beide zijn we op 1 september 2009 begonnen aan ons promotietraject 
en beide gaan we dit jaar promoveren. Ik heb genoten van onze vele koffie-
momentjes op het werk en zalm met spinazie momentjes bij jou of bij mij thuis en 
met veel plezier denk ik terug aan de gezellige tijd in atlanta, wat hebben we 
gelachen! veel succes met je opleiding interne geneeskunde en ik kijk uit naar 
jouw promotie!
stef en Carla, jullie hebben me destijds ingewerkt in ML-II, waarvoor veel dank! 
heel erg leuk en speciaal dat ik op jullie beide huwelijken aanwezig mocht zijn. 
Ook jullie hebben een nieuwe baan, ik mis onze swirl-dates, maar gelukkig zien 
we elkaar nog heel vaak tijdens onze diner-dates! stef, veel succes met de 
laatste loodjes van je proefschrift.
farhad, thanks you for all your help the past four years. we had a lot of fun in 
new Orleans and in the preparation for your PhD-defense. I am honoured to be 
your paranimf and enjoyed the Iranian meals you and azadeh prepared.
Isabel, Rui, João, Patricia, Celia, thanks for all the good times these past 4 years! 
I enjoyed going out with you guys, drinks in Blender, tiki’s, Black sheep, movies, 
BBQs, dinners! Good luck with your research the coming years!
arian, samen begonnen we 4 jaar geleden aan de 600 microarrays, hiep hiep 
array! Ik kijk uit naar jouw promotie en veel succes in de kliniek!
Imbritt, van ex-collega’s werden we door toeval spin en fitness maatjes. Bedankt 
voor je interesse, luisterend oor en vele gezellige spinuurtjes!
“A friend is one of the nicest things you can have,
and one of the best things you can be.”  - Douglas Pagels
Lieve vriendinnen en vrienden,
Miepieessss, Men (aBvtjess :D!), annuh, Cas, Caro, Curlz, Iris, Manonno, san en 
sjwel, bedankt voor alle geweldige tijden, jullie luisterend oor en interesse in mijn 
onderzoek! Wat is het fijn om zo’n superleuke, gezellige vriendinnengroep te 
hebben! Op naar de volgende miepenweekendjes!
anke, arjen, Cindy, Dominique, Jeffrey, Jesse, Julie, Jurian, Koen, Linda, Mark, 
Martijn, nicky, nicole, nout, Pieter, Pim, Rachel, Rachelle, Rianne, Robbie, Ro-
nald, Roy, sara, sjors, stef, stephanie, suus, tano, thanks voor de gezelligheid, 
good times en interesse in mijn promotie! Ik heb alweer zin in vastelaovend, 
Bday-parties, Kingsday, skivakanties, festivals, ut Preuvenemint J!! Wat is het fijn 
om zo’n leuke, gezellige vriendengroep te hebben!
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Mijn Rotterdamse matties, Maaike en Patricia, bedankt voor jullie interesse in 
mijn onderzoek, ik heb genoten van de vele gezellige uurtjes samen! Mede door 
jullie is Rotterdam mijn tweede thuis geworden.
Mijn Milanese bella’s, Loes, Mir en stef. Bello Milano, het is alweer 5 jaar geleden 
dat we er woonde, nog steeds zijn we vriendinnen, bellissimo!
“Family is everything.”
Mam, pap, bedaank veur alle steun en vertrouwe de aofgelaope jaore! altied 
staot geer veur us klaor, door dik en dun! zoonder uuch hat iech dit noets kinne 
bereike. Betere ouders kun je je niet wensen! Bedaank veur alles !!!
Bro, sjiek totstiech mien paranimf bis! Iech bin gruuts op alles watste bereik höbs 
en iech verheug miech noe al op dien promotie! same met Kel höbste twie 
sjoen kinder Pip en Lou. Roel en Kel bedaank tot geer der altied veur miech 
zeet!
Paat Brigitte en noonkel Ludo, altied zeet geer geïnteresseerd in de vorderingen 
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